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Polysaccharide-encapsulated bacteria comprise a major group of human pathogens. In this
thesis, encapsulated bacteria are represented by Haemophilus influenzae type b and
Streptococcus pneumoniae. Another notable example is Neisseria meningitides. Infections
with these organisms result in substantial morbidity and mortality, particularly in young
children, elderly and immunocompromised patients.
Host immunity against encapsulated bacteria depends primarily on the presence of antibodies
against their capsular polysaccharides. These specific antibodies confer protection against
infections with the corresponding bacteria by activating phagocytosis.
In infants and young children the antibody response to capsular polysaccharides is immature,
resulting in increased incidence of diseases such as pneumonia, meningitis, otitis media and
other forms of bacterial disease. Polysaccharide vaccines are ineffective in this age group.
Polysaccharide vaccines are also ineffective in many other patient groups with increased
susceptibility to encapsulated bacteria due to insufficient antibody responses to these antigens.
The antibody response to polysaccharides can be improved by coupling the polysaccharide to
protein carriers. The resulting conjugate vaccines are effective in inducing antibody responses
to the polysaccharide antigens and reducing the occurrence of invasive disease.
Haemophilus influenzae type b
Haemophilus influenzae is among the bacteria normally found in the pharynx. Up to 80% of
persons are carriers. Most people are colonized with unencapsulated strains, but in 3-5% of
people the isolates have capsules [1]. Haemophilus influenzae is the causative agent of a
spectrum of human diseases, the most serious of which is meningitis. Other invasive diseases
caused by this organism include pneumonia, epiglottitis, cellulitis and septic arthritis. Nearly
all invasive disease caused by Haemophilus influenzae is due to serotype b, one of the six (a-
f) antigenically distinct capsular types [2]. Non-encapsulated variants and mutants unable to
synthesize a capsule are usually not able to cause invasive disease [3;4]. These nontypable
Haemophilus influenzae isolates are common etiologic agents in mucosal infections such as
otitis media and sinusitis.
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A striking epidemiologic feature of invasive Haemophilus influenzae type b (Hib) disease has
been the age distribution. More than 90% of all infections occur in children less than 5 years
of age. The peak attack rate in developed countries occurs at 6-12 months of age. Before
introduction of conjugated Hib vaccines in the childhood vaccination schedules, Hib appeared
to be the most common cause of bacterial meningitis among children in the United States,
accounting for approximately 70% of bacterial meningitis cases among children <5 years of
age [5]. The incidence of invasive disease varies between different countries and in certain
populations. Populations identified to have an increased incidence of invasive disease include
Alaskan Eskimos, Apaches, Navajos and African Americans [6-10]. Before introduction of
vaccination against Hib, yearly an estimated number of 700 cases of invasive Hib diseases
occurred in the Netherlands, 50% of which were cases of meningitis and 15-30% epiglottitis
[11].
Type b Haemophilus influenzae strains produce the type b capsular polysaccharide, composed
of repeating units of polyribosylribitol phosphate (PRP). This capsule protects Hib against
engulfment and killing by phagocytic cells and complement mediated killing [12;13]. The
protective action of the capsule can be overcome by antibodies that bind to it and activate
complement. Both antibodies and complement deposited on the bacterial surface bind to
receptors on phagocytic cells, and initiate uptake and killing of the bacteria.
Streptococcus pneumoniae
Streptococcus pneumoniae regularly colonizes the upper respiratory tract, and can be an
invasive pathogen. It is the most common cause of community-acquired bacterial pneumonia
and otitis media and the third common cause of meningitis [14]. Almost every clinical isolate
of S. pneumoniae contains an external capsule; only rarely have unencapsulated strains been
implicated as the cause of infection, nearly always in cases of conjunctivitis [15;16]. In recent
years, the emergence of antibiotic-resistant strains of S. pneumoniae has made pneumococcal
disease management more difficult, thereby increasing morbidity and mortality and urging
development of preventive vaccination-strategies.
Many healthy individuals carry S. pneumoniae in their upper respiratory tract. Carriage rates
are highest in infants and young children attending out-of-home care, with carriage rates
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ranging from 21% in point-prevalence studies up to 65% in longitudinal studies [17-20].
Carriage rates tend to decrease with increasing age. Colonization and pneumococcal disease
are season-related, and peak during winter months [21].
Transmission of antibiotic-resistant strains of pneumococci is an increasing problem. Factors
associated with carriage of antibiotic resistant pneumococci include age younger than two
years, frequent upper respiratory tract infections, use of prophylactic antibiotics, frequent use
of antibiotics for febrile illnesses, and a history of recurrent acute otitis media or acute otitis
media unresponsive to antibiotic treatment [17-20;22;23].
Infections due to pneumococci are most frequently observed in infants and elderly persons,
and in patients with a variety of underlying conditions such as a poor splenic function,
asplenia, congenital malformations, malignancies and various other chronic diseases [24-27].
Among children < 5 years of age, it is estimated that pneumococcal infections account for at
least one million deaths annually [28]. Almost all of these childhood deaths occur in
developing countries. Population-based data on invasive pneumococcal disease suggest an
annual incidence of over 50 cases per 100,000 elderly adults (above the age of 65 years) [29].
S. pneumoniae is cultured from middle ear fluid in 18-52% of the cases of otitis media [30].
When antigen detection methods are employed, S. pneumoniae is found in even >60% of the
cases [31;32].
The importance of the pneumococcal capsule as a virulence factor has long be known. A clear
relationship was observed between capsular serotype and pneumococcal disease in humans
[21;33]. Pathogenic pneumococci produce polysaccharide capsules that show considerable
molecular variety: more than 90 pneumococcal serotypes have been described to date. The
serotypes that are responsible for disease differ between adults and children. Serotypes 14, 6,
19, 18, 9, 23, 7, 4, 1 and 15 are, in descending order, responsible for >85% of invasive
pneumococcal infections in children from developed countries. In developing countries the
order is 6, 14, 8, 5, 1, 19, 9, 23, 18, 15 and 7 [34]. In adults serotypes 1, 3, 4, 7, 8, 9, 12 and
14 cause most invasive pneumococcal infections; the relative frequency of isolated
pneumococcal serotypes varies per region [35;36].
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Host defence against encapsulated bacteria
The key component of the host defence against encapsulated bacteria is opsonophagocytosis
of the micro-organism. For this process, specific antibodies to the capsular polysaccharides,
complement, and phagocytes are required. The spleen is important in the initiation of the anti-
polysaccharide antibody response. Fc receptors on phagocytic cells form an essential bridge
between the humoral branch and the effector cells of the immune system. These elements in
host defence against encapsulated bacteria will be discussed.
The antibody response to bacterial capsular polysaccharides
Anti-polysaccharide antibodies
Specific antibodies to the capsular polysaccharides play a crucial role in the defence against
encapsulated bacteria. The protective role of antibodies to the Hib polysaccharide has been
shown convincingly. The inverse correlation of disease occurrence and the presence of
bactericidal antibodies in the serum of subjects at different ages was shown as early as 1933
[37]. The same relationship was demonstrated later for specific anticapsular antibodies [38].
Natural antibodies specific for Hib begin to occur at approximately 2 years of age and reach
adult levels by about 5 years. The increased susceptibility for invasive Hib diseases in early
childhood is thus correlated with the absence of serum bactericidal anti-Hib polysaccharide
antibodies. In the pre-antibiotic era it was also recognized that immune sera could be used for
the prevention and treatment of pneumococcal infections [39]. Protective antibodies are
directed against the capsular polysaccharide, and are therefore serotype specific.
Bacterial capsular polysaccharides
Bacterial capsular polysaccharides are linear or branched polymers composed of repeating
units of two to five different saccharide moieties. The virulence of a given encapsulated
bacterium depends primarily, though not exclusively, on the chemical composition and
structure of the capsular polysaccharide, and not on other capsular or cell wall components.
The various capsular polysaccharides are different in immunogenicity, and antibody
responses are age-related. Infants respond infrequently, and with low antibody levels to the
PRP polysaccharide of Hib [40]. The responses mature at the age of 18 months, but children
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aged 18-24 months do not respond as well as those older than 2 years [40]. The different
pneumococcal capsular polysaccharides also vary in immunogenicity. In young children,
capsular polysaccharides of pneumococcal serotypes 6 and 23 are poorly immunogenic,
serotypes 14 and 19F are intermediately immunogenic, and types 8, 12, 1, 7, 4, 9 as well as
serotype 3 induce good antibody responses as compared to adults after immunization with
pneumococcal polysaccharide vaccine [41-44].
T cell independent type 2 antigens
Capsular polysaccharides belong to the class of T cell independent type 2 (TI-2) antigens:
they are able to induce antibody responses in athymic nude mice, but not in mice with an X-
linked B cell maturation defect (CBA/N mice) [45]. A number of features distinguish
polysaccharides from proteins, belonging to the class of T cell dependent (TD) antigens
(Table 1). TI-2 antigens are high molecular weight molecules, carrying repeating epitopes. TI-
2 antigens are poorly metabolized in vivo, and may be retained in lymphoid organs for
prolonged periods. Up to months after immunization, polysaccharides can be demonstrated on
marginal zone macrophages of the spleen [46]. At high doses, polysaccharides can be
tolerogenic. TI-2 antigens do not induce classic immunological memory [40]. Importantly, the
onset of the responsiveness to polysaccharides is relatively late. Following vaccination,
affinity maturation of antibodies does not occur [47].
TI-2 TD
prototype antigen capsular polysaccharides proteins
T cells required no yes
T cell regulation yes yes
onset of responsiveness in ontogeny late early
induction of memory no yes
isotype/idiotype restriction yes no
Table 1. Characteristics of T cell independent type 2 and T cell dependent antibody responses.
Compared to protein antigens, the antibody response to TI-2 polysaccharide antigens is more
restricted in use of immunoglobulin variable (V) regions: following vaccination, infants and
adults produce serum antibody populations derived from one to three clones (reviewed by
[48]). The immunoglobulin isotypes of anti-polysaccharide antibodies are limited as well. The
human antibody response upon immunization with polysaccharide involves IgM, IgG1, IgG2
and IgA isotypes. In infants and children, the IgG anti-polysaccharide antibodies
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predominantly reside in the IgG1 subclass. With increasing age, a shift towards IgG2 occurs
[49-52]. The seemingly superiority of IgG2 anti-pneumococcal polysaccharide antibodies
compared to IgG1 antibodies remains to be explained. IgG1 is more effective in activating the
classical complement pathway [53], but IgG2 seems to be superior to other IgG isotypes in
activating the alternative pathway in the presence of high epitope density [54]. In phagocytic
assays, both IgG1 and IgG2 antibodies are effective [55-58], but phagocytosis of S.
pneumoniae [57;59]and group B streptococci [55] may be more dependent on IgG2 than on
IgG1 type antibodies, compared to H. influenzae type b [56;58].
Altogether, these data indicate that IgG2 represents the main IgG isotype in conferring
clinical protection against pneumococcal infection.
For better understanding it would be convenient if all bacterial capsular polysaccharides could
be considered TI-2 antigens. However, only the capsular polysaccharides of S. pneumoniae
serotype 4 [60] and 2 [61], the capsular polysaccharide PRP of H. influenzae type b [62] and
that of type III Group B Streptococcus [63] formally have been proven to behave as human
TI-2 antigens. For other capsular polysaccharides the relative late onset of responsiveness in
ontogeny and the restriction of antibodies to the IgG2 subclass are considered sufficient for
qualification as TI-2 antigen. For a number of polysaccharides, e.g. pneumococcal
polysaccharide type 3, observations such as early onset of reponsiveness make it unlikely that
they represent true TI-2 antigens.
Regulatory T cells
TI-2 antigens can induce an antibody response in the absence of T cells, but regulatory T cells
may influence the magnitude of the response. T cells that augment the anti-polysaccharide
antibody response are not antigen specific in their action and are not MHC-restricted. The in
vitro anti-PRP B cell response can be augmented either by autologous or allogeneic T cells
[62]. The T cells that augment the anti-polysaccharide B cell response are termed amplifier
cells in order to distinguish them from classic MHC-restricted CD4+ helper cells that
participate in B cell activation by (TD) protein antigens. The amplifier activity resides in the
CD4+ TCR T cell population, although some gd TCR T cell lines also can augment the in vitro
anti-polysaccharide B cell response [61]. How amplifier T cells become activated is unclear.
Up till now, neither processing nor antigen presentation in the context of class II MHC
molecules has been demonstrated for polysaccharides [64]. Potentially, CD1 molecules
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present on dendritic cells, which recently have been shown to be able to present lipid and
glycolipids [65], could present polysaccharides to the TCR.
The ontogeny of polysaccharide responsiveness and the role of complement receptor 2
(CD21) in B cell activation by polysaccharides
As mentioned above, the onset of responsiveness to polysaccharides is relatively late. This
defective anti-polysaccharide response at early age probably is due to immaturity of B cells of
neonates and infants: neonatal T cells are equally well capable as adult T cells in supporting
an in vitro anti-polysaccharide antibody response of adult B cells. However, the
unresponsiveness of neonatal B cells to polysaccharide could not be overcome by adult T
cells. Polysaccharide-specific B cells are present at birth, and responsiveness to
polysaccharides can be induced in vitro by treatment with 8-mercaptoguanosine [66], or in
vivo by protein conjugated polysaccharide vaccines (see below). These data indicate that if
physiological B cell activation routes are bypassed, neonatal B cells can respond to
polysaccharides.
T cell dependent protein antigens are bound and internalized by the B cell antigen receptor
(mIg), and re-expressed as processed peptides on class II MHC molecules. The peptide-MHC
complex on B cells can activate peptide-specific T cells provided that a costimulatory signal
is given to the B cell via CD40-CD40L interaction [67]. This model can not explain B cell
activation by polysaccharides since neither processing nor antigen presentation in the context
of class II MHC molecules has been demonstrated for polysaccharides [64].
The first step in B cell activation by polysaccharides is ligation and cross-linking of antigen
receptors (mIg). Indirect evidence points towards a role for complement receptor 2 (CR2;
CD21) in providing a second activation signal. CD21 is a 145 kD glycoprotein of the
complement receptor family which is expressed on mature B cells and also on follicular
dendritic cells (FDC) and at a low level on a subpopulation of T cells [68;69]. The highest
expression of CD21 is found on B cells which reside in the splenic marginal zone (MZ) [70].
CD21 is the receptor of the complement component C3 split products iC3b, C3dg and C3d.
CD21 also serves as the cellular receptor for the Epstein-Barr virus, and as an alpha-interferon
receptor [71;72]. Bacterial capsular polysaccharides can activate complement via the
alternative pathway of complement activation, without the need for anti-polysaccharide
specific antibodies. C3 split products are generated, which become deposited on the
polysaccharide. Thus complexed C3d can be bound by CD21 [73]. Complexes of
polysaccharides and C3d are better in vitro immunogens than native polysaccharide [74].
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Immunohistochemical studies have shown that 15 to 30 minutes after intravenously
administration of 23-valent pneumococcal polysaccharide vaccine to rats, polysaccharides are
localized on splenic marginal zone B lymphocytes. Double staining for polysaccharides and
follicular dendritic cells (FDC) indicates that at 3-5 days after immunization, polysaccharides
are localized on germinal center FDC [75]. In vitro incubation of polysaccharide on rat [75] or
adult human [76] spleen cryostat sections only results in binding of polysaccharides to
marginal zone B cells and germinal center FDC when the polysaccharides are preincubated in
C3 containing serum. Marginal zone B cells and FDC are the cells with the highest expression
of CD21. These data strongly suggest a sequence of events that start with activation of C3 and
subsequent deposition of C3d on pneumococcal polysaccharides. Through binding of C3d to
CD21, polysaccharides can localize on B cells in the marginal zone, where the anti-
polysaccharide antibody response can be initiated.The gradual disappearance of
polysaccharide from the marginal zone and the appearance of polysaccharide on germinal
center FDC that is seen 3-5 days after immunization may indicate a migration of marginal
zone B cells to the germinal center.
Figure 1. T cell independent B cell activation
The emerging mechanism is that C3d enables crosslinking of mIg and CD21 on
polysaccharide specific B cells, and thus bypassing the need for engagement of CD40/CD40L
in B cell activation (Figure 1). This mechanism also would explain why children up to the age
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of 2 years do not respond to polysaccharide antigens: newborn blood B cells as well as splenic
marginal zone B cells of children up to 2 years of age have a reduced expression of CD21
[70;74]. Acquisition of adult levels of CD21 expression coincides with onset of anti-
polysaccharide responsiveness [70]. The importance of marginal zone B cells, complement
receptors, and complement in the antibody response to a synthetic TI-2 antigen is shown
directly in recent studies in C3-/-, CRI/II-/-, and Pyk2-/- mice [77].
The role of the spleen in the defence against encapsulated bacteria
For many years, the spleen has been considered as a rudimentary organ without known
function. Consequently, surgical removal of the spleen because of trauma or disease was
thought to have little consequences for the health of the patient (historical review by [78]).
Although incidental reports mentioned a relationship between splenectomy and infection, it
was not until 1952 that a causative association was reported between splenectomy and the
occurrence of meningitis with sepsis. Since then the increased risk of septicaemia directly
related to splenectomy has been well defined. Such infections are generally termed
“overwhelming post splenectomy infections” (OPSI), and are most often caused by S.
pneumoniae (50%), followed by N. meningitides (12%), Escherichia coli (11%), H.
influenzae (8%) and Staphylococcus aureus (8%) [79-81]. The highest incidence of OPSI is
generally found in infancy and childhood. Patients who have undergone splenectomy for
haematologic diseases, reticuloendothelial diseases or portal hypertension have a higher
incidence than those undergoing splenectomy for trauma [81-85].
The spleen consists of two general components: the white pulp (5-10%) and the red pulp
(±85%).
White pulp
The white pulp is composed of three major compartments: the periarteriolar lymphocyte sheet
(PALS), the lymphoid follicle (LF) and the marginal zone (MZ) [86;87]. The PALS is the T
cell compartment of the white pulp, surrounding a central artery. The LF of the spleen are
globular structures attached to the PALS with similar structure as LF in other lymphoid
organs [88]. The primary LF consists of a homogeneous aggregate of small B cells in an
inactivated state. Upon activation, the primary LF will become a secundary LF with a
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germinal centre (GC) surrounded by a small rim of remaining small B cells, the lymphocyte
corona (LC). The GC of the secondary LF consists of differentiated B cells, a few T cells and
follicular dendritic reticulum cells. In the LF a special type of dendritic cells (follicular
dendritic cells (FDC)) is found, which are able to bind immune complexes. They can maintain
immune complexes on their surface for a long period without phagocytosis. GC provide a site
for rapid proliferation of B cells, with immunoglobulin isotype switch and affinity maturation.
The GC is surrounded by the LC, which in its turn is surrounded by the MZ. The MZ consists
of medium-sized lymphocytes, mostly B cells; the area is an anatomical demarcation between
the white and the red pulp. In the MZ the blood flow is low, and thus the MZ provides an
environment that allows prolonged and intimate contact between antigens in the bloodstream
and the lymphocytic system [86]. Because of the low flow in combination with the presence
of a special type of B cells, the MZ is supposed to have an unique and important role in the
primary immune response to TI-2 antigens, as is discussed above.
Red pulp
The red pulp consists of a loose reticular tissue rich in capillaries and venous sinusoids. The
main function of the red pulp is blood filtration. Macrophages in the red pulp have secretory
capacities. They synthesize components of the complement system, interferon, haematopoetic
colony-stimulating factors and fibroblast stimulating factors. They are part of the so-called
mononuclear phagocytic system (MPS).
The red pulp has a special role in phagocytosis of poorly opsonized particles. The greatly
retarded blood flow in the red pulp cords allows a very intimate and prolonged contact
between antigens and phagocytes. Thus, particles can be ingested without specific and/or high
affinity ligand-receptor interactions. An implication of this specialized phagocytosing
capacity is that the spleen is the most important site of clearance during the early phase of
bacterial invasion, before sufficient amounts of specific antibodies have been produced.
The role of Fcg Receptors
Effective host defence against encapsulated bacteria depends on the presence of opsonic anti-
capsular polysaccharide antibodies that trigger phagocytic uptake and killing by
polymorphonuclear neutrophils (PMN). Receptors for the constant region of these antibodies
(FcR) play a crucial role in phagocytosis. Specific receptors have been described for most
Introduction
21
immunoglobulin (Ig) isotypes, i.e. IgA, IgD, IgE, IgG and IgM. IgG represents the dominant
antibody class in plasma, and receptors for IgG (FcgR) have been intensively studied. Within
the various types of FcgR, genetic polymorphisms have been described which have an impact
for susceptibility to disease.
Leucocyte FcgR belong to the Ig superfamily and fall into three main classes, with their genes
located on the long arm of chromosome 1 [89]. Each class is divided in subclasses: FcgRI
(CD64) in FcgRIa1, Ib1 and 2, and Ic; FcgRII (CD32) subdivided in FcgRIIa1 and 2, IIb1, 2,
and 3, and IIc; and FcgRIII (CD16) in FcgRIIIa and b. These FcgR are capable of initiating a
variety of cellular effector functions such as phagocytosis, antibody dependent cytotoxicity
(ADCC), superoxide generation, antigen presentation, cytokine release, cell degranulation,
and regulation of antibody production.
The three classes differ in their affinity for and interaction with IgG subclasses. FcgRIa is the
only high affinity receptor and binds monomeric IgG1, 3 and 4. FcgRII are low affinity
receptors, as is IIIb; FcgRIIIa is a medium affinity receptor. FcgRII and III interact mainly
with immune-complexed IgG. For the various leucocyte FcgR genetically determined
polymorphisms have been described.
In the FcgRIIa gene, a G to A single base pair substitution results in an arginine (R) or
histidine (H) residue at position 131 in the membrane proximal Ig-like domain, which affects
receptor affinity and specificity. FcgRIIa-H131 exhibits higher affinity for human IgG3 and
IgG1 and represents the sole leucocyte FcgR capable of interaction with IgG2. PMN from
FcgRIIa-R131 homozygous individuals phagocytose IgG2-opsonized particles far less
efficiently than PMN from FcgRIIa-H131 homozygous individuals [58;90;91]. FcgRIIIb
represents the most abundant FcR on neutrophils, and bears the neutrophil antigen (NA)
polymorphism [92] with the isoforms NA1 and NA2. FcgRIIIb-NA1 exhibits a higher affinity
for immune-complexed IgG3, and IgG1- and IgG3-opsonized particles are more efficiently
phagocytosed via FcgRIIIb-NA1 than via IIIb-NA2 [93;94].
It is convincingly shown that the FcgRIIa class is important in phagocytosis of encapsulated
bacteria [58;91]. Inefficient phagocytosis might increase the risk of infections by encapsulated
bacteria. Since IgG2 is important in host defence against encapsulated bacteria, and FcgRIIa-
H131 represents the sole leucocyte FcgR capable of efficient interaction with IgG2, FcgRIIa
polymorphisms should influence phagocytosis mediated by antibodies of the IgG2 isotype.
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Increased frequencies of meningococcal disease were indeed reported in late complement
component deficient patients with the combined FcgRIIa-R/R131 -FcgRIIIb-NA2/2 genotype
[95]; and the FcgRIIa-R131 allotype is associated with more serious disease in these patients
[96]. Skewed distribution of FcgRIIa genotypes are also found in survivors from fulminant
meningococcal septic shock [97], although another study found comparable distributions of
FcgRIIa, as well as FcgRIIIa and FcgRIIIb genotypes among meningococcal disease patients
and controls (Van de Pol, thesis, University Utrecht). In children, the combination of the
FcgRIIa-R131 allele with low IgG2 anti-pneumococcal antibody titers seems to constribute to
a higher risk for recurrence of bacterial respiratory tract infections [98].
Risk groups for infections with encapsulated bacteria
Effective removal of encapsulated bacteria by phagocytosis requires the presence of anti-
capsular polysaccharide antibodies, complement, a functional spleen and phagocytes.
Absence or impaired function of one or more of these elements leads to increased
susceptibility to disease. Groups at increased risk for infections with encapsulated bacteria
because of defective anti-polysaccharide antibodies are the following:
Infants and young children
As already discussed above, young children up to the age of 18-24 months have a deficient
anti-polysaccharide antibody response possibly related to reduced expression of CD21 on
marginal zone B cells. This unresponsiveness to polysaccharides results in a high
susceptibility for infections with encapsulated bacteria as soon as maternally derived
antibodies diminish.
Elderly
Adults above 65 years of age generally are more susceptible to infections than younger adults.
It is unclear whether the immune changes associated with aging are sufficient in themselves to
explain the higher susceptibility to infections, or whether age-related disease and its impact on
host resistance are more important in this process [99]. Elderly are, next to infants and young
children, an important group at increased risk for pneumococcal infections. Retrospective
studies have shown some clinical effectiveness [100] and cost-effectiveness [101] of
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vaccination with pneumococcal polysaccharides in preventing invasive pneumococcal disease
in otherwise healthy elderly, but efficacy in high-risk elderly is poor. For preventing
pneumococcal pneumonia, prospective studies have been disappointing [102] or inconclusive
[100]. It is questionable whether limited protective efficacy of vaccination is due to an
inadequate antibody response [103-105].
Selective IgA deficiency
Selective IgA deficiency, defined as an isolated absence or near absence (<0.02 g/l) of serum
and secretory IgA, is the most common immunodeficiency order, with an estimated frequency
of 1:700 in the Caucasian polpulation [106]. The clinical expression varies widely: both
healthy individuals and patients with serious recurrent infections may present with IgA
defciency. A significant proportion of patients show aberrant anti-polysaccharide antibody
responses. Although total serum IgG2 levels may be normal, antibodies are preferentially
expressed in the IgG1 and IgG3 subclasses, whereas in healthy individuals anti-
polysaccharide antibodies reside predominantly in the IgG2 subclass [107-109]. IgA deficient
patients with frequent pneumococcal infections failed to produce IgG2-type anti-
polysaccharide antibodies after vaccination [110;111]. The basic defect leading to IgA
deficiency is unknown. IgA deficiency and common variable immunodeficiency may be
based on the same underlying genetic defect. The susceptibility for these two defects may
reside in the MHC class III region on chromosome 6 [112].
IgG2 deficiency and other subclass deficiencies
Some individuals have partial or total deficiencies of one or more subclasses of IgG -defined
as serum levels below 2 SD of the age-adjusted mean- despite normal or even elevated total
serum IgG concentrations. Since the initial description of selective IgG subclass deficiency
[113], many reports have described IgG subclass deficiencies in patients with recurrent
respiratory tract infections [50;114;115]. Most often these reports concern correlations
between susceptibility to infections and IgG2 deficiency, but in adults also an isolated IgG1
deficiency can be found [116;117]. In literature, 35-40% of children who developed invasive
Hib disease after a single dose of conjugated Hib vaccine at the age of >15 months were
described to have subnormal concentrations of serum immunoglobulins. Specifically, a high
prevalence of subnormal concentrations of IgG2 was observed [118;119]. In a recent large series
of Hib conjugate vaccine failures, an immunological deficiency, most frequently a deficiency of
IgG2, was detected in 30% of children who were vaccinated before 12 months of age. Those
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children with IgG2 deficiency presented at younger age, and had lower convalescent-phase anti-
Hib antibody levels than those with normal IgG2 concentrations [7]. Reports on Hib
polysaccharide vaccine failures showed that almost all of these children had normal serum
concentrations of immunoglobulins, including IgG2 [119;120]. Since human antibodies to
polysaccharide antigens reside predominantly in the IgG2 subclass, it is suggested that
susceptibility to infections in patients with low levels of IgG2 is caused by a specific
deficiency in the antibody response to polysaccharides. However, it became evident that no
strict causal relationship exists between low serum IgG2 and susceptibility to infections with
encapsulated bacteria; and that other IgG subclasses, particularly IgG1, contribute
significantly to the antibody response to several polysaccharides [49;121-124]. In fact, people
who lack the IgG2 heavy chain gene but are completely healthy have been described
[125;126]. Furthermore, healthy adults [127] as well as healthy children [128], both with
subnormal IgG2 levels, but normal responses to PRP have been described. This is in contrast
with symptomatic children with low IgG2 levels who showed aberrant responses to PRP
polysaccharide vacccination [128]. It therefore appears that not the IgG subclass level as such,
but rather specific antibody deficiencies to polysaccharide antigens seem to be the hallmark
for increased infections with encapsulated bacteria.
Selective anti-polysaccharide antibody deficiency
Patients with frequently recurrent bacterial respiratory tract infections, especially otitis media,
may have a selective anti-polysaccharide antibody deficiency, despite normal serum
immunoglobulin and IgG subclass levels. Only few of these patients with selective anti-
polysaccharide antibody deficiency have invasive infections [129]. They respond normally to
protein antigens, but fail to mount adequate antibody responses to polysaccharides [130-136].
The unresponsiveness to polysaccharides, resembling the unresponsiveness to
polysaccharides in infants, can sometimes be overcome by polysaccharide conjugate vaccines
[115;129;132;137-139]. However, these patients may need repeated vaccinations, a
phenomenon also observed in infants under the age of 6 months [115;137]. The fact that the
unresponsiveness to polysaccharides can be overcome by vaccination with conjugate vaccines
indicates that precursor B cells should be present, and that the defect of B cell maturation




The occurrence of infections with encapsulated bacteria in patients with congenital
deficiencies of complement components has been well documented [140]. A clinical picture
of recurrent infections in patients with complement deficiencies is not unexpected, since the
importance of complement in the opsonophagocytosis of encapsulated bacteria. The
importance of C3 in the initiation of the anti-polysaccharide antibody response [73;77] is
underlined by a study in a group of patients with inherited deficiencies of complement
components: three of four patients with a homozygous C3 deficiency were almost totally
deficient in anti-polysaccharide antibodies, whereas other deficiencies of complement
components were not associated with reduced anti-polysaccharide antibody levels [141].
Functional or anatomical hypo/asplenia
The increased risk of overwhelming postsplenectomy infections (OPSI), most often caused by
S. pneumoniae, may be explained by the special role of the spleen in host defence against
encapsulated bacteria (see before). The combination of impaired initiation of antibody
responses to polysaccharide antigens (which takes place in the marginal zone of the spleen)
and decreased phagocytic function of the spleen may determine the susceptibility for
pneumococcal sepsis in persons with anatomic or functional asplenia.
Indications for performing splenectomy are traumatic injury of the spleen, staging of
Hodgkin’s disease and conditions in which excessive MPS activity of the spleen results in
depletion of thrombocytes (such as idiopathic thrombocytopenic purpura, ITP) or erythrocytes
(such as spherocytosis). The frequency of OPSI is dependent on age and the cause of
splenectomy [81-83;142-145].
Functional asplenia is most often related to sickle cell disease (SCD), but may also be found
in SLE. Before the use of penicillin prophylaxis and pneumococcal polysaccharide
vaccination, rates of invasive disease in children with SCD exceeded those in healthy children
20-100 fold, with the greatest risk in children younger than 5 years [146]. These high rates of
invasive pneumococcal disease are also found in children with congenital asplenia [147].
The phagocytic function of the spleen can not easily be restored, but protective antibody
levels may reduce the risk of infection and enable the liver to remove optimally opsonized
bacteriae. When elective splenectomy is scheduled, pneumococcal vaccine should be
administered at least two weeks before surgery. Persons with functional or anatomic asplenia
should also be vaccinated with pneumococcal vaccine [148]. Although the overall efficacy for
preventing infection caused by serotypes included in the vaccine was reported to be 77%
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(95% CI, 14% to 95%) among persons with anatomic asplenia [149], results on
immunogenicity in asplenic or hyposplenic patients are conflicting [150-153]. Pneumococcal
conjugate vaccines may be more effective than pneumoccocal polysaccharide vaccines in all
asplenic patients, not only in the children < 2 years of age [154], because antibody responses
to conjugate vaccines may be less dependent on a functional spleen [155-157].
Apart from vaccination, other methods of prevention could be used. Oral penicillin is
recommended for prevention of pneumococcal disease in children with functional or anatomic
asplenia [158]. Autotransplantation of splenic tissue after splenectomy may restore defects in
the immune response [159-165].
Wiskott-Aldrich Syndrome (WAS)
This X-linked recessive syndrome is characterized by severe trombocytopenia, atopic
dermatitis, and, with age, progressive defects in both cellular and humoral immunity. Patients
have an impaired humoral response to polysaccharide antigens, as evidenced by markedly
diminished isohaemagglutinins, and poor or absent antibody responses to polysaccharides
[166]. Consequently, they have increased susceptibility for infections with encapsulated
bacteria. Later, gradual deterioration of T cell function affects the antibody response to TD
antigens as well.The abnormal gene, located on the proximal arm of the X-chromosome,
encodes for the WAS-protein (WASP), an important regulator of lymphocyte and platelet
function [167].
Ataxia-telangiectasia
Ataxia-telangiectasia (A-T) is a complex syndrome with neurologic, imunologic,
endrocrinologic, hepatic and cutaneous abnormalities. Recurrent, usually bacterial sino-
pulmonary infections occur in roughly 80% of the patients. Cells from patients as well as
those of heterozygous carriers have increased sensitivity to ionizing radiation, defective
DNA-repair and frequent chromosomal abnormalities. The sites of chromosomal breakages
may involve the genes that code for the T cell receptor and/or immunoglobulin heavy chains,
probably accounting for the combined T- and B cell abnormalities. The most frequent
humoral abnormality is selective IgA deficiency; IgG2 or total IgG may also be decreased.
Anti-polysaccharide antibody production has been shown to be impaired [168]. The gene




The risk for infections with encapsulated bacteria will also be high for persons with a
decreasing function of the immune system, including deterioration of the responsiveness to
polysaccharide antigens, or for patients with an increased rate of decline in serum antibody
concentrations as a result of: a) acquired immunodeficiency as e.g. infection with
immunodeficiency virus (HIV) [171], and conditions as leukemia, lymphoma, multiple
myeloma, or Hodgkins disease [172;173]; b) organ or bone marrow transplantation; c)
therapy with alkylating agents, antimetabolites, or systemic corticosteroids [174]; or d)
chronic renal failure or nephrotic syndrome [175;176].
Prevention of disease caused by encapsulated bacteria by vaccination
The aim of vaccination against encapsulated bacteria is to prevent disease caused by these
bacteria. Since antibodies to their capsular polysaccharides play a crucial role in the defence,
induction of protective levels of these antibodies should be achieved.
Polysaccharide vaccines
Pneumococcal, meningococcal and H. influenzae type b polysaccharide vaccines can
effectively induce anti-polysaccharide antibodies, and confer protection to disease in those
individuals able to respond to polysaccharide antigens [38;177-183].
Prevention of pneumococcal pneumonia by vaccination with heat-killed bacteria has been
undertaken initially by Wright in goldminers in South Africa [184], resulting in a 50%
reduction in mortality. In the period following, capsular polysaccharide vaccines have been
developed [39], resulting in the 23-valent PS vaccine that is licensed for use in persons above
2 years of age since 1983. This pneumococcal polysaccharide vaccine contains 25 mg of
purified capsular polysaccharides of each of the pneumococcal serotypes 1, 2, 3, 4, 5, 6B, 7F,
8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F. Based on US
surveillance data on respiratory tract and invasive pneumococcal isolates, these 23 capsular
polysaccharide antigens provide potential serotype-specific protection against at least 75% of
pneumococcal infections and potential serogroup cross-protection against an additional 14%
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of isolates. Thus, these vaccines provide potential protection against 85% to 90% of invasive
and respiratory infections caused by pneumococci [34;185].
Most pneumococcal polysaccharide-based vaccines induce protective immunity in adults and
children above the age of 2 years. The antibody response to most pneumococcal serotypes is
poor or inconsistent in children less than 2 years of age. Age-specific immune responses vary
by serotype, and the response to some common ‘pediatric’ pneumococcal serotypes (e.g. 6A
and 14) also is decreased in children aged 2-5 years [42;44;186].
Anti-pneumococcal antibody responses do occur in the elderly, in persons who have alcoholic
liver cirrhosis, COPD, and insulin-dependent diabetes mellitus [100;105;175], although
responses may be lower than those obtained after polysaccharide vaccination of young adults.
Immunocompromised patients, and those with a variety of clinical conditions, form a group at
increased risk of disease and most in need of protection. However, these patients often fail to
mount an adequate antibody response upon polysaccharide vaccination.
Despite suboptimal immunogenicity, effectiveness of pneumococcal polysaccharide vaccines
in protecting against invasive disease generally has ranged from 56%-81% in case-control
studies [149;187] in groups for which pneumococcal polysaccharide vaccination is currently
recommended in the USA [148]. Efficacy may be lower in high-risk, immunocompromised
populations [188].
Consideration of active immunization against Hib has been prompted by the frequency of
diseases produced by this pathogen, the high incidence of morbidity associated with Hib
meningitis [189], the significant mortality despite the availability of effective antibiotics [190]
and the emergence of resistence to ampicillin, the usual antibiotic of choice for therapy of Hib
infections [191]. H. influenzae type b polysaccharide vaccine was found to be 80% effective
in preventing invasive type b disease in children 24-35 months old, but it was ineffective in
children < 18 months of age, the group most susceptible to H. influenzae type b disease.
Efficacy was uncertain in children 18-23 months of age [38;182].
Polysaccharide protein conjugate vaccines
Vaccination with purified capsular polysaccharides has been only partially successfull [192],
since they do not reliably induce protective antibody responses in children younger than 2
years, the age group that shows the highest incidence of invasive infections with encapsulated
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bacteria. In addition, polysaccharide vaccine appears to confer only limited protection to
patients with underlying illnesses such as immunodeficiencies and hematologic malignancies,
and may not be effective against poorly immunogenic capsular types.
The immunogenicity of polysaccharides can be increased by covalent linking to a carrier
protein [193]. This approach is thought to work through recruitment of T cell help. The exact
mechanism of recruitment of T helper cells, and the specificity of these cells, remains a matter
of debate. The prevailing model is depicted in Figure 2. B cells with a B receptor complex
specific for the polysaccharide bind the covalent complex, internalize it, and process the
protein part into peptides. These peptides (T cell epitopes) are then presented, in the context
of class II major histocompatibility complex (MCH) molecules, to helper T cells bearing
specific T cell receptors (TCR). The activated helper T cells in turn stimulate B cell
proliferation and differentiation into antibody-secreting cells and/or into memory cells [194-
196].
Figure 2. B cell activation by polysaccharide protein conjugate
Conjugate vaccines of capsular polysaccharides have been prepared from H. influenzae type
b, S. pneumoniae, N. meningitidis and group B Streptococcus as well as from several other
bacterial species [197;198]. The anti-polysaccharide antibody response to these
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polysaccharide-protein conjugate vaccines bears the characteristics of a TD antibody
response: onset of responsiveness early in life and induction of memory.
H. influenzae type b conjugate vaccines have been successful examples of this appoach.
Conjugate vaccines, developed by coupling PRP to different carrier proteins, have proved to
be immunogenic in infants, children and adults [197;199-201]. Since their introduction in
childhood immunization schemes in several countries, the incidence of invasive Hib disease
in these countries has dropped dramatically [202-204].
A very important finding is that immunization with Hib conjugates has effect on the
oropharyngeal carriage of Hib. This is in contrast to what has been found with the PRP
polysaccharide vaccine which has no effect on the carriage rate of Hib [38;205]. All available
Hib conjugate vaccines have now been shown to reduce the carriage rate of Hib in a
vaccinated population [205-209]. The importance of this finding lies in its implications for the
transmission of the bacteria. The fewer the number of carriers, the fewer are the chances of
spread of the infection. This situation could lead to herd immunity -also protecting those not
vaccinated- and to eventual eradication of the disease.
Pneumococcal conjugate vaccines are developed to prevent invasive as well as mucosal
infections. The initial strategy has been to design a vaccine containing about seven of the
epidemiologically most important serotypes. These include types 4, 6B, 9V, 14, 18C, 19F,
and 23F, which together account for 52-81 % of the pneumococci causing invasive infections
in children [34], and 58% of those causing acute otitis media (AOM). In the 9-valent vaccine
serotypes 1 and 5 are added, and the 11-valent vaccines includes also serotypes 3 and 7V.
Addition of these 4 serotypes to the 7-valent vaccine increases the coverage to 73 to 92% of
invasive infections [210]. From a manufacturing point of view, preparation of this multivalent
vaccine poses formidable challenges, since at least seven separate vaccines must be produced,
controlled and combined in appropriate concentrations.
Safety and immunogenicity of candidate vaccines have been demonstrated in healthy adults
[211;212], and in children and infants [213-215]. A three dose series is usually administered
in infants, starting at two months of age, with doses 2 months apart. Potential target groups
for conjugate vaccines are, in addition to infants and young children, several risk groups
where the immunogenicity of polysaccharide vaccines is less than optimal. These include
various groups of immunocompromised patients as well as elderly. In these groups conjugate
vaccines seem able to induce a modest or good antibody response [154;173;211;216;217].
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Pneumococcal conjugate vaccine has also been demonstrated to be capable of inducing
antibody responses in patients with recurrent infections who had failed to mount an adequate
response to the polysaccharide vaccine [139]. In addition to immunogenicity in groups not
generally responding to pneumococcal polysaccharide vaccines, another important
characteristic of pneumococcal conjugate vaccine is its ability to induce immunologic
memory [214;218-221].
A recent clinical trial of the heptavalent CRM197 pneumococcal conjugate vaccines shows
that this vaccine is highly effective (efficacy in intention-to-treat analysis 93.9%, 95%
confidence interval 82.7-99.9%) in preventing invasive disease caused by isolates of the
vaccine serotypes [222]. No increase of disease caused by non-vaccine serotypes was
observed. The pneumococcal conjugate vaccine had little impact on otitis media irrespective
of etiology; in analysis of spontaneous draining ears, serotype-specific effectiveness was
66.7% [222]. In a Finnish trial an estimated vaccine efficacy of 57% (95% CI 44%-67%)
against culture-confirmed AOM caused by vaccine serotypes was found. Efficacy against
AOM irrespective of etiology was 6% (95% CI 14%-16%) [223]. In the Netherlands, a trial
measuring the efficacy of the 7-valent CRM197 pneumococcal conjugate vaccine followed by
booster vaccination with the 23valent polysaccharide vaccine in children with recurrent otitis
media acuta (OMAVAX) is currently ongoing.
Unlike pneumococcal polysaccharide vaccines, pneumococcal conjugate vaccines affect the
prevalence of nasopharyngeal carriage [224;225]: the prevalence of nasopharyngeal carriage
of pneumococci of the vaccine serotypes decreases [226]. Potential positive consequences
may include induction of herd immunity. A ‘new’ role may be to reduce carriage and spread
of disease caused by antibiotic resistant pneumococci [227], since pneumococcal conjugate
vaccines include most of the serotypes associated with increasing antimicrobial resistance -i.e
the serotypes 6B, 9V,14, 19A, 19F and 23F [228], of which only 19A is not included in the
heptavalent pneumococcal vaccine. A negative effect of widespread vaccination may be





Several approaches have been used to determine the protective concentration of anti-
polysaccharide antibodies [230]. Since invasive H. influenzae type b disease is extremely rare
in adults, and in adult sera anti-PRP concentrations are all > 0.15 mg/ml, this level is
considered to be protective [231]. The anti-PRP antibody concentrations in infants offer an
other possibility to estimate protective antibody concentrations. Maternally transferred
antibodies decline with time. The concentration at the age when invasive H. influenzae
disease starts to appear would indicate the level required for protection. A more direct
approach is to determine the serum anti-PRP concentration of passively given antibodies
which is needed for protection [131;232]. The latter type of study led to an estimated
concentration of 0.05-0.15 mg/ml specific antibody needed for protection. Analysis of
protection afforded by Hib polysaccharide vaccine learned that post-immunization titers of 1
mg/ml predicted protection over the following year [233].
All these estimates for protective antibody levels are based on the assumption that protection
from invasive Hib disease is mediated solely by serum antibodies and the role of cell-
mediated immunity is negligible. This assumption was justified since Hib polysaccharide is a
T cell independent antigen. But this matter becomes quite different when the character of the
polysaccharide vaccine is altered by conjugating it to a protein carrier and the immunological
memory plays a role in protection. The requirement for existing antibodies for protection may
be less, since the immunized infants are thought to be able to respond with a rapid and high
antibody response after exposure to the bacterium, even at an age when encapsulated bacteria
would normally not be able to evoke any immune response. After vaccination with Hib
conjugate, high antibody concentrations have been found in sera of children colonized by H.
influenzae type b [206]. Booster responses after Hib conjugate vaccination can even be
demonstrated in infants who did not show a detectable antibody response to the first
vaccination [202]. So after immunization with conjugate vaccines, protection can be seen at
lower serum antibody concentrations than after polysaccharide vaccine.
The protective concentration of anti-pneumococcal polysaccharide antibodies is not known. It
may be not the same for different clinical entities and/or for different pneumococcal
serotypes. A protective level against invasive infections of adults, 200-300 ng ab N/ml has
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been suggested [234]. Antibody concentrations > 0.15 mg/ml and >1.0 mg/ml are assumed to
be required for short-term and long-term protection, respectively [235]. These antibody levels
are extrapolated from studies of protection against Hib [232;233;236]. It has been shown that
anti-pneumococcal polysaccharide concentrations of > 1.0 mg/ml could be protective in
chinchillas [237] and mice [238]. Infant rats could be protected from bacteraemia and death
by 0.1-1.15 mg/ml (depending on serotype) passively acquired anti-pneumococcal antibodies
[239], and infant mice could be protected from bacteraemia by 0.05->0.4 mg/ml specific
antibodies [240].
Evaluation of the immunogenicity of the newly developed pneumococcal conjugate vaccines
is usually based on the measurement of serum antibody concentrations, measured by enzyme
immunoassay. It needs to be emphasized that estimates for protective antibody levels are
based on the assumption that protection from disease is mediated solely by serum antibodies.
After immunization with pneumococcal conjugate vaccines, immunological memory plays a
role in protection, and protection can be expected at lower serum antibody concentrations than
after pneumococcal polysaccharide vaccination.
Furthermore, qualitive characteristics of antibodies may be at least as important as the
antibody concentration [241-243]. Opsonophagocytic activity and relative avidity of
anticapsular antibodies both are believed to measure their functional activity [238;240;244].
Notable increases in opsonophagocytic activity are induced by conjugate vaccines in adults
and infants [245]. Different conjugates induce antibodies of different avidities [246], and
avidity further increases after boosting with conjugate, but not with polysaccharide vaccine
[247]. Pneumococcal conjugates thus are able to induce functionally active antibodies. An




Aim and Outline of this Thesis
Capsular polysaccharides of encapsulated bacteria such as Streptococcus pneumoniae and
Haemophilus influenzae type b are of major fundamental and applied interest. Anti-
polysaccharide antibodies confer clinical protection against infections caused by encapsulated
bacteria. A characteristic feature of the immune response to polysaccharides is the late onset
of responsiveness in ontogeny. Infants and young children are therefore particularly at risk for
infections with these bacteria, and prevention of disease by vaccination with capsular
polysaccharides is ineffective in this age group. Polysaccharide vaccines are also
suboptimally immunogenic in several other groups at risk for infections with encapsulated
bacteria. Because of this limited use of polysaccharide vaccines, polysaccharide-protein
conjugate vaccines have been developed. Clinical and epidemiological data indicate that this
conjugation of polysaccharides to protein carriers results in conjugate vaccines that induce
protective immunity in risk groups otherwise not covered by polysaccharide vaccines. The
way the immune system handles and reacts to polysaccharide conjugate vaccines is as yet
incompletely understood. This thesis applies an in vivo rat model to address this issue with the
aim to extrapolate the results to the clinical setting.
In addition the immune response to pneumococcal and Haemophilus influenzae type b
conjugate vaccine was studied in selected patients groups with the aim to contribute to the
development of new vaccination strategies to encapsulated bacteria.
Chapter 1 reviews the importance of anti-capsular polysaccharide antibodies in host defence
against encapsulated bacteria, including the immunobiology of the anti-polysaccharide
antibody response. The initiation of the antibody response to polysaccharides is assumed to
take place in the marginal zone of the spleen. Polysaccharides activate and bind complement
component C3d, and localize on splenic marginal zone B cells, specialized cells expressing
high levels of complement receptor 2 (CD21) on their surface. Activation of polysaccharide-
specific B cells is achieved by signaling via CD21-C3d interaction in combination with cross-
linking of B cell receptors by the polysaccharide. The mechanism of co-ligation of mIg and
CD21 may account for the fact that antigen-specific T cells are not strictly required for induction
of an anti-polysaccharide B cell response.
We hypothezised that the initiation of the anti-polysaccharide antibody response by conjugate
vaccines could be independent of signaling via CD21-C3d interaction. We addressed this
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hypothesis in chapter 2. In a rat model we studied the influence of complement depletion on
localization of pneumococcal polysaccharide and conjugate vaccines, and on the induction of
antibody responses.
Extending the hypothesis that initiation of the anti-polysaccharide antibody response might be
independent of CD21-C3d interaction, we reasoned that the antibody response to conjugate
vaccines might even be spleen- independent. In chapter 3 we studied, in the same rat model,
the effect of splenectomy on the antibody response to pneumococcal polysaccharide- and
conjugate vaccines. In order to achieve adequate antibody responses to as many serotypes as
possible –and not only to serotypes present in the conjugate vaccine-, we studied different
vaccination regimes, the effect of admixture of polysaccharides with the conjugate vaccine
and booster vaccination with polysaccharides after primary vaccination with the conjugate.
As mentioned earlier, the mechanism by which conjugate vaccines induce T and B lymphocyte
activation, still remains a matter of debate. In chapter 4 we investigated the cellular interactions
between B and T cells which could determine the magnitude and nature of the anti-
polysaccharide antibody response.
Polyvalent pneumococcal polysaccharide vaccines normally induce IgM, IgG1, IgG2 and IgA
type antibodies, of which especially in adults and older children IgG2 is the predominant isotype.
The inability to produce IgG2- and IgA-type anti-pneumococcal polysaccharide antibodies
appears to define a clinical entity of high susceptibility for mucosal infections with bacteria like
S. pneumoniae. Pneumococcal conjugate vaccines induce primarily an IgG1 type anti-
polysaccharide antibody response. It remains to be determined whether IgG1 type antibodies
only will be sufficient to prevent mucosal infections like acute otitis media. The induction of
IgG2 or IgA anti-pneumococcal polysaccharide antibodies may be necessary for optimal
protection against mucosal respiratory tract infections. We hypothesized that priming with a
conjugate vaccine, followed by vaccination with a pneumococcal polysaccharide vaccine might
induce an increased IgG antibody response and favors a shift towards an IgG2 type antibody
response. In chapter 5a we present the results of a study in five otitis-prone children vaccinated
with a pneumococcal conjugate vaccine, followed by booster vaccination with a pneumococcal
polysaccharide vaccine. In chapter 5b, we describe antibody responses obtained with this




The ultimate parameter for evaluation of vaccine efficacy is the incidence of disease in the
vaccinated group versus that in the nonvaccinated group. Since opsonophagocytosis is the crucial
defence mechanism against encapsulated bacteria, functional antibody levels measured by
phagocytosis assay employing human PMN may be used as correlates for protection. PMN
constitutively express two different receptors for IgG: FcgRIIa and FcgRIIIb. These receptors
show two genetically determined polymorphisms: the biallelic FcgRIIa-R131 and -H131
polymorphism, and the NA1/NA2 FcgIIIb polymorphism. In humans, only FcgRIIa-H131 can
efficiently interact with IgG2. Pneumococcal conjugate vaccines induce good antibody
responses, residing predominantly in the IgG1 subclass. Since only the FcgRIIa-H131 can
efficiently interact with IgG2, Fcg-receptor polymorphisms should mainly influence
phagocytosis mediated by antibodies of the IgG2 isotype. Therefore, in chapter 6 we studied
whether PMN Fcg-receptor polymorphism has an effect on in vitro phagocytosis of S.
pneumoniae mediated by antibodies induced by a pneumococcal conjugate vaccine.
The introduction of H. influenzae type b conjugate vaccines in childhood vaccination
programs has resulted in a dramatic reduction in invasive Hib infections. Despite this success,
H. influenzae type b conjugate vaccine failures are occasionally reported. In chapter 7a we
evaluated the H. influenzae type b conjugate vaccine failures reported in the Netherlands. In
chapter 7b we studied whether quantitative or qualitative (avidity) defects exist in anti-H.
influenzae type b antibodies in patients with H. influenzae type b conjugate vaccine failures.
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The antibody response to polysaccharides is evoked when polysaccharides bind complement
factor C3d, and these polysaccharide-C3d complexes subsequently localize on splenic
marginal zone B cells strongly expressing CD21 (complement receptor 2). Infants and
children under the age of two years express only low levels of CD21 on their marginal zone B
cells, and consequently do not adequately respond to polysaccharides. However,
polysaccharide-protein conjugate vaccines are able to induce antibodies at this young age.
Conjugate vaccines apparently overcome the necessity for CD21-C3d interaction for an anti-
polysaccharide antibody response.
We demonstrate in a rat model that splenic localization of pneumococcal polysaccharides
indeed is complement-dependent, and that the antibody response to pneumococcal
polysaccharides is impaired after complement-depletion. We show that pneumococcal
conjugates are able to initiate antibody responses without depending on the presence of
complement. Furthermore, polysaccharide conjugates do not specifically localize on splenic
marginal zone B cells. Thus, the induction of anti-polysaccharide antibodies by conjugate
vaccines apparently can occur independently of CD21-C3d interaction. These basic findings
may explain their effectiveness in young children, and may open the way for application of
conjugated vaccines in patient groups.
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Introduction
Antibodies directed to capsular polysaccharides are essential in the defense against infections
with encapsulated bacteria such as Streptococcus pneumoniae. In infants and young children,
the antibody response to polysaccharides is inadequate, resulting in increased incidence of
disease caused by encapsulated bacteria.
Polysaccharide molecules are made up of a number of repeating epitopes. As a consequence,
soluble polysaccharides have the capacity to cross-link antigen receptors on the surface of B
cells. Furthermore, polysaccharides can activate the complement system via the alternative
pathway, without the need for anti-polysaccharide antibodies [1]. Complement fragment C3d,
that is generated during this process, is bound by the polysaccharide molecules to form
polysaccharide-complement complexes [2]. These polysaccharide-C3d complexes are better
in vitro immunogens than native polysaccharides [3]. They have the ability to bind to B cells
via interaction of C3d with CD21 (complement receptor 2, CR2) [4]. The co-ligation of CD21
and antigen receptors may account for the fact that the antibody response to polysaccharides
(so-called T cell independent type 2 (TI-2) antigens [5]) can occur in the absence of a
functional thymus, although T cells can augment antibody production [6-8].
Splenic marginal zone B cells express the CD21 surface molecule in particularly high density,
and blood flow in the marginal zone is low. These two characteristics enable polysaccharide-
complement complexes to localize in the marginal zone by interaction of the complement
fragment C3d with CR2 on B cells [9-12], providing maximum opportunity for induction of a
humoral immune response [13;14]. The marginal zone of the spleen is thus a major site of
initiation of the anti-polysaccharide antibody response.
Infants and young children do not yet express high levels of CD21 on their splenic marginal
zone B cells, which explains their inability to respond to polysaccharide antigens [10].
Covalent conjugation of the polysaccharides to protein carriers overcomes this anti-
polysaccharide unresponsiveness in early life [15;16]. This suggests that conjugates might
initiate the anti-polysaccharide antibody response in a way that is not dependent on




The importance of marginal zone B cells, complement receptors, and complement in the
antibody response to a synthetic TI-2 antigen is shown in recent studies in C3-/-, CRI/II-/-, and
Pyk2-/- mice [17]. No such data exist for the antibody response to natural TI-2 antigens like
bacterial capsular polysaccharides, nor is it known whether presence of complement and
localization on marginal zone B cells is important for induction of antibody responses to
polysaccharides conjugated to proteins.
We studied the effect of complement depletion on the antibody response to pneumococcal
polysaccharide- and conjugate-vaccines in a previously described rat model, in which the in
vitro complement dependency of pneumococcal polysaccharide localization on splenic
marginal zone B cells was already shown [13].
Experimental Procedures
Animals, immunization, blood drawing and tissue preparation
Young adult male Wistar rats (Harlan, Horst, the Netherlands), of approximately 200 g, were
housed under standard laboratory conditions on a 12 h light-dark cycle. They were fed
standard laboratory rat food (Hope Farms, Inc., Woerden, the Netherlands) and tap water ad
libitum. The rats were immunized intravenously (i.v.) in the tail vein with either one of the
vaccines described below.
For serological studies, five rats per group were used. 1, 3, 6, 8, 14 and 21 days after
intravenous immunization, blood was obtained from the tail vein, and allowed to clot at 0ºC.
All rats were individually marked, so antibody titers could be analyzed separately for each rat,
and thus followed over time.
For pneumococcal polysaccharide localization studies and antigen detection in serum, at least
three rats per group were used. Rats were sacrificed at 15 minutes, 7 hours, and 5 days after
vaccination (the timepoints were based on previous experience [13]). Blood was drawn by
cardiac puncture and allowed to clot at 0ºC. Tissue blocks of spleen and liver were
immediately frozen by immersion in liquid 2-methylbutane (cooled in a freezer to -80ºC). The
tissue blocks were stored in a freezer at -80ºC until sectioned.
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In vivo complement inactivation.
Decomplementation was performed by i.v. injection of 1200 U of CVF, isolated as described
[18] in 200 µl of NaCl 0.9%. CVF-treatment was given 24 and 18 hours before immunization
and, when prolonged complement depletion was required -for serological studies- also 1, 3, 6
and 8 days after immunization.
Vaccines
For serological studies, the following vaccines were used:
1) A heptavalent PCV (Prevnar®; Wyeth Lederle Vaccines and Pediatrics, Rochester, NY)
including polysaccharides of pneumococcal serotypes 4, 6B, 9V, 14, 19F and 23F and an
oligosaccharide of serotype 18C, conjugated to CRM197 carrier protein. Each dose PCV
contains 2 µg polysaccharides of serotypes 4, 9V, 14, 18C, 19F and 23F, and 4 µg of serotype
6B in 0.5 mL aluminum phosphate reconstitution fluid.
2) As unconjugated equivalent of this vaccine, pneumococcal polysaccharide serotypes 4, 6B,
9V, 14, 18C, 19F and 23F (PPS, American Type Culture Collection, Rockville, MD) were
used. Each dose contained 20 µg of each of the pneumococcal polysaccharides type 4, 6B,
9V, 14, 18C, 19F and 23F in 0.5 mL saline.
For pneumococcal polysaccharide localization studies we used:
3) heptavalent PCV
4) an equivalent dose (2 µg per serotype) of the corresponding unconjugated polysaccharide
serotypes 4, 6B, 9V, 14, 18C, 19F and 23F
5) a ten-fold higher dose of one pneumococcal polysaccharide serotype (20 µg of PS19F)
Measurement of serum complement activity
Efficiency of decomplementation was assessed by a hemolytic assay of the classical
complement pathway employing sensitized sheep erythrocytes. Clotting of serum was allowed
to take place at 0°C to minimize complement activation. Inactivation of complement was
performed by heating rat serum at 56ºC for 30 min. 1:10 dilutions of the rat sera were
incubated with sensitized sheep erythrocytes for 30 mins at 37ºC. The OD at 405 nm of the
supernatant was used as a measure of complement activity. To correct for possible hemolysed
serum (resulting from the blooddrawing procedure) OD values resulting from incubation of
heat-inactivated serum with sensitized sheep erythrocytes were subtracted.
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Immunohistochemical detection of in vivo-administered PPS and PCV.
Sections (4 µm) of spleen and liver tissue were prepared, air dried for 20 min, fixed for 10
min in acetone (100%), air dried, washed in PBS (pH 7.4) for 5 min, incubated with a type-
specific polyclonal rabbit anti-PPS antibody (State Serum Institute, Copenhagen, Denmark) in
PBS. Endogeneous peroxidase activity was blocked with 0.075% (vol/vol) H2O2. Sections
were next incubated with peroxidase-conjugated swine anti-rabbit immunoglobulin (SARPER,
Dakopatts, Glostrup, Denmark). Peroxidase activity was visualized by using 3-amino-9-
ethylcarbazole plus H2O2 as a reagent. Finally, sections were counterstained in Mayer's
hematoxylin and embedded in Kaiser's glycerin-gelatin.
Detection of in vivo-administered PPS and PCV simultaneously with
immunohistochemical characterization of splenic cells.
For the simultaneous detection of PPS and immunohistochemical characterization of splenic
cells, sections were incubated with a type-specific polyclonal rabbit anti-PPS antibody (State
Serum Institute, Copenhagen, Denmark) in PBS and stained with SARPER as described above.
The sections were next incubated with a given monoclonal antibody (MoAb, Table 1) and
subsequently with an alkaline phosphatase-conjugated goat anti-mouse immunoglobulin
(Dakopatts). Alkaline phosphatase activity was visualized with naphthol AS-MX phosphate as
a substrate (Sigma Chemical Co., St. Louis, MO) and fast blue BB as a chromogen;
peroxidase activity was visualized by the 3-amino-9-ethylcarbazole reaction. Finally, sections
were embedded in Kaiser's glycerin-gelatin.
The following MoAbs were used for immunohistochemistry: ED1 and ED3 [19](Serotec Ltd,
Oxford, UK); T cell receptor (TCR) (Pharmingen, San Diego, CA, USA) and CD45R [20;21],
IgM, IgD, and HIS57 [22] (Table 1).
MoAb Clone Reactivity Reference
IgM HIS40 Immunoglobulin M, B cells [22]
IgD MaRD3 Immunoglobulin D, B cells [22]
CD68 ED1 Macrophages [19]
ED3 ED3 Marginal metallophilic macrophages [19]
TCR R73 ab T cell receptor [27]
HIS57 HIS57 Marginal zone B cells [22]
CD45R HIS24 B cells, leukocyte common antigen [20;21]
Table 1: Reactivity of monoclonal antibodies (MoAb) used.
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Detection of pneumococcal polysaccharide serotype 19F in rat serum
10µL of rat serum samples were spotted onto nitrocellulose filters (BioRad Trans-Blot, 0.45
µm) and dried at 37°C. Pre-incubation with blocking buffer (0.1 M Tris HCl, pH 7.5; 2.5%
milk powder; and Tween-20 0.05% vol/vol in 0.9% NaCl) for 30 min at room temperature
was followed by incubation with rabbit anti-PPS19F (State Serum Institute, Copenhagen,
Denmark) 1:10,000 in blocking buffer for 90 min at room temperature. After washing (0.1 M
Tris HCl, pH 7.5; Tween-20 0.05% vol/vol in 0.9% NaCl), the nitrocellulose filters were
incubated with peroxidase-labelled donkey anti-rabbit antibodies (Amersham NA934)
1:10,000 in blocking buffer for 60 min at room temperature. After treatment with ECLTM
(Amersham Pharmacia) for 1 min, a photofilm was developed for 1 min. 1:10 dilutions of PPS
19F (ATCC), starting concentration 10 µg/ml ) in 0.9% NaCl were used as a standard. This
assay has a sensitivity of detecting 0.1 µg/ml polysaccharide.
Anti-pneumococcal antibody determination by ELISA.
IgG- and IgM- antibodies against three (PS6B, PS19F and PS14) of the seven capsular
polysaccharide serotypes present in both vaccines were measured by ELISA in pre- and post-
immunization sera.
All serum samples were preincubated overnight with excess free common cell wall
polysaccharide (CPS) to remove anti-CPS antibodies [23;24]. Microtiter plates (Greiner
Labortechnik, Langerthal, Germany) were coated with pneumococcal capsular
polysaccharides (ATCC, 10 µg/ml in saline solution) at 37°C, overnight. Subsequently, plates
were washed with phosphate buffered saline (PBS), Tween-20 0.05% vol/vol and incubated
with serial dilutions of serum samples in PBS, 0.05% Tween-20, 1% bovine serum albumin
(BSA, vol/vol). After washing (PBS-0.05 % Tween-20), the plates were incubated for two
hours (37°C) with peroxidase labelled goat anti-rat IgM (Santa Cruz Biotechnology, Inc.) or
goat anti-rat IgG antibodies (Southern Biotechnology Associates, Birmingham, AL). After
washing and incubation with enzyme substrate for 20 min at room temperature, absorbance
was read at 450 nm on a Milennia ELISA reader (Flow Laboratories, Irvine, CA). The
antibody concentrations in the serum samples were calculated by comparison with a rat
hyperimmune serum pool generated from sera of both PCV and PPS vaccinated rats; this
hyperimmune serum pool was included in every ELISA-run as a standard. The antibody




Serum samples obtained pre-vaccination and at the different time points post-vaccination
from individual rats were analyzed simultaneously.
Statistical Analysis
Anti-pneumococcal antibody concentrations from rats of the different vaccine groups (having
received either the non-conjugated PPS vaccine or the 7-valent PCV, with or without CVF
treatment, 5 rats per group) were analyzed and compared for statistically significant
differences by repeated measurement analysis using the General Linear Model procedure of
the statistical package SPSS version 9.0 (SPSS Inc., Chicago, IL).
OD values as measure of serum-complement activity were compared for significant
differences between treated and untreated groups of rats at different time-points after CVF-
treatment by using the Mann-Whitney U test. P-values <0.05 were considered significant.
Results
Complement depletion by cobra venom factor
In vivo complement depletion was induced by cobra venom factor (CVF) administration. The
efficiency of complement depletion was assessed by a hemolytic complement assay.
Figure 1. Complement activity in rat serum
Rats were treated with 1200 U cobra venom factor (CVF) at T= -24 h, -18 h, and T= 1, 3, 6, and 8 days. Degree
of lysis of sensitized sheep erythrocytes by rat serum, expressed as OD, was used as a measure of complement-
activity.
Open symbols: CVF-treated animals; closed symbols: non-treated animals. Each data-point represents the mean
± SD of five animals. Statistically significant differences are indicated (*).
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The relative complement activity in serum decreased immediately after the first two injections
with CVF. By a regimen of alternate day CVF injections, significantly lower complement
activity as compared with control rats could be maintained for approximately 8 days. Despite
ongoing treatment with CVF, complement activity in serum from CVF-treated rats was
completely recovered after 14 days (Figure 1). CVF-treatment did not affect the overall
histological architecture of the spleen, nor did it alter the distribution of lymphocyte and
macrophage subpopulations in the spleen.
Splenic localization of pneumococcal polysaccharides
Control rats and CVF-treated rats were i.v. immunized with a mixture of serotype 4, 6B, 9V,
14, 18C, 19F and 23F pneumococcal polysaccharides (PPS). The in vivo splenic localization
of pneumococcal polysaccharides in control rats was similar as described earlier [13]. Fifteen
minutes after vaccination, PS19F was detected in the splenic marginal zone (Figure 2a). This
marginal zone localization decreased in time and was followed by increased localization in
the primary follicle corona (Figure 2b) at 7 hours after injection. After 5 days,
polysaccharides were predominantly localized in the border of the lymphocyte corona and the
germinal centers (Figure 2c).
Figure 2.
Splenic localization of pneumococcal polysaccharide 19F after pneumococcal polysaccharide vaccination
2 mg of the pneumococcal polysaccharides (PPS) 4, 6B, 9V, 14, 18C, 19F and 23F were injected i.v. in control
rats (panels a-c). Spleens were removed 15 minutes (a), 7 hours (b) and 5 days (c) after i.v. injection.
Peumococcal polysaccharides were detected immunohistochemically on 4  mm cryostat sections, using serotype
19F-specific polyclonal rabbit antiserum followed by a peroxidase reaction (brown). Original magnification 10x.
For pneumococcal polysaccharides of serotypes 4, 6B, 9V and 23F, a similar localization
pattern was observed, while PS14 did not localize in the spleen (data not shown). In
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complement-depleted rats, PPS were undetectable in the spleen at all three time-points. We
therefore repeated the localization experiments with a ten-fold higher dose (20 µg) PS19F
(Figure 3). Even with this dose, no splenic localization was observed after CVF-treatment
(Figure 3c).
Figure 3.(left hand side)
Complement dependency of splenic localization of
pneumococcal polysaccharide 19F after pneumococcal
polyssacharide and conjugate vaccination
20 mg of PS 19F was injected i.v. in control (panel a) and
in CVF-treated (panel c) rats. A heptavalent pneumococcal
conjugate vaccine (PCV, containing 2 mg of the
pneumococcal serotypes 4, 9V, 14, 18C, 19F and 23F and
4 mg of serotype 6B) was injected i.v. in control rats (panel
b) and in CVF-treated rats (panel d). Spleens were
removed 15 minutes after i.v. injection. Peumococcal
polysaccharide was detected immunohistochemically on 4
mm cryostat sections, using serotype 19F-specific
polyclonal rabbit antiserum followed by a peroxidase
reaction (brown). Insets show transition from marginal
zone (upper part) to germinal center (lower part). Original
magnification 10x; inset 25x.
Figure 4. (right hand side)
Splenic localization of pneumococcal




15 minutes after i.v. injection of PPS (a) or
PCV (b), pneumococcal polysaccharides
were detected immunohistochemically,
using serotype 19F-specific polyclonal
rabbit anti-pneumococcal polysaccharide
antibodies followed by a peroxidase reaction
(brown). Splenic marginal zone
macrophages are stained blue by MoAb
ED3. Insets show the marginal zone. 25x
original magnification, inset 40x.
In complement-sufficient rats, staining for the different polysaccharide serotypes 15 minutes
after injection of pneumococcal conjugate vaccine showed a particulate polysaccharide
staining pattern in the outer marginal zone (Figure 3b). After 7 hours, polysaccharides were
detected in the corona; no polysaccharide was detectable after 5 days (data not shown). In
complement-depleted animals, 15 minutes after PCV injection a same localization pattern
(Figure 3d) of polysaccharide 19F was seen as in untreated animals, although the staining was
less pronounced. In the splenic marginal zone, polysaccharides localized in association with
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marginal zone B cells (Figure 4a). PCV localized partly in proximity of ED3-positive cells
(Figure 4b).
Detection of pneumococcal polysaccharide 19F in rat serum
Because in decomplemented rats i.v. injected PPS does not localize in the spleen nor in the
liver (data not shown), we investigated whether complement depletion resulted in prolonged
circulation of PPS in blood. In serum of three complement-depleted rats, the concentration of
circulating PS19F was approximately 5 times higher than in the three control rats at T=7
hours (Figure 5), indicating prolonged circulation after complement-depletion. The presence
of CVF itself did not interfere with the binding of PS19F to nitrocellulose, nor did it interfere
with detection by the anti-pneumococcal antiserum used (data not shown).
Figure 5. Detection of pneumococcal polysaccharide19F in serum
10 ml of serum drawn 15 minutes or 7 hours after i.v PPS vaccination from 3 rats treated with CVF (lower panel)
and from 3 control rats (upper panel) was spotted on nitrocellulose filter. PS19F was detected using serotype
19F-specific polyclonal rabbit antiserum. After treatment with ECLÔ (Amersham Pharmacia) for 1 min, a
photofilm was developed for 1 min.
Anti-pneumococcal polysaccharide antibody responses.
On the base of localization data obtained earlier in this rat model (partly described in [13]),
IgM and IgG antibodies against three (PS6B, PS19F and PS14) of the seven capsular
polysaccharide serotypes present in both vaccines were determined.
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Figure 6. Serotype specific IgG and IgM anti-polysaccharide antibody response
Sera from rats immunized with PPS (lefthand panel) or PCV (righthand panel) were drawn at T= 0, 1, 3, 6, 8, 14,
and 21 days after i.v. vaccination. IgG and IgM antibody concentrations against PS 6B and PS 19F were
measured by ELISA. Antibody titers are expressed in U/ml. A rat hyperimmune serum pool used as a standard
was assigned 100 U/ml for each serotype. Open symbols: CVF-treated animals; closed symbols: non-treated
animals. Each data point represents the mean x/¸ SEM of 5 animals.
Immunization of control rats with PCV resulted in rises in IgG and IgM antibody titers for
serotypes 6B and 19F, with an early peak at 4-6 days, followed by a slow decrease in antibody
titers. Conjugating the poorly immunogenic PS14 to the protein carrier did not result in
enhancement of immunogenicity in these control rats (data not shown).
In complement-sufficient rats, maximum antibody titers for IgG- and IgM-anti-6B and PS19F
were reached 6 days after vaccination with 20 µg PPS (Figure 6). These titers dropped
quickly, and were only slightly above baseline level 21 days after vaccination. After
complement-depletion, antibody concentrations were significantly lower (p=0.043). Anti-
PS14 antibody titers were not detectable after PPS vaccination (data not shown).
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In contrast to the decreased response to polysaccharides after complement-depletion,
immunization with PCV after CVF-treatment resulted in hígher IgG and IgM antibody titers
than those obtained in control rats; and IgG and IgM anti-PS 14 antibodies were now
detectable. Especially IgG anti-PS19F antibodies persisted longer after decomplementation.
These differences did not reach significance.
Discussion
The initiation of the antibody response to polysaccharides is thought to be dependent on
polysaccharide-C3d-complex localization on marginal zone B cells by interaction with
complement receptor 2 (CD21). This model is based on the indirect argument that marginal
zone B cells acquire high levels of CD21 only relatively late during ontogeny: a time frame
that coincides with the acquisition of responsiveness to polysaccharides [10]. Direct evidence
comes from the recent findings of C3 and CRI/II dependent localization of a synthetic TI-2
antigen, TNP-Ficoll, on murine marginal zone B cells [17].
In this study, we showed that antibody responses to pneumococcal polysaccharide-protein
conjugates can be induced after complement-depletion. This finding is compatible with the
observed immunogenicity of conjugate vaccines in infants and young children. Apparently no
complement-dependent localization on marginal zone B cells is required for the initiation of
an anti-polysaccharide antibody response by conjugated polysaccharides. This hypothesis is
supported by our observations that conjugated polysaccharides localize in the splenic
marginal zone without obvious relation to marginal zone B cells. A similar localization also is
observed after complement-depletion, suggesting that it indeed is complement-independent.
The localization of unconjugated polysaccharides described in this study is consistent with
data reported earlier [13]. At an early time point after immunization, specific localization is
seen in the splenic marginal zone, in a staining pattern consistent with surface localization on
marginal zone B cells. This supports the importance of the marginal zone B cell subset in the
initial response to TI-2 antigens. In time, marginal zone localization decreases, concurrent
with an increasing concentration first in the outer follicular mantle and later in a dendritic
pattern in the complete follicle and follicle corona. Subsequently, in the center of the follicles,
transfer of polysaccharides to the surface of follicular dendritic cells (FDC) coincides with the
appearance of small germinal centers.
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It has been previously shown [13], that in vitro localization of pneumococcal polysaccharides
in the rat splenic marginal zone and follicle is complement-dependent. We are now able to
extend this in vitro finding to the in vivo situation: in CVF-treated rats, i.e. in the absence of
complement, no splenic localization of polysaccharides is observed. This in vivo finding
extends the arguments derived from human in vitro studies [25] in favour of the current
hypothesis that the initiation of an anti-polysaccharide antibody response is dependent on the
presence of complement (presumably C3d) in combination with the presence of a functionally
intact spleen. When these requirements are fulfilled, polysaccharide-complement complexes
are formed and localize at the surface of the marginal zone B cells by interaction with the
complement C3d receptor.
Several lines of evidence point towards a major role for marginal zone B cells in the immune
response against TI-2 antigens [9;10]. Our data strongly indicate that the splenic marginal
zone plays a major role in the immune response against native polysaccharides, but that the
response to conjugated polysaccharides is not dependent on this specific B cell compartment.
Consequently, an adequate response to conjugates may even be independent of the presence
of a functioning spleen.
All pneumococcal polysaccharide serotypes tested localized clearly in the splenic marginal
zone, except PS14. In humans, the localization patterns of all pneumococcal serotypes
including serotype 14 are very similar [25]. PS14 is the only neutrally charged pneumococcal
capsular polysaccharide, which may lead to trapping in extrasplenic tissue because of
effective interaction with glycosyl receptors in rat [26]. It is tempting to correlate this aberrant
pattern of PS14 localization with poor antibody responses to this serotype in this animal
species.
We speculate that in the absence of complement, the initiation of the anti-polysaccharide
antibody response is impaired because of insufficient formation of polysaccharide-C3d
complexes. Consequently decreased interaction with complement receptors on splenic
marginal zone B cells and thus less polysaccharide localization in the marginal zone leads to
prolonged circulation of polysaccharides in blood. The higher levels of PS19F circulating in
the bloodstream after CVF treatment are compatible with this hypothesis. The fact that the
antibody response is not inhibited completely after CVF-treatment may be due to incomplete
inactivation of complement. The interaction of C3d with the complement receptor is so
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efficient that even low levels of complement still present after CVF treatment could be
sufficient to induce a humoral immune response, even though splenic polysaccharide
localization is no longer visible.
In the absence of complement, the antibody response to conjugated polysaccharide tends to be
higher than in the presence of it. We speculate that this is due to the fact that complement
components other than C3d (possibly C3b) play a role in the binding of the protein portion of
the conjugate to receptors in e.g. the liver, resulting in lower levels of conjugate being
available for a specific humoral immune response.
In conclusion, both our data on antigen localization as well as antibody levels show that the
immune response to conjugated polysaccharides is distinctly different from that to native
polysaccharides. Splenic localization of polysaccharides, and consequently the initiation of an
anti-polysaccharide antibody response, is complement-dependent. The initiation of an anti-
polysaccharide antibody response is impaired in absence of complement (this study, [17])
and/or B cells with adequate expression of CD21 [10;17], reflecting this reduced splenic
localization. Coupling of polysaccharide to a protein carrier overcomes this C3d-CD21
dependency. These basic findings help to understand the success of conjugated vaccines in
groups that are traditionally at risk for infections with encapsulated bacteria, especially infants
and young children. This may open the way for application of conjugated vaccines in patient
groups with inadequate anti-polysaccharide responses because of either decreased levels of




Financial support for this study was kindly given by the Groningen Foundation for Pediatric
Oncology Research and the J.K. de Cock foundation.Wyeth Lederle Vaccines and Pediatrics,
Rochester, NY, generously provided the heptavalent pneumococcal conjugate vaccine for
these studies. Moabs CD45R, IgM, IgD, and HIS57 were a generous gift of Dr. Frans Kroese
(Department of Histology and Cell Biology, University of Groningen, Groningen, The
Netherlands).
Complement indepence of the response to conjugated polysaccharide
69
References
1. Fine DP. Pneumococcal type-associated variability in alternate complement pathway activation. Infect
Immun 1975; 12:772-8.
2. Winkelstein JA, Bocchini JA, Jr., Schiffman G. The role of the capsular polysaccharide in the activation
of the alternative pathway by the pneumococcus. J Immunol 1976; 116:367-70.
3. Griffioen AW, Toebes EA, Zegers BJ, Rijkers GT. Role of CR2 in the human adult and neonatal in vitro
antibody response to type 4 pneumococcal polysaccharide. Cell Immunol 1992; 143:11-22.
4. Griffioen AW, Rijkers GT, Janssens-Korpela P, Zegers BJ. Pneumococcal polysaccharides complexed
with C3d bind to human B lymphocytes via complement receptor type 2. Infect Immun 1991; 59:1839-45.
5. Mosier DE, Subbarao B. Thymus-independent antigens: complexity of B-lymphocyte activation revealed.
Immunol Today 1982; 3:217-22.
6. Rijkers GT, Mosier DE. Pneumococcal polysaccharides induce antibody formation by human B
lymphocytes in vitro. J Immunol 1985; 135:1-4.
7. Carter RH, Spycher MO, Ng YC, Hoffman R, Fearon DT. Synergistic interaction between complement
receptor type 2 and membrane IgM on B lymphocytes. J Immunol 1988; 141:457-63.
8. Mond JJ, Lees A, Snapper CM. T cell-independent antigens type 2. Annu Rev Immunol 1995; 13:655-92.
9. Timens W, Boes A, Poppema S. Human marginal zone B cells are not an activated B cell subset: strong
expression of CD21 as a putative mediator for rapid B cell activation. Eur J Immunol 1989; 19:2163-6.
10. Timens W, Boes A, Rozeboom-Uiterwijk T, Poppema S. Immaturity of the human splenic marginal zone
in infancy. Possible contribution to the deficient infant immune response. J Immunol 1989; 143:3200-6.
11. Amlot PL, Grennan D, Humphrey JH. Splenic dependence of the antibody response to thymus-
independent (TI-2) antigens. Eur J Immunol 1985; 15:508-12.
12. Siber GR, Ambrosino DM, McIver J, Ervin TJ, Schiffman G, Sallan S, Grady GF. Preparation of human
hyperimmune globulin to Haemophilus influenzae b, Streptococcus pneumoniae, and Neisseria
meningitidis. Infect Immun 1984; 45:248-54.
13. Harms G, Hardonk MJ, Timens W. In vitro complement-dependent binding and in vivo kinetics of
pneumococcal polysaccharide TI-2 antigens in the rat spleen marginal zone and follicle. Infect Immun
1996; 64:4220-5.
14. MacLennan IC, Liu YJ. Marginal zone B cells respond both to polysaccharide antigens and protein
antigens. Res Immunol 1991; 142:346-51.
15. Eskola J, Kayhty H, Takala AK, Peltola H, Ronnberg PR, Kela E, Pekkanen E, McVerry PH, Makela PH.
A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young
children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323:1381-7.
16. Ahman H, Kayhty H, Tamminen P, Vuorela A, Malinoski F, Eskola J. Pentavalent pneumococcal
oligosaccharide conjugate vaccine PncCRM is well-tolerated and able to induce an antibody response in
infants. Pediatr Infect Dis J 1996; 15:134-9.
17. Guinamard R., Okigaki M., Schlessinger J., Ravetch J.V. Absence of marginal zone B cells in Pyk-2-
deficient mice defines their role in the humoral response. Nature Immunology 2000; 1:31-6.
18. Beukelman CJ, Aerts PC, Van Dijk H, Willers JM. A one-step isolation procedure for phospholipase A2-
free cobra venom factor by fast protein liquid chromatography. J Immunol Methods 1987; 97:119-22.
Chapter 2
70
19. Dijkstra CD, Dopp EA, Joling P, Kraal G. The heterogeneity of mononuclear phagocytes in lymphoid
organs: distinct macrophage subpopulations in the rat recognized by monoclonal antibodies ED1, ED2
and ED3. Immunology 1985; 54:589-99.
20. Kroese FG, Butcher EC, Lalor PA, Stall AM, Herzenberg LA. The rat B cell system: the anatomical
localization of flow cytometry-defined B cell subpopulations. Eur J Immunol 1990; 20:1527-34.
21. Kroese FG, Wubbena AS, Opstelten D, Deenen GJ, Schwander EH, De Leij L, Vos H, Poppema S,
Volberda J, Nieuwenhuis P. B lymphocyte differentiation in the rat: production and characterization of
monoclonal antibodies to B lineage-associated antigens. Eur J Immunol 1987; 17:921-8.
22. Dammers PM, de Boer NK, Deenen GJ, Nieuwenhuis P, Kroese FG. The origin of marginal zone B cells
in the rat. Eur J Immunol 1999; 29:1522-31.
23. Musher DM, Luchi MJ, Watson DA, Hamilton R, Baughn RE. Pneumococcal polysaccharide vaccine in
young adults and older bronchitics: determination of IgG responses by ELISA and the effect of adsorption
of serum with non-type-specific cell wall polysaccharide. J Infect Dis 1990; 161:728-35.
24. Goldblatt D, Levinsky RJ, Turner MW. Role of cell wall polysaccharide in the assessment of IgG
antibodies to the capsular polysaccharides of Streptococcus pneumoniae in childhood. J Infect Dis 1992;
166:632-4.
25. Peset Llopis MJ, Harms G, Hardonk MJ, Timens W. Human immune response to pneumococcal
polysaccharides: complement-mediated localization preferentially on CD21-positive splenic marginal
zone B cells and follicular dendritic cells. J Allergy Clin Immunol 1996; 97:1015-24.
26. Harms G, Dijkstra CD, Hardonk MJ. Glycosyl receptors in macrophage subpopulations of rat spleen and
lymph node. A comparative study using neoglycoproteins and monoclonal antibodies ED1, ED2 and ED3.
Cell Tissue Res 1990; 262:35-40.
27. Hunig T, Wallny HJ, Hartley JK, Lawetzky A, Tiefenthaler G. A monoclonal antibody to a constant
determinant of the rat T cell antigen receptor that induces T cell activation. Differential reactivity with
subsets of immature and mature T lymphocytes. J Exp Med 1989; 169:73-86.
Antibody response to pneumococcal conjugates is spleen-independent
Chapter 3
Pneumococcal conjugate vaccine
overcomes the splenic dependency of the
antibody response to pneumococcal
polysaccharides
Mijke A. Breukels*, Andre Zandvoort§, Germie P.J.M. van den
Dobbelsteen¶, Adrie van den Muijsenberg*, Monique E. Lodewijk§,
Michel Beurret¶, Pieter A. Klok§, Wim Timens§, Ger T. Rijkers*
*Dept. of Pediatric Immunology, Wilhelmina Children’s Hospital, University Medical Center,
Utrecht, The Netherlands.
§Dept. of Pathology, University Hospital Groningen, Groningen, The Netherlands.





Protection against infections with Streptococcus pneumoniae depends on the presence of
antibodies against capsular polysaccharides that facilitate phagocytosis. Asplenic patients are
at increased risk for pneumococcal infections, since both phagocytosis as well as the initiation
of the antibody response to polysaccharides take place in the spleen. Therefore, vaccination
with pneumococcal polysaccharide vaccines is recommended prior to splenectomy, which, as
in case of trauma, is not always feasible.
We show that in rats after splenectomy vaccination with pneumococcal conjugate vaccine can
induce good antibody responses, particularly after a second dose. The spleen remains
necessary for a fast, primary response to (blood-borne) polysaccharides, even if presented in
conjugated form. The impaired antibody response to pneumococcal polysaccharides after
splenectomy can not be improved by co-administration of conjugates.
We conclude that pneumococcal conjugate vaccines can be of value in protecting asplenic or
hyposplenic patients against pneumococcal infections.
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Introduction
Protection against infections with encapsulated bacteria such as Streptococcus pneumoniae
depends on the presence of antibodies against capsular polysaccharides. These serotype-
specific antibodies facilitate phagocytosis, the main mode of host defence against S.
pneumoniae. The spleen is an important organ in the immune response to S. pneumoniae,
since it contains both antibody-producing B cells and phagocytes [1;2]. Asplenic patients are
therefore at increased risk for invasive infections with S. pneumoniae [3]. Although most
infections occur within the first few years after splenectomy, the risk of overwhelming
postsplenectomy infections is lifelong [4;5]. Therefore vaccination against S. pneumoniae is
indicated in this group. At present, the vaccine available for this aim is the 23-valent
pneumococcal polysaccharide vaccine [6].
In a number of trials the immunogenicity of pneumococcal polysaccharide (PPS) vaccine in
splenectomized patients has been assessed. Some studies have shown effectiveness of
vaccination in inducing protective concentrations of specific antibodies [7-10], while others
have shown limited serological responses [11]. As the initiation of the antibody response to
polysaccharides seems to depend on the presence of splenic tissue, and in particular a
functional marginal zone B-cel compartment [12-16], it may be expected that polysaccharide
vaccines are of limited use in asplenic patients. In analogy with infants and young children,
asplenic patients might profit from the recently developed pneumococcal conjugate vaccines.
Physical coupling of polysaccharides to carrier protein greatly improves the immunogenicity
of the polysaccharide, a principle first described in 1929 [17]; and conjugated polysaccharides
overcome the anti-polysaccharide unresponsiveness in early life [18;19]. This inability to
generate antibodies to polysaccharide antigens is found until the age of 18-24 months, and is
thought to be due to a still immature splenic marginal zone B cell compartment [19]. The
induction of anti-polysaccharide antibodies by conjugate vaccines suggests that conjugates
might initiate the anti-polysaccharide antibody response in absence of a functional splenic
marginal zone B cell compartment, and thus be of value in the management of hypo- and
asplenic patients.
To test this hypothesis of relative splenic independency of the anti-polysaccharide antibody
response after conjugate vaccination, we studied the immunogenicity of a tetravalent
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pneumococcal conjugate vaccine (PCV) after splenectomy. We used a rat model in which we
have previously shown that splenectomy had a clearly negative effect on the anti-
polysaccharide antibody response [20]. Because PCV contain only a limited number (4-11) of
pneumococcal serotypes compared with the 23-valent PPS, we studied the potential benefit of
admixture of additional polysaccharides with the PCV. We also studied the effects of booster-
immunization.
Since the spleen is a major lymphoid organ, containing 25% of all white blood cells, mainly
lymphocytes, it plays an important role in primary and secondary immune responses to all
antigens, irrespective of way of presentation. Furthermore, the spleen is the only site of
specific antibody production very early after exposure to blood-borne antigens. We therefore
studied the effects of splenectomy on the antibody responses after immunization with PPS or
PCV via two different routes, subcutaneously as well as intravenously, or only
subcutaneously.
Materials and Methods
Animals, splenectomy and immunization
Young adult male Wistar rats (n=60, Harlan, Horst, the Netherlands), of approximately 200 g,
were housed under standard laboratory conditions on a 12 h light-dark cycle. They were fed
standard laboratory rat food (Hope Farms, Inc., Woerden, the Netherlands) and tap water ad
libitum. Splenectomy was performed on 30 rats via an upper midline incision, under clean,
but not sterile, conditions [21]. Rats were allowed to recover from this surgical procedure for
6 weeks. At T=0 and at T=28 days, both the splenectomized rats and control rats were
immunized with one of the vaccines described below. In a first series, animals were
simultaneously immunized with 0.5 ml vaccine subcutaneously (s.c) as well as 0.5 ml
intravenously (i.v.) in the tail vein. In a second series of experiments the vaccine (0.5 ml) was
administered s.c. only in order to study the kinetics of the antibody response and the
importance of the spleen in this circumstance. Each experimental group consisted of five rats.
All rats were marked individually, to allow antibody titers to be analyzed longitudinally for
single rats.
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At T=0, and at days 5, 28, 33 (5 days after second vaccination) and 56 (28 days after second
vaccination), blood was obtained from the tail vein (timepoints were based on previous
experience (Breukels et al., manuscript in preparation). Blood was allowed to clot on ice for
two hours. Serum samples were stored at -20oC until analysis.
Vaccines
Pneumococcal polysaccharide serotypes 4, 6B, 9V, 14, 19F and 23F (American Type Culture
Collection (ATCC), Rockville, MD) were dissolved in saline to a concentration of 5 µg/ml for
each serotype. Each 0.5 ml dose of this vaccine (PPS) compares to one tenth of the human
dose.
A tetravalent pneumococcal conjugate vaccine (National Institute of Public Health and the
Environment (RIVM), Bilthoven, the Netherlands), consisting of 50 kD polysaccharides of
pneumococcal serotypes 6B, 14, 19F and 23F conjugated to tetanus toxoid carrier protein via
a cysteamine linker [22] containing aluminum phosphate as an adjuvant was used, mixed with
unconjugated polysaccharide serotypes 4 and 9V(ATCC). Each 0.5 ml dose of this vaccine
(PCV) contained 0.36 µg polysaccharides of the serotypes 14, 19F and 23F, and 1.08 µg of
serotype 6B, and 2.5 µg of the unconjugated pneumococcal polysaccharide serotypes 4 and
9V.
Type-specific anti-pneumococcal antibody determinations.
IgG serum antibody levels against all six polysaccharides included in the two vaccines
(serotypes 4, 6B, 9V, 14, 19F and 23) were measured by ELISA. All serum samples were
preincubated overnight with excess free common cell wall polysaccharide (CPS) to neutralize
anti-CPS antibodies [23;24].
Microtiter plates (Greiner Labortechnik, Langerthal, Germany) were coated with pneumococ-
cal capsular polysaccharides (ATCC, 10 µg/ml in saline solution) at 37°C, overnight. Subse-
quently, plates were washed with phosphate buffered saline (PBS), Tween-20 0.05% (vol/vol)
and incubated with serial dilutions of serum samples in PBS, 0.05% Tween-20, 1% bovine
serum albumin (BSA, vol/vol). After washing (PBS-0.05 % Tween-20), the plates were
incubated for two hours (37°C) with peroxidase labelled goat anti-rat IgG antibodies
(Southern Biotechnology Associates, Birmingham, AL). After washing and incubation with
enzyme substrate for 20 min at room temperature, absorbance was read at 450 nm on a
Milennia ELISA reader (Flow Laboratories, Irvine, CA).
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Serum samples obtained pre-vaccination and at the different time points after vaccination
from individual rats were analyzed simultaneously. The antibody concentrations in the serum
samples were calculated by comparison with a rat hyperimmune serum pool, generated from
sera of rats vaccinated with a heptavalent pneumococcal conjugate vaccine (Prevnar®; Wyeth
Lederle Vaccines and Pediatrics, Rochester, NY; containing the serotypes 4, 6B, 9F, 14, 18C,
19F and 23F) or a 23-valent pneumococcal polysaccharide vaccine (Pneumovax®, Merck,
Westpoint, PA). This pool was included in every ELISA-run as a standard. The antibody
concentrations in this hyperimmune pool were assigned 100 U/ml (100%) for each serotype.
Based on comparison of OD readings, type-specific antibody concentrations in this
hyperimmune standard were highest for serotypes 4, 9F, and 19F, and lower for serotypes 6B
and 23F. Both the hyperimmune serum pool as well as individual post-immunization samples
showed low OD readings for serotype 14. No reliable anti-PS14 antibody titers could
therefore be assigned to sera after vaccination, only trends in antibody titers could be
documented.
Statistical Analysis
Serological data from rats of the different vaccine groups, 5 rats per group, were analyzed and
compared for statistically significant differences by using the Mann-Whitney U test. P-values
< 0.05 were considered significant.
Results
Splenectomy impairs the antibody response to pneumococcal polysaccharides
In control rats, vaccination with the 6-valent pneumococcal polysaccharide mixture induced a
clear IgG antibody response to all serotypes except serotype 14 (Figure 1, left-hand side, data
for serotype 14 are not shown). Maximal geometric mean antibody titers, obtained at day 5,
ranged from 21 to 57 U/ml. In splenectomized rats maximum geometric mean antibody titers,
also reached at day 5, were significantly (p<0.01) lower, and remained <10 U/ml for the five
serotypes (range 2-10 U/ml).
Revaccination of control rats with PPS -after 4 weeks- resulted in significantly lower IgG
antibody titers after 5 days than after the first dose of PPS, with geometric mean serotype-
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specific antibody titers ranging from 4-12 U/ml (p<0.05). Also in splenectomized rats,
revaccination with PPS did not improve the IgG-type antibody response.
Figure 1. IgG antibody responses to vaccination with pneumococcal polysaccharides and pneumococcal
polysaccharide-protein conjugates in control and splenectomized rats.
Control rats (closed symbols) and splenectomized rats (open symbols) were vaccinated i.v. and s.c. at day 0 and
at day 28 with a) 2.5 mg of each of the pneumococcal polysaccharide (PPS) serotypes 4, 6B, 9V, 14, 19F and 23F
or with b) a tetravalent pneumococcal conjugate vaccine (PCV) consisting of polysaccharides of pneumococcal
serotypes 6B, 14, 19F and 23F conjugated to tetanus toxoid. Each 0.5 ml dose of PCV contained 0.36 µg
polysaccharides of the serotypes 14, 19F and 23F, and 1.08 µg of serotype 6B. IgG anti-pneumococcal antibody
titers were determined by ELISA in serum samples drawn at day 0, 5, 28, 33 and 56. Antibody titers are
expressed in U/ml. A rat hyperimmune serum pool used as a standard was assigned 100 U/ml for each serotype.
Shown are geometric mean antibody titers x: SEM.
Right panels show IgG antibody responses after vaccination with PPS. Antibody responses to serotypes 4 and 9V




Antibody response to pneumococcal conjugate vaccine
In control rats, the primary response after vaccination with PCV resulted in serotype-specific
antibody titers at day 5 that were comparable with or slightly higher than those acquired after
one dose of PPS (geometric mean antibody titers 27-83 U/ml) (Figure 1, right-hand side).
Antibody titers to PS14 were also slightly higher than after vaccination with PPS (data not
shown). Antibody titers reached a maximum after 5 days and remained at plateau level or
decreased only slightly.
After splenectomy, IgG antibody titers at day 5 were significantly lower (p< 0.01) than those
in controls 5 days after vaccination with PCV. However, in the period between day 5 and day
28, IgG antibody titers increased steadily and reached levels comparable with those in control
rats at day 28. These antibody titers were higher than the maximal antibody titers reached by
vaccination of splenectomized rats with PPS.
Revaccination with PCV 4 weeks after the first PCV dose resulted in a further increase in
antibody concentration in control rats. In splenectomized rats, the increase in IgG after
secondary vaccination with PCV was even more pronounced. The response to the second dose
of PCV did not differ in kinetics between the control and splenectomy groups: in both groups
already 5 days after vaccination high antibody titers were observed. These levels persisted
until at least 28 days after the second PCV vaccination in both groups. In the splenectomy
group these titers were significantly higher than maximum titers obtained after PPS
vaccination (p< 0.05).
It thus can be concluded that a pneumococcal conjugate vaccine can overcome polysaccharide
unresponsiveness in splenectomized rats.
Combined i.v. and s.c. vaccination compared with s.c. vaccination only.
S.c. injection of PPS 4 and 9V in control rats resulted in a lower antibody responses compared
with combined i.v. and s.c. injection (p< 0.05), although still a rise in antibody titer was
observed with a maximum at day 5 (range 2-13 U/ml). A second s.c dose of PPS after 4
weeks did not result in an increase in antibodies (Figure 2). S.c injection of PPS4 and 9V in
splenectomized rats did but slowly induce an antibody response, reaching a maximum 5 days
after a second injection.
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Figure 2. IgG anti-pneumococcal antibody response after subcutaneous (s.c.) vaccination compared with
combined subcutaneous as well as intravenous (i.v.) vaccination with PPS or PCV.
Control rats (closed symbols) and splenectomized rats (open symbols) were vaccinated s.c. (broken lines) or i.v.
as well as s.c. (drawn lines) at day 0 and at day 28 with a tetravalent (6B, 14, 19F, 23F) pneumococcal conjugate
vaccine mixed with 2.5 mg of the unconjugated polysaccharide serotypes 4 and 9V. Anti-pneumococcal antibody
titers were determined by ELISA. See legend Figure 1 for further details.
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After s.c. injection of PCV in control rats, the specific antibody titers to serotypes 6B, 19F
and 23F rose gradually over the first 4 weeks, to reach equal or even higher titers than the
maximal titers achieved already at day 5 after combined i.v. and s.c injection (Figure 2).
A second dose of PCV resulted in a further rise in IgG antibody titer, which was maintained
longer than after combined i.v. and s.c injection. S.c. vaccination of splenectomized rats with
PCV resulted in an identical (both in magnitude and kinetics) IgG antibody response as in
control rats.
Co-administration of non-conjugated polysaccharide with PCV.
Above data indicate that in splenectomized rats antibody responses to PCV were higher, and
were maintained for longer periods, than antibody responses to PPS. We administered PPS
together with PCV to see whether admixture of PPS with PCV would improve the antibody
Figure 3. Antibody response to serotype 4 and 9V polysaccharides admixtured with native or conjugated
polysaccharides.
Control rats (closed symbols) and splenectomized rats (open symbols) were i.v. and s.c. vaccinated on day 0 and
on day 28 with 2.5 µg of the pneumococcal polysaccharide serotypes 4 and 9V mixed with conjugated (broken
lines) or native polysaccharides (drawn lines) of the serotypes 6B, 14, 19F and 23F. See legend Figure 1 for
further details.
response to PPS and thus increase the limited serotype coverage of PCV. In Figure 3 the anti-
PPS 4 and anti-PPS 9V IgM- and IgG antibody responses are depicted. No differences in
antibody responses are seen after admixture of PPS 4 and 9V with the 4-valent PCV
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compared with unconjugated forms of the PPS 6B, 14, 19F and 23F; this holds true for both
polysaccharides in control as well as in splenectomized rats. The poor immunogenicity of
non-conjugated polysaccharides in splenectomized rats therefore can not be improved by
concommitantly immunization with conjugate vaccine.
Booster vaccination with PPS or PCV after a first vaccination with PCV
In control rats, booster vaccination with PPS as well as PCV after primary PCV results in an
increase in serotype-specific IgG antibody titers for all serotypes. In splenectomized rats,
PCV booster vaccination clearly results in a better anti-polysaccharide antibody response as
PPS.
Figure 4. Booster vaccination with conjugated versus native polysaccharides.
Control rats (closed symbols) and splenectomized rats (open symbols) were i.v. and s.c. vaccinated on day 0 with
a tetravalent pneumococcal conjugate vaccine consisting of polysaccharides of pneumococcal serotypes 6B, 14,
19F and 23F conjugated to tetanus toxoid. At day 28, animals were booster vaccinated with either pneumococcal
polysaccharide serotypes 4, 6B, 9V, 14, 19F and 23F (drawn lines) or the tetravalent conjugate vaccine (broken




After splenectomy, PPS booster induces no increase in IgG anti-19F and 6B antibody titers,
whereas boosting with PCV results in a rise in antibody titer for both serotypes (PCV-
PPS versus PCV-PCV p<0.05 for IgG anti-6B and p=0.07 for IgG anti-19F). For serotype 23F
both vaccination schedules do result in a comparable rise in antibody titer.
Discussion
Despite the wide range of antibiotics available, invasive pneumococcal infections remain a
substantial cause of morbidity and mortality [25-27]. Patients with anatomical or functional
asplenia are particularly at risk [3;28], because the spleen is the most important site of
phagocytosis of poorly opsonized antigens in the early phase of bacterial invasion, before
sufficient amounts of specific antibodies have been produced [2]. After splenectomy, the liver
will partially take over the phagocytic function of the spleen. However, the liver needs a
higher level of opsonization because of the relatively high blood flow [29]. Because of the
splenic dependency of the anti-polysaccharide antibody response, the opsonization of
encapsulated bacteria may be suboptimal after splenectomy [1]. Therefore, immunization with
pneumococcal polysaccharide vaccine is recommended prior to elective splenectomy [6],
although efficacy data are scarce [30]. However, vaccination prior to splenectomy is not
always feasible, as after trauma.
Pneumococcal conjugate vaccines (PCV) are developed to enhance the immune response to
pneumococcal polysaccharides. Potential target groups include, in addition to young children,
several risk groups for pneumococcal infections where the immunogenicity of the
pneumococcal polysaccharide vaccine (PPS) is suboptimal. Asplenic or hyposplenic patients
might benefit from vaccination with PCV, because polysaccharide-protein conjugates can
initiate an antibody response to the polysaccharide without the need for a functional spleen
[31-33]. We therefore tested the immunogenicity of PCV in splenectomized rats and showed
that a series of two doses of PCV given 6 weeks after splenectomy results in antibody titers
that are at least as high as in control rats, whereas the antibody response to PPS is impaired by
splenectomy (Figure 1). This indicates that the immunogenicity of PCV, in contrast with that
of PPS, is not impaired by splenectomy.
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When antibody titers start to decline after primary vaccination of control rats with PCV, a
second vaccination with PCV results in a rise again. However, the decline in antibody titers
after vaccination with PPS could not be influenced significantly by revaccination with PPS.
This phenomenon is also observed after meningococcal A and C polysaccharide vaccination
in infants [34]. It is unlikely that this is due to high levels of circulating antibody, since
antibody titers at day 28 are identical in splenectomized and control animals, and in
splenectomized animals no significant difference in antibody titers is observed after a second
PPS dose compared with the first.
We have used rather high doses of PPS for immunization: 0.1 human dose i.v and 0.1 human
dose s.c.. Therefore the inability of the second dose to cause an increase in anti-
polysaccharide antibodies may be due to high-dose-tolerance, caused by in vivo persistence of
polysaccharides. In our study, the persistence of PPS did not seem to affect the antibody
response to PCV administered 4 weeks after PPS (data not shown). This finding provides an
extra argument in favor of the hypothesis that PCV induce anti-polysaccharide antibody
responses by a different mechanism of antigen presentation or at a different localization than
PPS.
The spleen is not only of particular importance for phagocytosis of poorly opsonized foreign
particles and for the antibody response to TI-2 antigens, as is indicated above, but it is also the
site of antibody generation very early after exposure to all blood-borne antigens. We show
that the spleen produces the fast primary antibody response to PCV injected in the
bloodstream. After i.v. vaccination of control animals with PCV, maximum antibody titers are
reached already at day 5 (figures 1 and 2). However, in the absence of splenic tissue, the
antibody response to i.v. injected PCV is delayed, antibody titers rise gradually to reach a
maximum after 28 days. These data indicate that extrasplenic lymphoid tissues (lymph nodes)
are able to generate a primary antibody response to PCV. However, this response is slower
than the splenic response. The primary antibody responses to PCV of both splenic and other
lymphoid tissue are qualitatively comparable: ultimately equally high antibody titers are
reached. The antibody response to a second dose of PCV is similar in the presence or absence
of splenic tissue, and results in high antibody titers after 5 days.
When antigens are not introduced via the bloodstream, the fast primary splenic antibody
response does not take place. Subcutaneously administrated PCV results in a comparable
antibody response pattern as i.v. administration of PCV after splenectomy; the response is
probably generated in extra-splenic tissue. Subcutaneously administered PPS ultimately
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reaches the marginal zone of the spleen, but slower and more diffuse than after i.v.
vaccination, resulting in a blunted antibody response.
PCV, as we show, have the advantage that they can induce antibody responses in the absence
of a spleen, but have as major drawback the limitation of the number of serotypes that can be
included. The licenced heptavalent pneumococcal conjugate vaccine (Prevnar®, Wyeth
Lederle Vaccines and Pediatrics, Rochester, NY) includes seven serotypes. Although 11-
valent PCV are under evaluation, the same coverage of serotypes as the 23-valent PPS will
not be reached. Theoretically, admixture of PPS with PCV could be an approach to broaden
the coverage. Conjugation of polysaccharide to protein changes the nature of the anti-
polysaccharide antibody response, from a T cell independent to a T cell dependent response
[35;36]. Antigen-presenting B cells probably take up the conjugated polysaccharide–protein
molecule and internalize it via membrane immunoglobulins and present the peptides of the
protein to T helper cells in association with major histocompatibility complex class II
molecules on their surfaces. This induces T helper cells to stimulate polysaccharide-specific B
cells to mature into antibody-producing plasma cells or into memory cells [37-39]. According
to this model, activation of polysaccharide-specific B cells could take place either via direct
physical interaction with peptide-specific T helper cells, or via soluble factors secreted by
peptide-specific T cells [40]. Our experimental data indicate that responses to PPS 4 and 9V
do not improve by admixture with 4-valent PCV containing serotypes 6B, 14, 19F and 23F
(figure 5). Distinct differences in localization may explain this finding: in the splenic marginal
zone PPS specifically localize on marginal zone B cells, whereas for PCV this localization on
marginal zone B cells is far less pronounced (Breukels et al., manuscript in preparation).
Physical interaction of serotype 4 and 9V specific B cells with peptide-specific T cells may
not take place, and soluble factors secreted by peptide-specific T cells may be short-range
acting cytokines unable to stimulate more distantly located B cells.
An alternative way to extend the coverage of PCV to more serotypes could be booster
vaccination with the 23-valent PPS. In infants and children, priming with PCV leads to
induction of memory: significant booster responses to serotypes included in the PCV are
observed after additional doses of either PCV or polysaccharide vaccine [41-43]. In control
rats, after priming with PCV, we indeed observed secondary responses to PPS and PCV that
were higher than primary responses. But in splenectomized rats booster responses were
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observed only after a second dose of PCV, and not after PPS. So even after priming with
PCV, the response to PPS appears to be spleen-dependent.
It should be noted that both the capacity to respond to bacterial polysaccharide antigens, and
the unique capacity of the spleen to phagocytose poorly opsonized bacteria are lost by
splenectomy. Spleen-saving procedures or splenic autotransplantation at the time of
splenectomy may potentially preserve or restore at least part of the splenic immune function,
and should be pursued. Protection provided by conjugate vaccines is limited to the antigens
present in the vaccine. The clinical efficacy of pneumococcal conjugate vaccines for asplenic
and splenectomized patients in preventing overwhelming postsplenectomy infections
therefore remains to be established, but this type of vaccines, extended with more vaccine
antigens, seems at present to be the best option for patients with (functional) asplenia.
Our data indicate that the spleen is of prime importance in the antibody response to PPS. In
the absence of splenic tissue, the ability to mount a primary antibody response to PPS is lost.
This may explain the greatly increased risk of invasive infections with encapsulated bacteria
like S. pneumoniae after splenectomy. We show that antibody response to PCV is independent
of the spleen: in control as well as in splenectomized rats and after i.v as well as s.c. PCV
vaccination, antibody responses are generated. We therefore conclude that PCV may be of
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An in vitro culture system for the induction of an anti-polysaccharide response is used to study
the cellular interactions which determine the magnitude and nature of this B lymphocyte
response. Healthy adult volunteers were vaccinated with the Haemophilus influenzae type b
polysaccharide (PRP)-tetanus toxoid (TT) conjugate vaccine. Optimal in vitro anti-PRP and anti-
TT antibody responses were obtained when B cells were cultured with equal amounts of T cells.
The in vitro response is antigen dependent and antigen specific. Culturing with PRP mixed with
TT in the presence of T cells induces the highest number of anti-PRP antibody secreting cells
(ASC) (128.4 x/: 15.9 (geometric mean x/: SD) IgM anti-PRP ASC/106 cells, 9.3 x/: 7.6 IgG
anti-PRP ASC/106 cells). Culturing without T cells induced no anti-PRP ASC; culturing with
only PRP, in the presence of T cells, yielded low numbers of anti-PRP ASC (3.7 x/: 5.2 IgM
anti-PRP ASC/106 cells and 1.2 x/: 2.2 IgG anti-PRP ASC/106 cells). Transwell studies show
that the requirements for the antibody response against the polysaccharide are different from
those of an anti-protein response. Cytokines formed as a consequence of contact between
protein-specific B and T cells are on itself not sufficient to activate TT specific B cells (3.9 x/:
4.6 anti-TT ASC/106 cells); direct T-B cell contact appeared to be an absolute requirement.
However, physical contact between B and T cells in one compartment of the Transwell system,
results in the release of soluble factors able to stimulate B cells in the other compartment to
secrete anti-polysaccharide antibodies (36.3 x/: 8.6 anti-PRP ASC/106 cells).
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Introduction
The defence against infections with encapsulated bacteria such as Haemophilus influenzae type b
and Streptococcus pneumoniae depends primarily on the ability to produce antibodies against the
capsular polysaccharides of these microorganisms. The immune response against these antigens
(that are categorised as so-called T cell independent type 2 (TI-2) antigens) has several
characteristics. There is no memory formation [1], the isotypes used are preferentially IgM and
IgG2, and idiotype use of anti-TI-2 antibodies is restricted [2]. Furthermore, responsivity to TI-2
antigens develops relatively late in life [1;3;4], implying that children up to the age of 18-24
months, in general, are less able to produce anti-polysaccharide antibodies. They (hence) do have
an increased susceptibility for infections with these encapsulated bacteria. Polysaccharide based
vaccines are not effective in this age group [1;5].
Coupling of polysaccharides to carrier proteins converts the anti-polysaccharide response into a
response with a T cell dependent character. Polysaccharide-protein conjugate vaccines are able to
induce anti-polysaccharide antibodies in 2-3 months old children. Moreover, H. influenzae type b
polysaccharide (polyribosyl ribitol phosphate, PRP) protein conjugate vaccines have proven to
be clinically effective during infancy and virtually eliminated invasive H. influenzae type b
disease [6-8]. The mechanisms by which these conjugate vaccines induce T and B lymphocyte
activation, still remains a matter of debate.
T-cell dependent (TD) protein antigens are bound and internalized by the antigen receptor on B
cells (mIg), and re-expressed as processed peptides in MHC class II molecules. The peptide-
MHC class II complex on B cells is then able to activate specific T cells. In this interaction,
CD40-CD40L functions as an essential ligand-receptor pair which provides a second activation
signal [9]. Because polysaccharide processing does not occur [10], this model is not valid for TI-
2 antigens.
In vivo, the first step in B cell activation by polysaccharides occurs via ligation and cross-linking
of mIg. A second activation signal is probably provided by co-ligation of complement receptor 2
(CR2, CD21). Polysaccharide-C3d complexes, formed by complement activation through the
alternative pathway, have the ability to bind to CD21 [11]. The mechanism of co-ligation of mIg
and CD21 may account for the fact that antigen-specific T cells are not strictly required for
induction of an anti-polysaccharide B cell response.
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While the in vitro B cell response against TI-2 antigens can be induced in the absence of T cells,
the presence of T cells does augment the magnitude of the response [12]. The T cells that
mediate this function have been termed "amplifier" cells, to distinguish them from helper T cells
in the T cell dependent (TD) antibody response to protein antigens [13]. The in vivo anti-
polysaccharide antibody response induced by polysaccharide-protein conjugates bears the
characteristics of a TD antibody response. In such an antibody response, the role of T helper cells
and the specificity of these cells is still unclear.
In order to investigate the cellular interactions which determine the magnitude and nature of the
anti-polysaccharide antibody response, we used the previously described in vitro culture system
for restimulation of in vivo primed human B lymphocytes [14]. Using this system we showed
that an in vitro anti-PRP antibody response can be induced in human B cells, derived from in
vivo primed individuals. Vaccination with conjugated polysaccharide (PRPTT, Haemophilus
influenzae type b polysaccharide covalently linked to tetanus toxoid) is required to obtain a
positive in vitro anti-PRP antibody response [14]. The in vitro generation of anti-PRP antibody
secreting cells (ASC) was shown to be T cell dependent, antigen dependent and antigen specific.
In the present paper we further investigated the cellular interactions between B and T cells which
determine the magnitude and nature of the anti-polysaccharide antibody response. We therefore
modified the culture system, using the Transwell system to physically separate the cell
populations. The results show that T- and B cell derived soluble factors are able to stimulate
antigen primed B cells to secrete anti-polysaccharide antibodies and that physical contact
between T- and B cells is not absolutely required for anti-polysaccharide B cell differentiation.
Materials and Methods
Immunization
Healthy adult volunteers were given an intramuscular immunization with a full dose of PRPTT
(Act-Hib®, Pasteur Mérieux, Lyon, France) which contains 10 mg of the Haemophilus
influenzae type b polysaccharide covalently linked to tetanus toxoid (± 24 mg). Blood samples
were collected 3 to 4 weeks after immunization.
In the Netherlands, children are routinely immunized at the age of 3, 4, 5 and 12 months with
diphtheria, pertussis, tetanus and poliomyelitis vaccine. Booster immunizations are given at the
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age of 4 and 9 years with diphtheria, tetanus and poliomyelitis vaccine. All adult donors used in
this study were vaccinated according to this schedule during childhood.
Lymphocyte preparations
Peripheral blood mononuclear cells (PBMC) were isolated from heparinized blood (100 ml)
from healthy adult donors by density gradient centrifugation on Ficoll Isopaque (Pharmacia,
Uppsala, Sweden; 1.077 g/cm3) at 1000g for 20 minutes. The cell suspension was washed twice
with MEM-Tris (Tris buffered minimal essential medium, Gibco, Grand Island, NY). T cells
were separated from non-T cells by rosetting with 2-aminoethylisothiouroniumbromide (Sigma
Chemical Co, St. Louis, MO) treated sheep erythrocytes (SRBC). The non-T fraction was then
depleted of monocytes by treatment with iron carbonyl. After these procedures the monocyte-
depleted non-T cell fraction contained an average of 40% B cells (25-72%) and less than 1% T
cells. A fixed concentration of 5% monocytes was used in all experiments by mixing appropriate
numbers of monocyte depleted non-T cells and non-T cells not depleted for monocytes.
Culture conditions
Cultures were set up according to a 1:1 T/non-T cell composition and each culture was
supplemented with 5% monocytes [14]. A total of 2 x 106 cells in a volume of 2 ml was cultured
at 37°C, 100% humidity and 5% CO2. The medium consisted of RPMI-1640 (Flow Laboratories,
Irvine, UK) supplemented with 200 mg/ml glutamine, 100 IU/ml penicilline, 100 mg/ml
streptomycine, 10-5 M 2-mercaptoethanol and 10% heat inactivated pooled (5 donors) human AB
serum. After culturing for 6 days, cells were washed once in MEM-Tris supplemented with 1%
bovine serum albumin (BSA, Organon Technika, Oss, Netherlands). Cells were then
resuspended in 1.0 ml RPMI-1640 supplemented with 200 mg/ml glutamine, 100 IU/ml
penicilline, 100 mg/ml streptomycine, and 10% heat inactivated fetal calf serum (FCS, Flow
Laboratories, Irvine, UK).
In some experiments the monocyte depleted non-T cell fraction was physically separated from
the T cell plus 5% monocyte fraction by the use of the Transwell system wells (Costar®,
Cambridge MA), 6.5 mm wide with pore size of 0.4 mm. In preliminary experiments it was
demonstrated that the Transwell system allowed for transfer of biologically active cytokines
across the membrane (data not shown). After 6 days of culture, cells from the various
compartments were analysed separately for specific antibody secreting cells (ASC).
Chapter 4
94
Determination of anti-TT and anti-PRP specific antibody secreting cells
B cells secreting anti-tetanus toxoid (TT) or anti-PRP IgG or IgM antibody were enumerated by
a modification of the ELISA-SPOT test described by Sedgwick and Holt [15]. Polyvinyl chloride
96-well microtiter plates (Flow) were coated overnight at 4°C with 100 ml of tyramine coupled
PRP (5 mg/ml) in 0.9% NaCl or TT (1 mg/ml) in bicarbonate buffer pH 9.6. Plates were also
prepared for the detection of all IgG or IgM secreting lymphocytes by coating with goat anti-
human IgG or IgM (Tago Inc, Birmingham, AL) at a 1 in 1,000 dilution in bicarbonate buffer pH
9.6 overnight at 4°C. All plates were then blocked following three washes with phosphate
buffered saline (PBS) with 1% BSA in MEM for 30 minutes at 37°C. The cultured cells were
added to the coated wells in serial dilution starting with 200,000 cells per well. The plates were
subsequently incubated for 3-4 hours at 37°C, 100% humidity and 5% CO2. The wells were then
washed with PBS to remove all cells and incubated with 100 ml alkaline phosphatase (AP)
conjugated goat anti-human IgM or IgG (Tago) at a dilution of 1 in 1,000 in PBS plus 1% BSA
for 2 hours at 37°C. After extensive washing with PBS plus 0.05% Tween-20 (w/v), 100 ml of
the AP substrate 5-Bromo-4-chloro-3-indolylphosphate (0.1 mg/ml) in 1 M 2-amino-2-methyl-1-
propanol buffer pH 10.25 (Sigma), containing 5 mM MgCl2, 0.01% Triton X405 (Sigma), 0.01%
sodium azide and 0.6% 36°C gelling agarose (Sigma) was added to each well. Blue spots
representing antibody producing cells were counted after overnight incubation at room
temperature using an inverted microscope (Zeiss, Oberkochen, Germany). Antibody secreting
cells (ASC) were expressed as the number per 1 x 106 input cells.
The specificity of the ASC was assessed by addition of excess soluble antigen (50 mg/ml) during
incubation of cultured cells on antigen coated plates. This procedure resulted in a >80%
reduction of the number of spots, whereas remaining spots were significantly reduced in size as
compared to the non-inhibited situation.
Antigens
The following antigens were used for in vitro cultures: polyribosyl ribitol phosphate (PRP,
Pasteur Mérieux, Lyon, France) final concentration 5 ng/ml; Tetanus toxoid (TT; National
Institute of Public Health and Environment, Bilthoven, The Netherlands) 1.5 µg/ml; PRPTT
conjugate at a final PRP concentration of 0.5 µg/ml and TT concentration of 1.2 µg/ml. Two TT-
peptides encompassing T helper epitopes) were synthesized [16]: 156 (corresponding to TT
sequences 830-843, QYIKANSKFIGITE) and 158 (corresponding to TT sequences 947-967,
FNNFTVSFWLRVPKVSASHLE). These peptides were used in a concentration of 7.5 mg/ml.
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Results
In vitro induction of the anti-PRP (and anti-TT) antibody response
Adult volunteers were given a single dose of the PRPTT vaccine (Act-Hib®, Pasteur Mérieux,
Lyon, France). 3-4 weeks following vaccination peripheral blood mononuclear cells (PBMC)
were isolated and purified B cells, mixed with equal numbers of T lymphocytes were cultured
and stimulated with various forms of PRP (Figure 1).
Figure 1. In vitro anti-PRP response of blood B cells.
In vitro anti-PRP response of blood B cells obtained 3-4 weeks after vaccination with PRPTT. B cells (0.5 x 106/ml)
were cultured with an equal number of irradiated T cells and 5% monocytes in medium containing 10% heat
inactivated pooled human AB serum and various antigens as indicated. After 6 days of culture, IgG and IgM anti-
PRP (antibody secreting cells (ASC) were determined with a spot-forming cell assay and are expressed per 106
lymphocytes. PRP, final concentration 5 ng/ml; TT, 1.5 µg/ml; PRPTT, 0.5 µg PRP/ml, 1.2 µg TT/ml. The data are
from 21 independent experiments, with different donors. Not all antigens were included in all experiments.
In vitro culturing with PRP only, induced low numbers of IgM (geometric mean 3.7 x/: 5.2) and
IgG (1.2 x/: 2.2) anti-PRP ASC/106 cells, comparable to ASC numbers detected in cells cultured
in medium only (IgM anti-PRP 2.8 x/: 3.8, IgG anti-PRP 2.0 x/: 2.7). Restimulation with PRPTT
induced 23.3 x/: 13.9 IgM anti-PRP ASC/106 cells, and 4.9 x/: 7.3 IgG anti-PRP ASC/106 cells.
Comparable ASC responses were obtained in cultures stimulated with PRP+TT (TT in equal
amounts as present in the conjugate) (128.4 x/: 15.9 IgM anti-PRP ASC/106 cells, 9.3 x/: 7.6 IgG
anti-PRP ASC/106 cells)(Figure 1). From cells cultured with TT only, variable numbers of IgM
anti-PRP ASC were obtained, and less IgG anti-PRP ASC (2.4 x/: 4.9 anti-PRP ASC/106 cells).
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Anti-TT ASC were obtained only after culturing with TT, either free or mixed with PRP or
conjugated to PRP. The response to TT consisted predominantly of IgG ASC (Figure 2).
Figure 2. In vitro IgG anti-TT response of blood B cells.
In vitro IgG anti-TT response of blood B cells obtained 3-4 weeks after vaccination with PRPTT. See legend Figure
1 for details.
It thus can be concluded that an optimal in vitro antibody response to PRP also requires
stimulation with TT. There is, however, no absolute need for polysaccharide and protein to be
physically coupled. Next to PRP and TT, T cells are required for an optimal in vitro anti-PRP B
cell response [14](see also Figure 3).
Relation between the in vitro induced anti-PRP response and T cell proliferation
PRPTT vaccination in adults actually is a booster vaccination with respect to the TT component.
The in vitro proliferative T cell response induced by TT (Table I) is in magnitude comparable to
that induced by a T cell mitogen such as poke weed mitogen (PWM). Because of the magnitude
of this T cell response, the question arised whether the T cells that augment the anti-PRP B cell
response would be antigen (TT) specific, or that the T cell proliferation was due to an aspecific
activation process. To address this question, two TT peptides, 156 and 158, encompassing two
different universal T helper epitopes, were synthesized [16]. Although these peptides are claimed
to be universally antigenic irrespective of MHC haplotype, both peptides induced T cell
proliferation above background values in only 50% of unvaccinated donors tested (Table I).
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Donor 1 2 3 4 5 6 7 8 9
Medium 0.6* 0.2 1.2 0.3 0.5 0.4 0.3 0.3 0.5
Pokeweed mitogen 21 42 22 15 24 35 49 14 57
Peptide 156 9.7 0.5 2.0 3.1 0.6 0.8 0.3 0.3 4.2
Peptide 158 1.8 6.2 1.8 2.8 0.7 1.1 2.5 0.3 28
Tetanus toxoid 61 57 43 70 25 101 82 12 78
Table I. T cell proliferative response upon stimulation with tetanus toxoid and tetanus toxoid peptides.
T cells, obtained from 9 healthy human volunteers (not vaccinated with PRPTT), were reconstituted with autologous
irradiated non-T cells and cultured at a density of 0.5 x 106/ml with different antigens. Cells were cultured for 6 days,
the last 16 hrs in the presence of 1 mCi [3H]thymidine. *Data are expressed as mean [3H]thymidine incorporation (x
1000 cpm) of quadruplicate cultures. Antigen concentrations used: tetanus toxoid: 1.5 µg/ml; tetanus toxoid peptides
156 and 158: 7.5 µg/ml. Pokeweed mitogen: 5 µg/ml.
An association was found between the ability of a given TT peptide to induce T cell proliferation
and to support the in vitro anti-PRP antibody response (Table II). Note that because the peptides
encompass T helper epitopes, they are unable to induce an anti-TT B cell response.
These data show that TT peptide specific T cell activation is able to support the anti-PRP B cell
response.
ASC/106 cells T cell proliferation
anti-PRP anti-TT (cpm ´ 1000)
Medium 5 <5 1.8*
PRP <5 <5 <1
PRPTT 88 316 13.5
PRP + tetanus toxoid 165 497 48.5
PRP + peptide 156 114 <5 23
PRP + peptide 158 <5 <5 <1
tetanus toxoid 221 1340 58
Table II. Relation between the in vitro anti-PRP response of blood B cells obtained 3-4 weeks after vaccination with
PRPTT and the in vitro induced T cell proliferation.
B cells (0.5 x 106/ml) were cultured with an equal number of irradiated T cells and 5% monocytes in medium
containing 10% heat inactivated pooled human AB serum and different antigens. After 6 days of culture, anti-PRP as
well as anti-TT ASC were determined with a spot-forming cell assay and are expressed per 106 lymphocytes. T cells
were reconstituted with autologous irradiated non-T cells and cultured at a density of 0.5 x 106/ml with different
antigens. Cells were cultured for 6 days, the last 16 hrs in the presence of 1 mCi [3H]thymidine. *Data are expressed
as mean [3H]thymidine incorporation (x 1000 cpm) of quadruplicate cultures. Antigen concentrations used: TT, 1.5
µg/ml; PRPTT, 0.5 µg PRP/ml, 1.2 µg TT /ml, TT-peptides 156 and 158: 7.5 µg/ml. Data from one representative
donor out of 4 independent experiments.
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Interaction between T and B lymphocytes in the anti-PRP antibody response
In order to characterize in more detail the T cell help necessary for an anti-PRP B cell response,
Transwell studies were set up. In this system it is possible to physically separate different cell
populations, while diffusion of antigen and soluble mediators remains possible.
Culturing of B lymphocytes with only PRP induces no or minimal IgM anti-PRP ASC (data not
shown). Also no anti-PRP antibody response is seen when the B cells (lower compartment) are
cultured with PRP plus TT in the absence of T cells in the upper compartment (Figure 3 a).
Culturing of B and T lymphocytes together with 5% antigen presenting cells in one
compartment, with only PRP as antigen, induces a few IgM anti-PRP ASC (Figure 1).
In vitro culture of B lymphocytes and T lymphocytes in the lower compartment with PRP plus
TT as antigens induces both anti-PRP (geometric mean 151.9 x/: 18.4 ASC/106 cells) and anti-
TT ASC (110.1 x/: 17.0) (Figure 3 b). Culturing the B cells physically separated from the T cells
and the monocytes, however, elicits no anti-TT ASC (3.0 x/: 5.2) and hardly any anti-PRP ASC
(21.7 x/: 5.3) (Figure 3 c). When B and T cells are cultured together with 5% monocytes in the
lower compartment, and B cells only in the upper compartment of the Transwell system, quite
remarkable results are obtained. The lower compartment shows results as expected: both anti-
PRP (140.8 x/: 19.6) and anti-TT ASC (105.0 x/: 13.8) (Figure 3 d). Assessing ASC from the
upper (B cells only) compartment shows that anti-PRP ASC are generated (36.3 x/: 8.6), but no
anti-TT ASC (3.9 x/: 4.6) (Figure 3 e). This result suggests that soluble mediators derived from T
cells can support an anti-polysaccharide antibody response by B lymphocytes, while an anti-
tetanus toxoid antibody response does not take place under these circumstances.It can be
concluded that optimal in vitro B cell activation by polysaccharides requires T lymphocyte
activation. However, there seems to be a distinct difference between the T cell help necessary for
B cell activation by polysaccharides and the T cell help needed in an anti-protein response. In the
latter situation physical interaction between T and B lymphocytes is required; for a
polysaccharide response soluble mediators are sufficient.
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Figure 3. In vitro anti-PRP and anti-TT response of blood B cells under various culture conditions using the
Transwell system.
In lane a, B cells (0.7 x 106) were cultured in medium containing 10% heat inactivated pooled human AB serum and
PRP + TT. In the control experiment (lane b), B cells (0.7 x 106) were cultured with an equal number of irradiated T
cells and 5% monocytes in medium containing 10% heat inactivated pooled human AB serum and PRP + TT. By
means of a Transwell system, B cells (0.7 x 106) were also cultured separately from T cells (0.7 x 106) with 5%
monocytes (lane c). The last two lanes (d and e) show the results of culturing B cells (0.7 x 106) separated by the
Transwell system from the lower compartment containing B cells (0.7 x 106) and an equal number of irradiated T
cells and 5% monocytes. After 6 days of culture, anti-PRP as well as anti-TT ASC were determined with a spot-
forming cell assay and are expressed per 106 lymfocytes. All cultures were stimulated with PRP (5 ng/ml) + TT (1.5
µg/ml). * = compartment from which the ASC are depicted. The data represent 9 separately conducted experiments,
with 9 different donors.
Discussion
The proposed cellular interaction mechanism for protein conjugated polysaccharides combines
the models for TI-2 and TD B cell activation. The B cell receptor of a polysaccharide-specific B
cell recognizes the polysaccharide component and binds and internalizes the polysaccharide-
protein conjugate. Intracellularly, the protein is processed and peptide fragments are
subsequently presented in MHC class II molecules. Peptide-specific T cells become activated
and produce B cell stimulating cytokines. In this way, the polysaccharide-specific B cell receives
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T cell help from the peptide- (protein-) specific T cell [17;18]. Whether it is sufficient to have
activated (peptide-specific) T cells, producing B cell stimulatory cytokines, in the proximity of
polysaccharide-specific B cells, or that physical contact between the two cell types is necessary,
is unknown.
From our experiments it can be concluded that for the formation of anti-polysaccharide ASC, the
presence of (TT-)activated T cells is needed. This is in accordance with the above described
model for the working mechanism of conjugate vaccines: the activated TT-peptide-specific T
cells, produce cytokines that stimulate polysaccharide-specific B cells.
As we have shown, this T cell help can be induced by culturing with PRP+TT, with PRPTT, as
well as with PRP mixed with TT-peptides. The number of anti-PRP ASC generated correlates
with the magnitude of the T cell proliferative response to these antigens (Table II).
The highest number of anti-PRP ASC are obtained after culturing with PRP mixed with TT or
conjugated to TT (Figure 1). We do find IgM anti-PRP ASC when culturing with TT only, even
although at the time of sampling (3-4 weeks after vaccination with PRPTT) no anti-PRP (nor
anti-TT) ASC are found in a direct ASC assay (data not shown). We presume that at the time of
sampling there are cells present in the peripheral blood of the vaccinees, that are committed to
become anti-PRP ASC. They apparently only need activation provided by cytokines secreted by
activated (anti-TT) T cells.
In vivo, admixture of polysaccharide and protein does not change the nature of the anti-
polysaccharide antibody response. For an effective conjugate vaccine, the polysaccharide and the
protein need to be physically coupled [19]. In vitro, however, mixtures of polysaccharide and
protein are as effective as a conjugate in inducing B cell activation in donors immunized with the
conjugate vaccine [20]. These data therefore are compatible with Mosier’s postulate [21] that the
function of a conjugate would merely be to ensure localization of protein antigens (required for T
cell activation) at the site of polysaccharide homing. In vitro, protein and polysaccharide are
present in close relationship with B as well as T cells, so physical coupling might not be
necessary. Throughout all our experiments, PRP conjugated to TT induced anti-PRP responses
equal to those seen after restimulation with mixture of PRP and TT. This confirms the earlier
observations mentioned previously.
T cells in the anti-polysaccharide response
101
In our in vitro system, the presence of T cells is necessary for an optimal anti-protein as well as
for an anti-polysaccharide ASC response (Figure 3). The requirements for the antibody response
against the polysaccharide, however, are different from those in the response against proteins.
In agreement with the described model for activation of protein-specific B cells in the
introduction, direct physical contact between B cells and (activated) T cells is necessary for
induction of an anti-protein antibody response (Figure 3).
When T cells and antigen presenting cells are physically separated from the B cells by the
Transwell membrane, no anti-TT antibody secreting cells were found. Also, when contact
between B and T cells was possible in one compartment of the Transwell system, the release of
soluble factors due to T-B cell contact in that compartment did not result in an anti-TT antibody
response in the other compartment. Apparently, cytokines formed as a consequence of contact
between protein-specific B and T cells are in itself not sufficient to activate protein specific B
cells; direct T-B cell contact is an absolute requirement.
The Transwell studies also indicate that contact between B and T cells is necessary to induce an
optimal anti-PRP antibody response (Figure 3). When T cells and APC were physically
separated from the B cells by the Transwell membrane, hardly any anti-PRP specific antibody
secreting cells were found (Figure 3 c). The presence of low levels of anti-PRP ASC when the B
cell fraction was cultured with PRP + TT may be explained by T cell activation in the upper
compartment by TT. These activated T cells may secrete cytokines which augment
differentiation of PRP-activated B cells in the lower compartment.
When contact between B and T cells was possible in one compartment of the Transwell system,
this apparently resulted in the release of soluble factors able to stimulate B cells in the other
compartment to secrete anti-PRP antibodies (Figure 3 e). Both in Figure 3 c and e, T
lymphocytes are cultured with antigen presenting cells (monocytes in 3 c, B cells and monocytes
in 3 e) and TT. These T lymphocytes can produce cytokines which can diffuse to the other
compartment. Yet, this does not result in anti-PRP ASC formation in 3 c, while in 3 e anti-PRP
ASC are generated. The difference between 3 c and e is the presence of B lymphocytes in 3 e.
Our results suggest that cytokines are produced by B cells that can activate anti-polysaccharide-
specific B cells to make antibodies.
These results are partly in accordance with the proposed model for the working mechanism of a
conjugate vaccine: the polysaccharide-specific B cells internalize the conjugate, process the
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protein part and express the peptides in their MHC to activate peptide-specific T cells. Direct
physical contact between B and T cells is necessary in this part of the process. Activated T cells
than secrete cytokines that activate the polysaccharide-specific B cells to become ASC. We now
have shown that in this part of the process, the activated B cells may secrete cytokines that are
able to activate other polysaccharide-specific B cells to become ASC. The nature of these soluble
mediators is currently under investigation.
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Children with recurrent episodes of otitis media can have a deficient IgG2 antibody response to
polysaccharide antigens. We have vaccinated 5 otitis-prone children with heptavalent
pneumococcal conjugate vaccine. While the patients did show an IgG1 antibody response to all
pneumococcal serotypes included in the conjugate vaccine, the IgG2 response, especially to
serotypes 6B, 9V, 19F and 23F, was poor. However, vaccination with a 23-valent polysaccharide
vaccine 6 months after conjugate vaccination did induce an 11.5-163 fold increase in IgG2 anti-
polysaccharide antibody titers. It can be concluded that a specific IgG2 anti-polysaccharide
antibody deficiency can be overcome by priming with a pneumococcal conjugate vaccine,
followed by a booster with a polyvalent polysaccharide vaccine.
Pneumococcal conjugate primes for IgG2 response
Introduction
Acute otitis media (AOM) is the most frequently occurring bacterial infection in infants and
young children. By the age of three years, 71% of children have had one or more episodes of
AOM [1]. Streptococcus pneumoniae is the main pathogen in bacterial AOM, involved in at least
50-60% of the cases. The defense against infections with these bacteria, characterized by their
polysaccharide capsule, depends primarily on antibodies against the capsular polysaccharide.
The peak incidence of childhood AOM is between 6-18 months of age, which matches the period
after maternally derived antibodies have disappeared and before onset of antibody formation to
polysaccharide antigens. Up to 5% of all children are highly susceptible to infections with
Streptococcus pneumoniae, manifested in frequently recurrent episodes of AOM. This condition,
termed otitis prone, can persist beyond the age of 2 years. Otitis-prone children are suggested to
be immunologically different from age matched healthy children in their inability to mount an
adequate IgG2 antibody response to S. pneumoniae [2]. We previously described a group of
children with frequent recurrent mucosal respiratory tract infections. These children showed low
to absent IgG2 and/or IgA anti-pneumococcal polysaccharide antibody responses following
vaccination with pneumococcal polysaccharide vaccine, despite normal serum IgG2 en IgA
immunoglobulin levels [3]. Recently, D’Hooghe et al. observed in a group of patients with otitis
media with effusion (OME), significantly lower IgG2 and/or IgA anti-pneumococcal
polysaccharide antibody responses following vaccination with pneumococcal polysaccharide
vaccine compared to age-matched, healthy controls (Dhooge et al, manuscript in preparation). In
all these three studies, the IgG1 anti-polysaccharide antibody responses was normal. These
observations suggest that IgG2 anti-polysaccharide antibodies are required for clinical protection
against AOM.
Polysaccharide conjugate vaccines have been developed to change the nature of the anti-
polysaccharide antibody response into a T cell dependent response and thus induce responsivity
early in life. Pneumococcal conjugate vaccines (PCV) indeed have been shown to be
immunogenic in infants [4-6] and to induce immunological memory [6]. PCV induce primarily
an IgG1 type anti-polysaccharide antibody response [6]. It remains to be determined whether
IgG1 antibodies only will be sufficient to prevent mucosal infections like AOM in an otitis prone
childhood population. In view of above arguments, the induction of IgG2 or IgA anti-
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pneumococcal polysaccharide antibodies may be necessary for optimal protection against
mucosal respiratory tract infections.
Based on the results of a study of O'Brien [6] and our own -unpublished- observations, we
hypothesized that priming with a conjugate vaccine, followed by vaccination with a
pneumococcal polysaccharide vaccine might induce an increased IgG antibody response and
favor a shift towards an IgG2 type antibody response. We here present the results of a
preliminary study in five otitis-prone children vaccinated with a pneumococcal conjugate
vaccine, followed by booster vaccination with a pneumococcal polysaccharide vaccine.
Methods
Patient population
The patients included in this study were referred to the Department of Immunology of our
hospital by their pediatrician or otolaryngologist because of recurrent AOM with otorhea for at
least 6-8 episodes per year. All five patients were Caucasian and older than two years of age (2.1
- 12.5 years at time of conjugate vaccination). The episodes of AOM were characterized by signs
of pain, irritability, new otorhea and additional symptoms like fever ( > 38.5 °C) and
concomitant signs of upper respiratory tract infection. The diagnosis AOM was confirmed when
patients also had otoscopic signs typical for AOM (Casselbrant,1992). None of the patients had
anatomic abnormalities, nor suffered from recognized disease entities like cystic fibrosis or
granulocytopenia. Total serum immunoglobulin levels (IgG and IgG subclasses, IgA and IgM)
were normal for age. In two patients total IgE levels were increased (300 and 53 U/l,
respectively). Complement-activity was normal as were antibody responses to tetanus and
diphtheria toxoid. Two of the patients had previously (2 and 7.5 years respectively before
conjugate) received a 23-valent pneumococcal polysaccharide (PnPS) vaccine (Pneumovax,
Merck, Sharp and Dohme, Haarlem, The Netherlands), containing 25 mg of purified type-specific
capsular polysaccharides of 23 pneumococcal serotypes (1, 2, 3, 4, 5, 6B, 8, 9N, 9V, 10A, 12F,
14, 15B, 17F, 18C, 19F, 20, 22F, 23F, 33F) to assess their capacity to respond to polysaccharide
antigens. Both patients mounted an IgG1 and IgM anti-pneumococcal polysaccharide response;
no IgG2 (post vaccination titers <20 U/ml for 6/8 and 8/8 tested serotypes respectively) and
hardly any IgA anti-polysaccharide antibodies were induced.
Pneumococcal conjugate primes for IgG2 response
Written parental consent was obtained before immunization intramuscularly with a heptavalent
pneumococcal conjugate vaccine (PCV, containing pneumococcal polysaccharides serotypes 4,
6B, 9V, 14, 18C, 19F and 23F, conjugated either to CRM197 (Wyeth Lederle Vaccines and
Pediatrics, Rochester, NY) or conjugated to meningococcal outer membrane protein (OMP;
Merck Research Laboratories, Blue Bell, PA). Latter PCV was given in the context of a
compassionate use protocol. A booster vaccination with 23-valent PnPS vaccine was given 6
months after the vaccination with PCV. Serum was drawn before and 2-4 weeks after each
vaccination and stored at -80 °C until use.
Determination of type specific anti-polysaccharide antibodies.
IgG1-, IgG2-, IgA- and IgM-type serum antibody levels to the seven pneumococcal
polysaccharides included in the conjugate vaccine and to two pneumococcal polysaccharides not
included in the PCV (serotypes 1 and 12), were measured by ELISA as described previously [3].
Pre- and postvaccination serum samples were analyzed simultaneously. All serum samples were
preincubated overnight with excess free common cell wall polysaccharide (CPS) to remove anti-
CPS antibodies. A standard serum from a normal non-vaccinated adult was included in every
ELISA-run as a control.
Antibody concentrations of patient samples were expressed relative to a reference adult
hyperimmune plasma pool [7]. The latter was assigned 100 U/ml (100%) for each serotype.
Results
Anti-pneumococcal antibody responses following PCV
Vaccination with PCV induced a significant (2.7 - 43 fold) increase in IgG1 antibody levels for
all pneumococcal serotypes included in the vaccine (4, 6B, 9V, 14, 18C, 19F and 23F; see Table
1). Mean IgG2-anti-pneumococcal polysaccharide antibody levels after vaccination with PCV
remained <20 U/ml for all serotypes, except for serotype 14. The reason is that one patient
mounted an extremely high IgG2 anti-PS14 antibody response (1968 U/ml). The IgA antibody
response was >20 U/ml for 4 of the serotypes included in the PCV. As expected, antibody levels





a range b range range
IgG1-PS4 6 (1-19) 116 (16-207) 43.0 (8.0-120)
IgG1-PS6B 151 (21-615) 295 (30-1115) 2.7 (1.4-5.2)
IgG1-PS9V 85 (1-396) 99 (3-442) 3.6 (1.0-13.0)
IgG1-PS14 26 (7-67) 267 (16-922) 6.0 (2.3-13.8)
IgG1-PS18 14 (7-32) 139 (70-252) 15.9 (5.3-36.0)
IgG1-PS19F 171 (13-675) 405 (32-1264) 4.2 (1.1-14.2)
IgG1-PS23F 55 (8-198) 117 (33-251) 5.3 (1.3-15.0)
IgG2-PS4 2 (1-6) 12 (1-28) 9.8 (1.0-28.0)
IgG2-PS6B 1 (1-3) 1 (1-2) 1.1 (0.7-2.0)
IgG2-PS9V 1 (1-1) 2 (1-2) 1.2 (1.0-2.0)
IgG2-PS14 8 (1-16) 522 (1-1968) 35.0 (1.0-123)
IgG2-PS18 2 (1-3) 19 (4-36) 12.8 (4.0-28.0)
IgG2-PS19F 1 (1-1) 1 (1-3) 1.4 (1.0-3.0)
IgG2-PS23F 1 (1-1) 2 (1-4) 1.6 (1.0-4.0)
IgA-PS4 3 (1-10) 65 (3-274) 32.0 (1.2-13.7)
IgA-PS6B 4 (1-9) 68 (2-295) 10.8 (1.4-33.0)
IgA-PS9V 3 (2-5) 5 (2-12) 1.5 (1.0-2.4)
IgA-PS14 9 (4-14) 235 (9-852) 4.4 (2.1-8.5)
IgA-PS18 136 (6-471) 142 (61-223) 6.2 (0.4-14.8)
IgA-PS19F 6 (3-10) 21 (7-69) 4.6 (0.9-17.0)
IgA-PS23F 7 (4-12) 16 (6-39) 2.4 (0.9-9.8)
IgG1-PS1 8 (3-13) 6 (5-8) 0.8 (0.6-1.1)
IgG1-PS12 45 (23-65) 34 (23-42) 0.8 (0.6-1.3)
IgG2-PS1 4 (1-15) 4 (1-13) 1.0 (0.9-1.0)
IgG2-PS12 6 (1-24) 4 (1-17) 0.9 (0.7-1.0)
IgA-PS1 14 (5-23) 10 (5-15) 0.8 (1.0-1.5)
IgA-PS12 10 (4-14) 10 (4-16) 1.1 (0.7-1.6)
Table 1. Serotype specific antibody response to pneumococcal conjugate vaccine in children with recurrent otitis
media:
Mean antibody levels to pneumococcal serotypes included in the PCV (4, 6B, 9V, 14, 18, 19F and 23F) and 2 non-
PCV serotypes (1 and 12) before and after vaccination with PCV. The range in antibody titers and fold increase in
titer is indicated between brackets.
Antibody responses following pneumococcal polysaccharide vaccination
Six months after vaccination with the PCV, patients were booster vaccinated with a 23-valent
PnPS vaccine. This booster vaccination with non-conjugated polysaccharides now induces a
clear-cut IgG2 antibody response, illustrated for serotypes 9V and 23F in Figure 1. Among the 7
PCV serotypes, post PnPs IgG2 titers to 6B and 23F are the lowest, although for both serotypes
the fold increase in IgG2 antibodies is >10 (Table 2).
Pneumococcal conjugate primes for IgG2 response
pre-vaccination post-vaccination fold-increase
a range b range range
IgG1-PS4 56 (16-180) 778 (38-2109) 23.8 (2.4-63.9)
IgG1-PS6B 66 (30-96) 2677 (284-5000) 40.2 (9.5-89.5)
IgG1-PS9V 11 (3-24) 568 (29-2058) 47.9 (9.7-137)
IgG1-PS14 126 (28-316) 1813 (489-5000) 31.3 (2.3-126)
IgG1-PS18 88 (12-314) 732 (49-1569) 25.1 (0.7-54.1)
IgG1-PS19F 58 (17-138) 3103 (93-5000) 76.2 (2.0-178)
IgG1-PS23F 49 (19-134) 246 (46-744) 10.3 (0.4-39.2)
IgG2-PS4 6 (1-12) 125 (18-230) 28.3 (1.5-138)
IgG2-PS6B 1 (1-7) 31 (2-54) 17.0 (2.0-25.5)
IgG2-PS9V 5 (1-17) 65 (27-143) 47.9 (1.6-143)
IgG2-PS14 92 (1-334) 273 (174-447) 48.8 (1.3-224)
IgG2-PS18 146 (2-334) 98 (36-221) 26.4 (0.2-49.5)
IgG2-PS19F 1 (1-3) 184 (17-558) 163.2 (17.0-558)
IgG2-PS23F 3 (1-9) 18 (10-30) 11.5 (1.4-28.0)
IgA-PS4 40 (5-135) 219 (13-488) 10.4 (1.9-25.7)
IgA-PS6B 31 (7-111) 165 (27-368) 14.0 (1.8-52.6)
IgA-PS9V 7 (4-13) 169 (14-485) 23.7 (3.5-38.8)
IgA-PS14 59 (19-172) 241 (49-635) 8.9 (1.2-33.4)
IgA-PS18 57 (19-122) 491 (39-1132) 8.7 (0.6-19.1)
IgA-PS19F 16 (7-23) 954 (56-1596) 55.7 (8.0-98.4)
IgA-PS23F 16 (7-26) 65 (20-174) 3.9 (1.4-6.8)
IgG1-PS1 6 (3-10) 82 (11-144) 10.0 (1.8-18.4)
IgG1-PS12 32 (19-46) 488 (36-1209) 13.2 (1.4-28.8)
IgG2-PS1 4 (1-13) 29 (6-74) 22.7 (1.2-74.0)
IgG2-PS12 4 (1-17) 15 (7-23) 8.2 (1.4-22)
IgA-PS1 12 (5-20) 58 (17-155) 3.8 (1.1-7.8)
IgA-PS12 11 (4-16) 40 (17-73) 3.5 (1.6-5.6)
Table 2. Antibody response to polyvalent pneumococcal polysaccharide vaccine in PCV primed patients.
Mean antibody levels to pneumococcal serotypes included in the PCV (4, 6B, 9V, 14, 18, 19F and 23F) and 2 non-
PCV serotypes (1 and 12) before and after vaccination with PCV. The range in antibody titers and fold increase in
titer is indicated between brackets.
Booster vaccination with the PnPS vaccine also induced a substantial IgA antibody response and
a further increase in IgG1-anti-pneumococcal polysaccharide antibodies (Figure 1 and Table
2).he antibody titers reached after vaccination with PnPS against serotypes not included in the
PCV (1 and 12) were considerably lower.
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Figure 1. Antibody response to serotypes 9V (upper panels) and 23F S. pneumoniae polysaccharides (lower panels)
in children with recurrent otitis media.
Open symbols represent patients who received the OMP pneumococcal conjugate vaccine (PCV), closed symbols are
the patients vaccinated with the CRM PCV. Six months after PCV all patients received a 23-valent pneumococcal
polysaccharide vaccine (PnPS).
Discussion
Polyvalent pneumococcal polysaccharide vaccines normally induce IgM, IgG1, IgG2 and IgA
antibodies of which especially in adults and older children IgG2 is the predominant isotype.
Although it has been demonstrated that anti-polysaccharide antibodies confer protection against
infections with encapsulated bacteria, the actual contribution of the various isotypes to host
defense is unknown. Patients with an IgA and/or IgG2 deficiency have an increased
susceptibility for mucosal infections with encapsulated bacteria. We previously described a
childhood population with recurrent mucosal upper respiratory tract infections, where
encapsulated bacteria like S. pneumoniae are a major pathogen. Striking was the low to absent
IgG2 and IgA antibody response: 43% of all children had defective IgG2 antibody responses and
22% also low IgA antibody responses following vaccination with the 23-valent PnPS vaccine
[3]. Therefore, the inability to make IgG2- and IgA-type anti-pneumococcal polysaccharide
Pneumococcal conjugate primes for IgG2 response
antibodies appears to define a clinical entity of high susceptibility for mucosal infections with
bacteria like S. pneumoniae.
The frequent occurrence of infections with encapsulated bacteria in infants and young children
reflects the ontogeny of the components of host defense [8;9]. The existing polysaccharide
vaccines are of limited use in infants and young children because for many polysaccharide
antigens, adequate antibody titers are not attained until the age of 18-24 months or later [10].
However, covalent conjugation of a protein carrier to bacterial capsular polysaccharides induces
upon immunization a T cell dependent antibody response and priming for an anamnestic or
secondary response [10-12]. Pneumococcal conjugate vaccines (PCV) have recently been shown
to be safe and immunogenic in healthy infants and young children [13-15]. They are known to
prime the vaccinees to respond to a nonconjugated polysaccharide vaccine [14;15]. Furthermore,
secondary immunization with pneumococcal polysaccharide vaccine after priming with a
conjugate vaccine, elicited in those healthy infants and young children an increase in both IgG1
and IgG2 subclasses [6].
In children with recurrent mucosal respiratory tract infections, an aberrant response to
pneumococcal polysaccharide vaccines is frequently observed [3;16]. The data in this study
indicate that the specific IgG2 anti-polysaccharide antibody deficiency in patients with recurrent
respiratory tract infections, can be overcome by vaccination with PCV followed by booster
vaccination with a polyvalent pneumococcal polysaccharide vaccine. Otitis prone children as
well as other patient groups at risk for invasive infections with encapsulated bacteria therefore
might benefit from such a vaccination schedule.
The mechanism of how a PCV can prime for a PnPS inducible IgG2 response is unknown. It
would be desirable if priming would also occur for serotypes not included in the PCV. Our data
on the PnPS booster vaccination induced IgG2 response to serotypes 1 and 12 are not conclusive
in that respect. A larger group of patients, as well as a control group not primed with PCV, are
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Despite good IgG1 responses, patients with recurrent bacterial respiratory tract infections
often show poor IgG2- and IgA anti-pneumococcal antibody titers as compared with healthy
age-matched controls, both before and after immunization with pneumococcal polysaccharide
vaccines.
Also, children with a partial IgG2 and/or IgA deficiency have an increased susceptibility for
mucosal infections with Streptococcus pneumoniae. In children, pneumococcal conjugate
vaccines induce primarily IgG1 antibody responses. We show that in patients with recurrent
respiratory tract infections, both with normal IgA and IgG2 serum immunoglobulin levels as
well as in and in patients with partial IgG2 and/or IgA deficiency, the combination of
pneumococcal conjugate vaccine followed by pneumococcal polysaccharide vaccination not
only increases IgG1 type antibody responses, but also induces IgG2 and IgA anti-
pneumococcal antibody responses. This vaccination stategy may be optimal to prevent
recurrences of respiratory tract infection in susceptible subjects and has to be clinically
investigated in these infection-prone children.
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Introduction
Streptococcus pneumoniae is a major pathogen in respiratory tract infections (RTI) in
children, like acute otitis media (AOM), sinusitis, bronchitis and community-acquired
pneumonia [1-3]. In the past, two studies have shown a beneficial effect of vaccination with
polyvalent pneumococcal polysaccharide vaccine in preventing recurrent attacks of AOM in
children over 2 years of age. The duration of the protective effect was limited to one year
[4;5]. However, in large efficacy trials, immunization with the polyvalent pneumococcal
polysaccharide vaccines was not successful in the overall reduction of RTI including AOM,
nor in reduction of antibiotic use in infants and preschool children [4;6-8;9].
This lack of efficacy is explained by the fact that most polysaccharide antigens are poorly
immunogenic in children below 5 years of age, and by the fact that polysaccharide antigens
do not induce immunological memory [10;11]. Furthermore, despite good IgG1 responses,
children with recurrent bacterial RTI may show poor IgG2- and IgA anti-pneumococcal
antibody titers as compared with non-otitis prone controls, both before and after immunization
with polysaccharide vaccines [12;13] and some children fail to respond at all to vaccination
with polysaccharide antigens [14-17]. There seems to be a correlation between impaired
antibody responses to pneumococcal polysaccharide vaccine and recurrent attacks of
pneumococcal AOM.
Pneumococcal conjugate vaccines (PCV) seem to overcome many of these major drawbacks
in infants and children. In contrast to polysaccharide vaccines, both the heptavalent (PCV7)
and nonavalent PCV (PCV9) induce good IgG antibody responses in infants when given as a
separate injection at 2, 4, 6 and 12-15 months of age concomitantly with routine infant
vaccinations. Induction of memory seems to occur, since significant booster responses are
observed after additional doses of either PCV or pneumococcal polysaccharide vaccine (PPV)
given at intervals of a few months to a year after the primary series [11;18;19]. Importantly,
PCV is able to induce IgG antibody responses in otitis-prone children [20] and in patients
with RTI who previously had failed to respond to the polysaccharide vaccine [21].
Furthermore, in highly otitis-prone children, PCV followed by PPV induced, apart from
specific IgG1-, also IgG2- and IgA- anti-pneumococcal antibody responses [22].
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PCV7 was shown to be highly effective in preventing invasive disease in healthy infants in
the randomized efficacy trial by the Northern California Kaiser Permanente Vaccine Study
Center Group. This study, including 37,830 infants, showed a 93.9% efficacy in preventing
invasive disease (intent-to-treat analysis, 95% confidence interval (CI) 79.6 to 98.5% [23]).
The effect of PCV7 on the incidence and severity of AOM was evaluated as a secondary end-
point in this study. Total otitis media-related visits were decreased by 8.9% (95% CI 5.8-
11.8%) in PCV7 vaccine recipients. A more pronounced reduction in AOM was observed
among those children with frequent episodes of AOM: a 9.1% (95% CI 4.1-13.8%) decrease
in those children with at least 3 episodes in 6 months or 4 episodes in one year, and a 22.8%
decrease (95% CI 6.7%–36.2%) in those children with 5 episodes in 6 months or 6 episodes in
a year. In the analysis of spontaneous draining ears, vaccine efficacy was 65% for AOM
caused by vaccine-serotypes. In a Finnish trial, an estimated vaccine efficacy of 57% (95% CI
44%-67%) against culture-confirmed AOM, caused by vaccine serotypes was found. Efficacy
against AOM, again in healthy infants, irrespective of etiology was 6% (95% CI 4%-16%)
[24].
Data from the nineteen-eighties from Rosen and from Makela [4;5] with the 14-valent
polysaccharide vaccine in children with previous attacks of AOM as well as the recent Black
data [23] suggest that the children with recurrent AOM or recurrent respiratory tract
infections may be the ones to benefit from pneumococcal vaccination, both with the conjugate
and polysaccharide vaccine. The optimal vaccination strategy to achieve not only adequate
IgG responses and memory at an early age and in non-responders, but preferably also IgG2-
and IgA responses in children with frequent recurrent AOM or RTI has to be determined.
In this study we analyzed antibody responses after pneumococcal vaccination of children with
frequent RTI. The patients had either normal serum immunoglobulin concentrations or partial
IgG2 and/or IgA deficiency, which is frequently observed in these infection-prone children.
We compared antibody responses after vaccination with PCV7 followed by a PPV booster
with responses obtained after vaccination with PPV only. In younger (12-18 months old)
otitis-prone children we evaluated the immunogenicity of two doses of PCV7.




The protocol was approved by the local research ethics committees.
A total of 65 patients (1-6 years old) were included in this study. They were referred to the
Department of Pediatric Immunology of the University Hospital Utrecht by pediatricians or
otolaryngologists because of recurrent and often prolonged upper respiratory tract infections.
All patients suffered from recurrent acute otitis media or sinubronchitis episodes for which
they needed antibiotics (at least 3 episodes in 6 months, or at least 4 in the previous year).
Patients with underlying chronic or progressive disease, craniofacial abnormalities, asplenia,
Down syndrome, immunodeficiencies other than partial serum IgA- and IgG2 deficiencies, as
well as patients with a history of seizures or previous pneumococcal vaccination were
excluded. Written informed consent was obtained from the parents or legal guardian before
enrollment.
Patients were recruited between April 1996 and September 1999. Before January 1998, all
patients included were over 2 years of age and were immunized intramuscularly with 23-
valent pneumococcal polysaccharide vaccine (PPV23), containing 25 mg of purified capsular
polysaccharides of each of the pneumococcal serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A,
11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F and 33F. After January 1998, patients
were included from the age of 12 months. They were vaccinated with the investigational
heptavalent pneumococcal conjugate vaccine (PCV7), containing the polysaccharides of the
pneumococcal serotypes 4, 9V, 14, 19F and 23F and an oligosaccharide of serotype 18C (2 mg
each) and polysaccharide type 6B (4 mg), conjugated to CRM197 carrier protein (Wyeth
Lederle Vaccines and Pediatrics, Rochester, NY). Children over 24 months of age receiving
PCV7 were boosted with PPV23 six months after vaccination with PCV7. Children 12-23
months of age received two doses of PCV7, at least 6-8 weeks apart. Serum was drawn before
and 2-4 weeks after each vaccination and stored at -20ºC until analysis.
Determination of serum immunoglobulins and antibody response to protein antigens
Concentrations of IgM, IgG and IgG subclasses, and IgA were determined on 2 or more
occasions by radial immunodiffusion. A range of 2SD below to 2SD above the age-adjusted
mean was considered normal [25;26]. Diphtheria and tetanus-toxoid antibodies were
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determined as described [27]. A titer of less than 0.1 U/ml for a fully vaccinated child was
considered below normal.
Determination of specific anti-pneumococcal polysaccharide antibodies
IgG1-, IgG2-, and IgA-type serum antibody levels to four pneumococcal polysaccharides
included in both the conjugate vaccine and polysaccharide vaccine (serotypes 4, 6B, 9V and
19F) were measured by ELISA as described previously [17]. All serum samples were
preincubated overnight with excess free common cell wall polysaccharide (CPS) to remove
anti-CPS antibodies [28;29]. A standard serum from a normal non-vaccinated adult was
included in every ELISA-run as a control. Pre- and post-vaccination serum samples from
individual patients were analyzed simultaneously. Antibody concentrations of patient samples
were calculated using a reference adult hyperimmune plasma pool [30]. The latter was
assigned 100 U/ml (100%) for each serotype. Weight-based antibody concentrations were
assessed in comparison with the anti-pneumococcal standard serum lot 89-S [31;32].
Statistical analysis
Comparability of groups regarding to age and comparisons of anti-pneumococcal antibody
responses between groups were made by two-sided t-tests. P-values <0.05 were considered
statistically significant. Log-transformed values were used in calculations of means of
responses to each pneumococcal serotype, expressed as geometric mean antibody titers.
Results
Patients
Before April 1998, 27 children with normal concentrations of serum immunoglobulins
(Tables 1a and 2a) and 13 with partial IgA and/or IgG2 deficiency (Tables 1b and 2b) were
vaccinated i.m. with a single dose of PPV23.
After April 1998, 25 children were vaccinated i.m. with PCV7; 16 of those 25 had normal
serum immunoglobulin concentrations (Tables 1a and 2a) while 9 patients had a partial IgA
and/or IgG2 deficiency (Tables 1b and 2b). Eight of the 25 patients were younger than 2
years; they received a second vaccination with PCV after 6-8 weeks. Of the 17 patients older
than 2 years, 12 received a booster with PPV23 at least 6 months after vaccination with
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PCV7. The antibody responses to diphtheria and tetanus toxoid were adequate for all 65
patients (data not shown). The groups of children over 2 years of age, both with normal
immunoglobulins or with partial IgA and/or IgG2 deficiency, receiving either PCV7-PPV23
or PPV23, did not differ in age (Tables 1 and 2).
Anti-pneumococcal antibody responses in children over 2 years of age.
In children over two years of age with recurrent respiratory infections, including those with
partial serum-IgA and/or IgG2-deficiency, one dose of PCV induced an IgG1 antibody
responses against all serotypes tested. The IgG1 type responses to 6B and 19F were
significantly higher than after vaccination with PPV23 (p < 0.05). However, after one dose of
PCV7, no increase in specific IgG2 nor in IgA- antibodies was observed for any serotype,
despite the fact that they were at least 24 months of age. After boosting with PPS23 of
children with normal serum immunoglobulin concentrations not only further increases in the
IgG1 antibody responses were observed, but now also IgG2 and IgA-anti-pneumococcal
polysaccharide responses were induced, reaching significance for IgG2 and IgA anti-6B and -
19F (p<0.01), and IgA anti-9V (p<0.05) as compared with vaccination with PPV23 only.
Importantly, even in children with partial serum IgG2- and IgA-deficiency, boosting with
PPV23 resulted in a rise in IgG2- and IgA-type anti-pneumococcal antibody titers, reaching
significance for IgG2 anti-6B (p<0.05) and IgG2- and IgA- anti-19F (p<0.01) as compared
with a single dose of PPV23.
Anti-pneumococcal antibody responses in children 12-18 months of age
In children 12-18 months old, a single dose of PCV did not induce high antibody titers, but
primed for high IgG1 responses after the second dose, although anti-6B antibody production
remained poor in the children with normal serum immunoglobulin concentrations. This may
be due to their younger age. Two doses of PCV did not induce significant amounts of IgG2-
and IgA antibodies at this early age.
Discussion
S. pneumoniae is an important cause of bacterial RTI and the most common cause of AOM
and sinusitis among young children [33]. Otitis media is the most frequent reason for pediatric
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office visits in the United States, resulting in more than 15 million visits per year [34].
Although serious complications are rare nowadays, direct and indirect economic costs of otitis
media were estimated at $3.8 billion a year in 1995 [35]. AOM is also the leading reason for
prescribing antibiotics during childhood, and the use of antibiotics for treatment of RTI
contributes substantially to increased antimicrobial resistance [36-38]. It is established that
acquisition and carriage of S. pneumoniae in the nasopharynx is associated with the
occurrence of AOM [39-41].
The lack of efficacy of pneumococcal polysaccharide vaccines (PPV) in preventing AOM
[4;7;8] may be explained by their poor immunogenicity in children under 5 years of age
[10;11], and their inability to reduce nasopharyngeal carriage [42]. In contrast, pneumococcal
conjugate vaccines (PCV) are immunogenic even in infants and toddlers [18;43;44] and
reduce nasopharyngeal carriage of S. pneumoniae of the vaccine serotypes [45-48]. The
reduction of nasopharyngeal carriage of vaccine serotypes suggests that immunoprophylaxis
by pneumococcal conjugate vaccination might result in reduction of RTI caused by S.
pneumoniae. Data from two large efficacy trials in healthy infants indeed show a 5-10%
reduction in the occurrence of AOM [23;24]. Most importantly, in otitis-prone children the
efficacy is higher [23].
Otitis-prone children differ from healthy age-matched controls in their inability to produce
IgG2 and IgA type anti-pneumococcal antibodies after immunization with polysaccharide
vaccines [12;13]. In this study we show that one dose of PCV induces good IgG1 antibody
responses in most of these children over 2 years of age, even in those with partial serum IgA
and/or IgG2 deficiency. However, only low IgA- or IgG2 responses are obtained. After
priming with PCV, booster vaccination with PPV23 induces not only a further rise in IgG1-
type anti-pneumococcal antibodies, but also the IgA- and IgG2 anti-pneumococcal antibodies
which might be of importance in the defense against mucosal infections by encapsulated
bacteria. This shows that after priming with conjugate, polysaccharides are able to induce
isotype switching to IgG2 and IgA. In children 12-18 months of age, two doses of PCV
induce good IgG1-type anti-pneumococcal antibody concentrations, but IgG2- and IgA levels
remain low, even in the group with normal total serum IgA-and IgG2 antibody concentrations.
Booster vaccination with PCV after primary PCV vaccination apparently does not induce
isotype switching in this age group. This may be due to the fact that these children were
below two years of age. An alternative explanation could be that the high (25 mg) amount of
polysaccharides in the 23-valent polysaccharide vaccine (re)activates polysaccharide-specific B
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cells in a way that causes isotype switching, whereas the lower (2-4 mg) amount of
polysaccharide coupled to proteins in the PCV, does not. To obtain IgG2- and IgA anti-
pneumococcal antibodies, we therefore advocate booster vaccination with PPV23 after
completion of primary vaccination schedules with PCV from the age of 24 months. Further study
is needed to see whether 23-valent PPV can induce IgA and IgG2 after priming also in children
younger than 24 months. In children over two years, one dose of PCV followed by a booster
vaccination with 23-PPV results in both IgG1, IgG2 and IgA anti-pneumococcal antibodies. The
23- PPV might also offer the advantage of expanded serotype coverage.
In conclusion, this immunogenicity study shows that the combination of PCV7 followed by
23-valent PPV not only induces IgG1 type anti-pneumococcal antibody responses, but also
IgG2 and IgA type responses. Taken into account the results of the clinical efficacy studies
that showed a beneficial effect of PCV7 [23] and 14-valent PPV [4] in children with recurrent
AOM, we suggest that the sequential use of PCV7 and PPV23 may contribute significantly to
the prevention of frequent recurrence of AOM. Such a vaccination schedule could be used in
patients with recurrent upper respiratory tract infections both with normal serum
immunoglobulin concentrations and in patients with partial IgG2 and/or IgA deficiency. In the
Netherlands, a large double-blinded randomized clinical trial measuring the efficacy of this
vaccination schedule in preventing recurrent episodes of AOM in otitis-prone children
(OMAVAX-study) is currently ongoing.
Ad. Tables 1 and 2
1Dysimmunoglobulinemia was expressed as follows:
Patients vaccinated with PPV: 8 patients with partial IgG2 deficiency, 3 patients with partial IgA deficiency and
2 patients with combined partial IgG2- and IgA deficiency.
Patients vaccinated with PCV followed by PPV: 1 patient with partial IgG2 deficiency, 2 patients with partial
IgA deficiency and 2 patients with combined partial IgG2- and IgA deficiency.
Patients vaccinated with doses of PCV: 2 patients with partial IgG2 deficiency, 1 patient with partial IgA




Number of patients 27 12 8
Age (months) 43 (24-71) 44 (24-70) 48 (24-70)
Serotype Isotype geo range geo range geo range
4 IgG1 0.22 (0.01-4.00) 0.23 (0.02-1.23) 0.21 (0.08-1.33)
4 IgG2 0.43 (0.03-9.88) 0.68 (0.10-5.20) 1.53 (0.60-9.22)
4 IgA 0.26 (0.02-1.83) 0.19 (0.05-0.82) 0.20 (0.12-0.54)
6 IgG1 0.27 (0.02-6.02) § 0.39 (0.02-5.13) ** 1.00 (0.02-32.20)
6 IgG2 0.46 (0.23-2.06) 0.91 (0.23-10.05) ** 2.97 (0.23-52.52)
6 IgA 0.14 (0.01-0.65) 0.07 (0.01-1.24) 0.13 (0.01-1.31)
9 IgG1 1.30 (0.03-12.27) 0.56 (0.13-6.01) 1.07 (0.35-3.36)
9 IgG2 0.72 (0.04-25.17) 0.81 (0.04-62.30) * 1.89 (0.04-334.0)
9 IgA 0.67 (0.16-3.65) 0.48 (0.14-4.42) 0.93 (0.16-4.60)
19 IgG1 0.32 (0.03-1.14) § 0.62 (0.22-1.27) ** 1.12 (0.28-10.36)
19 IgG2 0.14 (0.05-7.19) 1.74 (0.05-126.3) ** 5.40 (1.50-18.74)
19 IgA 0.56 (0.06-4.31) 0.35 (0.06-1.78) 0.93 (0.23-2.15)
        post PCV1 post PCV2
Number of patients 4 4
Age (months) 13 (12-16) 13 (12-16)
Serotype Isotype geo range geo range
4 IgG1 0.09 (0.00-0.60) 0.18 (0.01-0.72)
4 IgG2 0.20 (0.03-0.68) 0.57 (0.15-7.24)
4 IgA 0.03 (0.01-0.14) 0.03 (0.01-0.08)
6 IgG1 0.07 (0.02-0.40) 0.05 (0.02-1.86)
6 IgG2 0.23 (0.23-0.46) 0.91 (0.23-18.95)
6 IgA 0.02 (0.01-0.07) 0.06 (0.01-2.53)
9 IgG1 0.10 (0.05-0.19) 1.48 (0.30-20.45)
9 IgG2 0.45 (0.09-2.34) 0.58 (0.13-2.65)
9 IgA 0.08 (0.03-0.32) 0.34 (0.05-3.47)
19 IgG1 0.14 (0.01-0.90) 1.04 (0.03-29.52)
19 IgG2 0.19 (0.05-0.33) 5.97 (1.22-94.93)
19 IgA 0.02 (0.02-0.02) 0.43 (0.02-10.43)
Table 1a. Geometric mean (geo) antibody responses, (mg/ml) to pneumococcal vaccination in children with
recurrent bacterial respiratory tract infections and normal serum immunoglobulin levels.
§ indicates a significant difference in antibody concentration after vaccination with PCV compared with PPV; §
p<0.05.
* indicates a significant difference in antibody concentration after vaccination with PCV followed by booster
vaccination with PPV(PCV+PPV), compared with PPV only; * p<0.05, ** p<0.01.
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PPV PCV PCV+PPV
Number of patients 13 5 5
Age (months) 50 (34-72) 52 (40-71) 52 (40-71)
Serotype Isotype geo range geo range geo range
4 IgG1 0.13 (0.00-0.40) 0.13 (0.02-0.32) 0.22 (0.04-0.45)
4 IgG2 0.23 (0.03-2.14) 0.23 (0.03-0.75) 0.50 (0.03-1.08)
4 IgA 0.10 (0.01-0.36) 0.13 (0.07-0.46) 0.10 (0.02-0.30)
6 IgG1 0.46 (0.02-5.48) § 2.13 (0.13-24.41) ** 4.91 (0.08-34.51)
6 IgG2 0.69 (0.23-12.33) 1.83 (0.23-59.83) * 2.74 (0.23-24.44)
6 IgA 0.10 (0.01-0.55) 0.19 (0.01-0.86) 0.17 (0.01-0.82)
9 IgG1 1.06 (0.01-4.70) 0.47 (0.14-1.29) 1.48 (0.18-8.49)
9 IgG2 0.49 (0.04-17.84) 0.45 (0.09-18.52) 1.75 (0.13-78.03)
9 IgA 0.39 (0.02-4.35) 0.24 (0.08-1.38) 0.87 (0.24-4.68)
19 IgG1 0.27 (0.02-3.50) § 1.48 (0.21-4.03) ** 6.53 (0.70-41.90)
19 IgG2 0.19 (0.05-7.05) 1.41 (0.28-13.29) ** 16.86 (4.27-72.38)
19 IgA 0.41 (0.02-2.73) 1.34 (0.91-2.00) ** 3.06 (0.35-16.31)
post PCV1       post PCV2
Number of patients 4 4
Age (months) 16 (13-18) 16 (13-18)
Serotype Isotype geo range geo range
4 IgG1 0.18 (0.06-0.37) 0.33 (0.16-0.62)
4 IgG2 0.17 (0.03-6.31) 0.80 (0.13-7.89)
4 IgA 0.06 (0.03-0.12) 0.05 (0.03-0.10)
6 IgG1 0.76 (0.12-5.04) 8.42 (0.30-126.0)
6 IgG2 1.14 (0.23-68.05) 1.60 (0.23-67.14)
6 IgA 0.04 (0.01-0.66) 0.13 (0.01-0.67)
9 IgG1 0.16 (0.13-0.21) 0.45 (0.09-2.28)
9 IgG2 0.36 (0.09-3.73) 0.72 (0.04-12.50)
9 IgA 0.10 (0.03-0.31) 0.10 (0.03-0.22)
19 IgG1 0.32 (0.04-9.97) 1.49 (0.04-6.73)
19 IgG2 0.33 (0.23-0.80) 0.70 (0.14-11.79)
19 IgA 0.08 (0.02-0.41) 0.19 (0.02-0.85)
Table 1b. Geometric mean (geo) antibody responses (expressed in mg/ml) to pneumococcal vaccination in
children with dysimmunoglobulinemia1 and recurrent bacterial respiratory tract infections.
§ indicates a significant difference in antibody concentration after vaccination with PCV compared with PPV; §
p<0.05.
* indicates a significant difference in antibody concentration after vaccination with PCV followed by booster




Number of patients 27 12 8
Age (months) 43 (24-71) 44 (24-70) 48 (24-70)
Serotype Isotype geo range geo range geo range
4 IgG1 130 (5-2313) 133 (11-713) 119 (46-771)
4 IgG2 17 (1-393) 27 (4-207) 61 (24-367)
4 IgA 27 (2-191) 20 (5-85) 21 (12-56)
6 IgG1 16 (1-357) §23 (1-304) **59 (1-1909)
6 IgG2 2 (1-9) 4 (1-44) **13 (1-230)
6 IgA 12 (1-54) 6 (1-103) 11 (1-109)
9 IgG1 190 (5-1787) 82 (19-876) 156 (51-489)
9 IgG2 16 (1-560) 18 (1-1386) *42 (1-7430)
9 IgA 42 (10-227) 30 (9-275) 58 (10-286)
19 IgG1 53 (5-190) §103 (37-212) **187 (46-1730)
19 IgG2 3 (1-153) 37 (1-2689) **115 (32-399)
19 IgA 29 (3-222) 18 (3-92) 48 (12-111)
post PCV1 post PCV2
Number of patients 4 4
Age (months) 13 (12-16) 13 (12-16)
Serotype Isotype geo range geo range
4 IgG1 54 (1-346) 104 (7-416)
4 IgG2 8 (1-27) 23 (6-288)
4 IgA 3 (1-15) 3 (1-8)
6 IgG1 4 (1-24) 3 (1-110)
6 IgG2 1 (1-2) 4 (1-83)
6 IgA 2 (1-6) 5 (1-211)
9 IgG1 14 (7-27) 216 (43-2979)
9 IgG2 10 (2-52) 13 (3-59)
9 IgA 5 (2-20) 21 (3-216)
19 IgG1 24 (2-150) 173 (5-4932)
19 IgG2 4 (1-7) 127 (26-2021)
19 IgA 1 (1-1) 22 (1-538)
Table 2a. Geometric mean antibody responses (expressed in U/ml) to pneumococcal vaccination in children with
recurrent bacterial respiratory tract infections and normal serum immunoglobulin levels.
§ indicates a significant difference in antibody concentration after vaccination with PCV compared with PPV; §
p<0.05.
* indicates a significant difference in antibody concentration after vaccination with PCV followed by booster
vaccination with PPV(PCV+PPV), compared with PPV only; * p<0.05, ** p<0.01.
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PPV PCV PCV+PPV
Number of patients 13 5 5
age (months) 50 (34-72) 52 (40-71) 52 (40-71)
Serotype Isotype geo range geo range geo range
4 IgG1 77 (1-229) 77 (11-184) 130 (25-262)
4 IgG2 9 (1-85) 9 (1-30) 20 (11-43)
4 IgA 10 (1-38) 14 (7-48) 10 (2-31)
6 IgG1 27 (1-325) §126 (8-1447) **291 (5-2046)
6 IgG2 3 (1-54) 8 (1-266) *12 (1-107)
6 IgA 8 (1-46) 16 (1-72) 14 (1-68)
9 IgG1 154 (1-684) 68 (20-188) 215 (26-1237)
9 IgG2 11 (1-397) 10 (2-412) 39 (3-1736)
9 IgA 24 (1-271) 15 (5-86) 54 (15-291)
19 IgG1 45 (3-585) §247 (35-674) **1091 (117-7000)
19 IgG2 4 (1-150) 30 (6-283) **359 (91-1541)
19 IgA 21 (1-141) 69 (47-103) **158 (18-841)
    post PCV1     post PCV2
Number of patients 4 4
age (months) 16 (13-18) 16 (13-18)
Serotype Isotype geo range geo range
4 IgG1 102 (35-215) 190 (94-359)
4 IgG2 7 (1-251) 32 (5-314)
4 IgA 6 (3-13) 5 (3-10)
6 IgG1 45 (7-299) 499 (18-7471)
6 IgG2 5 (1-298) 7 (1-294)
6 IgA 3 (1-55) 11 (1-56)
9 IgG1 23 (19-31) 65 (13-332)
9 IgG2 8 (2-83) 16 (1-278)
9 IgA 6 (2-19) 6 (2-14)
19 IgG1 54 (6-1666) 249 (7-1124)
19 IgG2 7 (5-17) 15 (3-251)
19 IgA 4 (1-21) 10 (1-44)
Table 2b. Geometric mean (geo) antibody response (expressed in U/ml) to pneumococcal vaccination in children
with dysimmunoglobulinemia1 and recurrent bacterial respiratory tract infections.
§ indicates a significant difference in antibody concentration after vaccination with PCV compared with PPV; §
p<0.05.
* indicates a significant difference in antibody concentration after vaccination with PCV followed by booster
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Fcg receptors show two genetically determined polymorphisms: the biallelic FcgRIIa-R131
and -H131 polymorphism, and the NA1/NA2 FcgIIIb polymorphism. Using 10 pre- and
postconjugate vaccination antisera from adults, we analyzed in vitro phagocytic capacities of
three different combinations of polymorphonuclear leukocyte FcgR allotypes: those
homozygous for the H131 and Na1 allotype, those homozygous for the R131 and Na2
allotype, and those heterozygous for both receptors. For pre- and post vaccination sera, mean
phagocytosis levels for the homozygous H131/Na1 allotype were 4-fold higher than for the
homozygous R131/Na2 allotype. There was a strong and significant correlation between IgG2
ELISA antibody titers and phagocytosis levels for the homozygous H131/Na1 Fcg receptor
allotype and the heterozygous allotype, but not for the homozygous R131/Na2 allotype. There
was no relation between IgG1 ELISA titer and phagocytosis level. Apparently the IgG2
antibodies induced are functionally the most important. This may explain the large impact of
Fcg receptor polymorphisms on the in vitro phagocytosis of pneumococci mediated by
conjugate antisera.
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Introduction
Pneumococcal conjugate vaccines (many of which are being evaluated in phase III trials) may
be able to protect risk groups that are not covered by polyvalent polysaccharide vaccines.
Ultimately, the parameter for evaluation of the efficacy of these vaccines is the incidence of
pneumococcal disease in the vaccinated group versus that in the nonvaccinated group.
Because clinical protection against infection with encapsulated bacteria depends on antibodies
against capsular polysaccharides, pneumococcal antibody levels after vaccination can be used
as a surrogate marker for vaccine efficacy. Since the crucial defense mechanism against S.
pneumoniae consists of antibody and complement-mediated phagocytosis, the assessment of
functional antibody levels may give a better indication of vaccine efficacy. We have
developed a fast, standardized phagocytosis assay based on flow cytometry [1]. This assay is
serotype specific and exhibits, in general, highly significant correlations with ELISA and
classical killing assay (W.T.M. Jansen et al., unpublished data). All functional components of
the assay are of human origin (e.g. human complement and human polymorphonuclear
leukocytes [PMNLs]).
PMNLs constitutively express two different receptors for IgG: FcgRIIa and FcgRIIIb. These
receptors show two genetically determined polymorphisms: the biallelic FcgRIIa-R131 and -
H131 polymorphism, and the NA1/NA2 FcgIIIb polymorphism. In humans, only FcgRIIa-
H131 can efficiently interact with IgG2. FcgRIIIb NA1 homozygotes have a higher
phagocytosing capacity than the NA2 homozygotes for IgG1 and IgG3 opsonized particles
[2]. Of the general Caucasian population, about 25% is FcgRIIa-RR, 50% FcgRIIa-RH and
25% FcgRIIa-HH [3]. Genotype frequencies for the Na1 and Na2 FcgIIIb polymorphism are ~
0.37 and ~ 0.67, respectively [4].
In infants, children, and the elderly, pneumococcal conjugate vaccines elicit a different
antibody response than polysaccharide vaccines in induction of memory and a higher
immunogenicity. Polysaccharide conjugates induce a shift in IgG isotype from IgG2 towards
IgG1 [5]. Since only the FcgRIIa-H131 can efficiently interact with IgG2, Fcg-receptor
polymorphisms should mainly influence phagocytosis mediated by antibodies of the IgG2
isotype. Therefore, we studied whether PMNL Fcg-receptor polymorphism has an effect on in






Healthy adult volunteers (n=10) were immunized intramuscularly with heptavalent
pneumococcal conjugate vaccine (PCV; Wyeth Lederle Vaccines and Pediatrics Rochester,
NY). PCV includes polysaccharides of serotypes 4, 6B, 9V, 14, 19F and 23 F conjugated to
CRM197 carrier protein, and an oligosaccharide conjugate of serotype 18C. Each dose
contains 2 mg saccharides of pneumococcal serotypes 4, 9V, 14, 18C, 19F and 23F, and 4 mg
of serotype 6B. Serum was drawn before and 3-4 weeks after vaccination and stored at -80°C
until use.
Determination of type specific anti-polysaccharide antibodies
IgG-, IgG1- and IgG2- serum antibody levels to pneumococcal serotype 23F polysaccharide
were measured by ELISA as described previously [6]. Pre- and postvaccination serum
samples were analyzed simultaneously. All serum samples were preincubated overnight with
excess free common cell wall polysaccharide (CPS) to remove anti-CPS antibodies. A serum
sample from a normal non-vaccinated adult was included in every ELISA as a control.
Antibody concentrations were expressed relative to a reference adult hyper immune plasma
pool [7]. The latter was assigned 100 U/ml (100%) for each isotype.
Typing for FcgRIIa and FcgRIIIb polymorphisms
The allotypes of the FcgRIIa and FcgRIIIb receptors in white Dutch Caucasian donors were
determined by nested polymerase chain reaction (PCR) as described [8]. To determine the
FcgRIIa-RR/HH polymorphism, a 1100 bp fragment containing the polymorphic region was
amplified. This PCR product was used in two allele-specific-PCRs, one with a histidine (H)
primer and one with the arginine (R) primer. To determine FcgRIIIb-NA1/NA2
polymorphism a 506 bp fragment was amplified. This PCR product was used in two separate
PCRs with specific primers for NA1 and NA, which require different annealing temperatures.
All products were run on a 1.5% agarose gel and photographed.
Phagocytosis assay
The assay was performed as described previously [1]. A pneumococcal strain, serotype 23F,
was grown three times to log phase to ensure high encapsulation, then heat
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inactivated and labeled with fluorescein isothiocyanate (FITC). Human pooled serum was
depleted of IgG by protein G affinity chromatography and used as complement source.
Human PMNLs were isolated from the blood of healthy, Fcg receptor-typed volunteers by a
ficoll-histopaque gradient.
Serial dilutions of heat-inactivated serum samples and a fixed amount of complement (2%
vol/vol) were made in bovine serum albumin-Hanks’ balanced salt solution (BSA-HBSS) and
pipetted into round-bottomed micro-titer plates. Samples of 2.5 H 106 pneumococci were
added to each well and incubated for 30 min at 37°C with shaking on a micro-titer plate
agitator. Next, plates were placed on ice and 2.5 H 105 PMNLs in 50ml BSA-HBSS were
added to each well. Phagocytosis was done at 37°C with shaking. After washing with ice-cold
BSA-HBBS, the cells were fixed with 2% paraformaldehyde in phosphate buffered saline and
analyzed by flow cytometry (FACScan, Becton Dickinson, San José, CA). The percentage of
FITC positive PMNLs was used as a measure for the phagocytic activity of serum. Results are
expressed as 25% phagocytosis titers (serum dilution resulting in 25% FITC-positive
PMNLs).
Statistical analysis
Correlations between ELISA and FACS phagocytosis titers were analyzed by linear
regression tests. Statistical significance of correlations was assessed by Pearson correlation
analysis. Statistically significant differences between pre- and post vaccination phagocytosis
titers for a given PMNL allotype, as well as differences in phagocytosis titers between
different PMNL allotypes, were assessed with a Wilcoxon signed rank test. P <0.05 was
considered statistically significant.
Results
To study the effect of PMN Fcg receptor polymorphism on the phagocytosis of S.
pneumoniae, we compared three different allotype combinations: PMNL that were
homozygous for both receptors (HH11), which were expected to give the highest
phagocytosis; PMNL that were heterozygous for both receptors (HR12), which were expected
to give an intermediate phagocytosis, and PMNL that were homozygous for both receptors
(RR22), which were expected to give the lowest phagocytosis.
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Different allotypes were distinguished by allele specific PCR as shown in Figure 1.
Figure 1. Polymerase chain reaction analysis of FcgRIIa and FcgRIIIb genotype.
DNA was amplificated with FcgRIIa-H131 or -R131 specific primers (upper and lower left panels, respectively)
or using FcgRIIIb-Na2 or -Na1 specific primers (upper and lower right panels respectively). Amplified products
were analyzed by agarose gel electrophoresis and EtBr staining. The figure shows the three possible allele
combinations for FcgRIIa (homozygous R131, lane a; R/H131, b; H/H131, c) and for FcgRIIIb (Na1/Na1, d;
Na1/Na2, e; Na2/Na2, f). M denotes bp ladder.
Vaccination with a heptavalent pneumococcal conjugate results in an increase in functional
antibody titers for all three PMNL allotypes, as measured by the in vitro phagocytosis of type
23F S. pneumoniae (p <0.01, all allotypes). The degree of phagocytosis depends on the
allotype of FcgRIIa and FcgRIIIb. The highest fold-increase (FI) in phagocytosis as well as
geometric mean phagocytosis titer (GMPT) of the 10 postvaccination sera tested was obtained
with HH11 PMNLs (FI, 17.2; GMPT, 38; Figure 2). Using RR22 PMNLs, vaccination
induced the smallest increase in phagocytosis (FI, 4.7; GMPT, 9.4); and with heterozygous
PMNLs (HR12), we observed intermediate values (FI, 13.3; GMPT, 20.6).
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Figure 2. S23F phagocytosis titers pre (open squares) and post (closed squares) immunization with a heptavalent
conjugate vaccine for three different PMN allotypes.
For the pre vaccination sera, p-values for the difference in phagocytosis titers between the allotypes were: HH11
versus RR22 p < 0.05; HR12 versus RR22 p < 0.05. For the post-vaccination antisera, all the observed
differences in phagocytosis titers were significant: HHII PMN versus HR12 PMN p < 0.005; HR12 PMN versus
RR22 PMN p < 0.05; HHII PMN versus RR22 p < 0.005. (RR: FcgRIIa RR / FcgRIIIb NA2NA2, HR: FcgRIIa
HR / FcgRIIIb NA1NA2 and HH: FcgRIIa HH / FcgRIIIb NA1NA1).
The pre-immune serum sample causing the high pre-immune phagocytosis titer corresponds to the post-immune
serum sample with the highest phagocytosis titer with the three allotypes.
Since FcgRIIa H131 and R131 differ in their ability to interact with IgG2 antibodies, we next
measured subclasses of IgG anti-23F antibodies (Table 1) and studied their relation to
phagocytosis (Table 2). For both total IgG and IgG2, there was a strong and significant
correlation between phagocytosis of 23F S. pneumoniae by HH11 PMNLs and post-
vaccination ELISA titer. A significant correlation was also observed for HR12 PMNLs but
not for RR22 PMNLs. Surprisingly, ELISA IgG1 titers did not correlate at all with
phagocytosis, independent of the PMN allotype.
Discussion
Our data clearly demonstrate that FcgR polymorphisms affect the magnitude of in vitro
phagocytosis of pneumococci mediated by pneumococcal conjugate antisera. Both
phagocytosis titer as well as fold increase in titer obtained with PMNLs homozygous for
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histidine and NA1, are 4-fold higher than those obtained with PMNLs that are homozygous
for arginine and NA2. These data have important consequences for the usage and















































































Table 1. IgG, IgG1 and IgG2 antibody levels (U/ml)against serotype 23F S. pneumoniae before (pre) and 3-4
weeks after (post) vaccination with heptavalent pneumococcal conjugate vaccine.
PMNL allotype IgG IgG1 IgG2
RR22 0.25 0.05 0.19
HR12 0.46* 0.04 0.48*
HH11 0.58* 0.0 0.64**
Table 2. Correlation (r²) between postvaccination anti-23F antibody levels and phagocytosis titers of
polymorphonuclear leucocyte (PMNL) FcgR allotypes.
PMNL FcgR allotype combinations used were as follows: RR22: FcgRIIa RR/FcgRIIIb NA2NA2;
HR12:FcgRIIa HR/FcgRIIIb NA1NA2; and HH11FcgRIIa HH/FcgRIIIb NA1NA1. *p<0.05; **p<0.01.
There is no consensus about what level of antibodies defines a vaccine responder. Most
studies define a responder as a vaccinated person who shows a 2- or 4-fold increase in
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antibody level after immunization: however, other studies specify different levels of
postimmunization antibody as thresholds [9]. Nor is there agreement on quantitative
protective antibody levels. The same uncertainties also apply to our functional antibody assay.
Indeed, the data reveal that FcgR allotype combination of the vaccinee is another important
variable that may determine conjugate vaccine efficacy. Clearly, the definition of protective
functional antibody levels awaits the outcome of ongoing vaccine efficacy trials.
Our data suggest that individuals with the most unfavorable FcgR allotype combination would
have to produce four times more antibodies than persons with the optimal allotype
combination to reach equivalent antibody titers. This finding not only underscores the
importance of FcgR polymorphism for phagocytosis of S. pneumoniae, but also has impact for
the design of in vitro assays for functional antibodies. Clearly, the FcgR allotype combination
of donor PMNLs must be known. Whether an optimal (FcgRIIa HH131, FcgRIIIbNa1/Na1) or
a less favorable combination of FcgR should be used in functional antibody assays remains to
be determined.
Although the effect of Fcg receptor polymorphism has been studied extensively at the
molecular level, little is known about the clinical relevance of these different allotypes in the
normal population. Sanders et al. [3] showed that of 48 children with frequent bacterial
respiratory tract infections and normal IgG2 titers, a smaller proportion were of the FcgRIIa-
HH phenotype than in a large healthy white control population. Platonov et al. [10] showed
that FcgRIIa polymorphisms are associated with susceptibility to and severity of
meningococcal disease.
The use of protein conjugated polysaccharide vaccines results in an anti-polysaccharide
antibody response with characteristics of a T cell dependent response, including IgG1
antibodies. Yet, our data indicate that the level of phagocytosis correlates with IgG2 ELISA
titers and not with IgG1 titers. This suggests that in both polysaccharide and protein-
conjugated polysaccharide vaccines, the functionally most active antibodies are of the IgG2
isotype. The concept that IgG2 anti-polysaccharide antibodies are important for the protection
against encapsulated bacteria seems to be supported by clinical observations and experimental
data. Rodriguez et al. [11] showed that FcgRIIa and IgG2 are crucial in phagocytosis of
pneumococci. Patients with IgG2 deficiency are prone to infections with S. Pneumoniae and
Haemophilus influenzae type b [12]. Otitis-prone children tend to have similar IgG1 anti-
pneumococcal antibody levels compared to age-matched controls, but lower IgG2 levels [13].
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The same isotype distribution of anti-pneumococcal antibodies is observed in children with
otitis media with effusion (I.J. Dhooge et al., unpublished data). Moreover, since the
polymorphism in FcgRIIa determines the capacity to interact with IgG2 antibodies, but
binding of IgG1 does not differ between the H131 and R131 isoforms, the dominance of IgG2
antibodies in phagocytosis would explain the effect of FcgR polymorphisms in this study.
Clearly, functional experiments with purified IgG1 and IgG2 anti-polysaccharide antibodies
(induced by either conjugated or non-conjugated polysaccharide vaccines) are required in
order to substantiate this conclusion.
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Infant vaccination with conjugated Haemophilus influenzae type b (Hib) vaccine is highly
effective in protecting against invasive Hib infections, but vaccine failures do occur. Twenty-one
vaccine failures are reported since the introduction of the Hib conjugate vaccine in the
Netherlands. Of the 14 evaluable patients, 6 children had an absent antibody response (< 1.0
µg/mL IgG anti-Hib) to Hib polysaccharide in convalescent serum, including one child with
hypogammaglobulinaemia and one child with IgG2 deficiency. After revaccination almost all
children developed anti-Hib antibodies.
In case of Hib vaccine failure, case investigation, including measurement of serum
immunoglobulin concentrations as well as specific anti-Hib antibodies should be performed.
Invasive Hib disease after infant conjugate Hib vaccination may be the presentation of an
underlying immunodeficiency, but more often only a decreased antibody response to Hib is
found; revaccination with conjugated Hib vaccine is advised.
Haemophilus influenzae type b vaccine failures
145
Introduction
Infant vaccination with conjugated Haemophilus influenzae type b (Hib) vaccine is highly
effective in protecting against invasive Hib infections [1;2]. In the Netherlands, vaccination with
conjugate Hib vaccine has been incorporated into the National Vaccination Program for children
born after April 1, 1993. At the time of introduction, the Hib vaccine was given at the ages of 3,
4, 5, and 11 months, concomitantly with the DTP and poliomyelitis vaccinations. Unlike the
policy of several other countries, no catch-up vaccination did take place for children under the
age of five years. From January 1999 onwards, infants are vaccinated at 2, 3, 4 and 11 months of
age.
In the years following the introduction of Hib vaccination, the number of cases of invasive
Hib disease dropped impressively [3;4]. But invasive Hib disease did not disappear
completely. This might be expected, since cases of invasive Hib disease still occur in not yet
fully vaccinated infants, and vaccine coverage in the Netherlands, although high (95,5% of all
infants received at least three doses of Hib vaccine; January 1997), is not complete. But also
true vaccine failures did occur in children who were completely (3 or 4 times) vaccinated with
the conjugate vaccine. We here report the clinical and immunological follow-up of the 19
children who developed invasive Hib disease despite having received at least three
vaccinations as an infant.
Methods
Surveillance of invasive Hib infections
Since 1975, invasive Hib isolates and surveillance data on Hib meningitis in the Netherlands
are collected by the Netherlands Reference Laboratory for Bacterial Meningitis (RBM) in
Amsterdam. Since 1994, Haemophilus influenzae isolates from all normally sterile sites are
sent to the RBM. These isolates are identified and typed for capsular polysaccharide serotype
using coagglutination [5]. Capsular polysaccharide serotyping was controlled by PHLS
Haemophilus Reference Unit, Oxford, UK
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Collection and testing of serologic data
The laboratory of the department of Immunology, Wilhelmina Children’s Hospital, University
Medical Center Utrecht, is a central facility for anti-Hib antibody determinations. Sera from
patients with invasive Hib infections are sent in by clinicians. Since 1999, active
immunological follow-up of patients with invasive Hib infections despite vaccination is
realized by combining the serological data with the RBM data system.
IgG, IgG1 and IgG2 (and IgM, data not shown) anti-Hib antibody titers were determined by
ELISA as described, and calibrated using a standard anti-Hib hyperimmune serum, containing
27.2 µg/mL IgG-anti-Hib, 4.05 µg/mL IgG1-anti-Hib and 9.48 µg/mL IgG2-anti-Hib [6].
Total serum concentrations of IgG, IgA and IgM, as well as serum concentrations of IgG
subclasses were determined by radial immunodiffusion in serum samples obtained at onset of
illness, except for patients d, g, i, and n, for whom the serum samples obtained at
convalescence were used.
Vaccine failures
Cases of invasive Hib infections are defined as vaccine failures when they occur despite at
least three vaccinations with the conjugated Hib vaccine (or after one vaccination in a child >
1 year). In the Netherlands the Hib vaccine used is the PRP-T vaccine
(polyribosylribitolphosphate conjugated to tetanus toxoid, Pasteur Mérieux Sérums et
Vaccins, Lyon, France)
Subjects
We obtained additional clinical information and evaluated the immune status of patients who
developed invasive Hib disease despite three or four vaccinations. The invasive Hib infection
was proven by culturing Hib from blood and/or cerebrospinal fluid. Vaccination records were
checked. Serum samples were taken at the time of disease and after reconvalescence (3-4 weeks
after the onset of the disease). For patients with IgG anti-Hib antibody concentrations < 1.0
µg/mL in sera obtained 3-4 weeks after the onset of the disease, revaccination with the Hib
vaccine was recommended. Booster vaccination was also given when anti-Hib antibodies were
slightly above this level. In both cases informed consent was obtained. Three to four weeks after
revaccination, IgG, IgG1, IgG2 and IgM anti-Hib antibody concentrations were determined
again. Vaccination was repeated in case of persistently low antibody concentrations.




In the 7 years after the introduction of the Hib vaccination program for infants in the
Netherlands, a total number of 1.13 million children received at least three doses of Hib vaccine.
21 true vaccine failures were reported: 17 (81%) cases of Hib meningitis, one (5%) Hib cellulitis,
and 3 (19%) cases of Hib epiglottitis. Bacterial isolates of 19 (90%) of these patients were
directly sent to the RBM. From the two (10%) additional (epiglottitis-) patients, bacterial isolates
from blood were typed at the local clinical microbiology laboratories, and sera of these patients
were sent to the laboratory of the department of Immunology, University Medical Center
Utrecht. Checking of vaccination data confirmed that these two cases were vaccine failures, too.
The mean age of the meningitis patients was 26 (9-62, median 25) months; the mean age of the
epiglottitis patients was 38 (25-56, median 33) months. Clinical information was obtained in 18
(86%) of the 21 children, 11 boys and 7 girls. One of them (patient c) experienced another
episode of meningitis -of unknown cause- at the age of 3 months. After the second (Hib)
meningitis at the age of 10 months, he received antibiotic prophylaxis till the age of 33 months.
Patient a did not experience other invasive infections before the Hib meningitis. She received
antibiotic prophylaxis after the diagnosis of hypogammaglobulinaemia. A third patient (patient t)
was known with trisomy 16p. Apart from a 2½ years old girl (patient o), who died from Hib
meningitis, all children recovered without major sequelae. Importantly, they experienced no
further serious infections during the follow-up period. All but one patient (patient f) were of
Caucasian origin. Height and weights of all children were within the normal range (± 2 SD) for
age according the Dutch standard curves.
Serological investigations
Serum samples were available in 14 (67%) cases. Results of the analysis of humoral immunity
are shown in Table 1. Serum immunoglobulin concentrations were within the normal range
(±2 SD) for age in 12 (86%) of the 14 patients. In patient f, the serum concentration of IgG2
was below minus 2 SD the mean concentration for his age. Patient a was shown to have




Patient Sex Age, m Disease IgA IgG IgM IgG1 IgG2 IgG3 IgG4
a F 24 meningitis 0.04 3.3 0.73 2.8 0.15 0.25 <0.1
b M 13 meningitis 0.65 9.9 0.9 8.2 0.9 0.55 0.15
c M 10 meningitis 0.17 5.5 1.37 4.0 0.3 0.2 <0.1
d M 27 meningitis 0.83 9.5 1.16 5.9 1.65 0.6 0.55
e F 36 meningitis 1.23 7.7 1.5 7.3 1.05 0.1 0.1
f M 11 meningitis 0.36 6.4 0.94 5.1 <0.1 0.45 <0.1
g M 33 epiglottitis 0.75 6.0 1.5 5.7 0.9 0.4 <0.1
h F 28 meningitis 0.45 11.7 0.95 9.4 1.3 0.6 0.3
i M 62 meningitis 1.11 11.7 1.84 9.8 0.9 0.5 <0.1
j F 18 meningitis 0.78 9.9 2.83 8.2 1.41 0.74 <0.05
k M 56 epiglottitis 0.91 9.0 0.96 5.3 1.65 0.25 0.65
l M 38 meningitis 1.00 9.8 1.65 7.3 1.5 0.2 0.1
m M 25 epiglottitis 0.60 9.3 1.3 9.1 1.5 0.2 0.4
n M 42 meningitis 3.62 12.8 1.5 10.4 2.61 0.27 0.25
o F 28 meningitis
p F 33 meningitis
q F 9 meningitis
r M 25 meningitis
s F 13 cellulitis
t M 22 meningitis
u M 8 meningitis
Table 1. Clinical characteristics and serum immunoglobulin concentrations (g/L)
Patient c experienced a first meningitis (unknown cause) at the age of 3 months; he received antibiotical
prophylaxis from 10-33 months of age.
Patient o died from complications of Hib meningitis.
Patient t had trisomy 16p.
Serum samples used for determination of immunoglobulin concentrations were obtained at onset of disease for
all patients except patients d, g, i, and n, for which convalescence serum samples were used.
Serological data were not available for patients o-u.
Underlined values are below the normal range for age.
Normal values serum immunoglobulin concentrations:
15 months - 4 years: IgA 0,30-0,90 g/L; IgG 4,6-7,8 g/L
12-24 months: IgG1 2,0-6,5 g/L; IgG2 0,35-2,2 g/L
6-12 months: IgG2 0,10-0,50 g/LTable 2. Anti-Hib antibody concentrations during the acute phase (0), after
convalescence (I), after revaccination (II and III) for patients a-n.
Specific anti-Hib antibody concentrations in acute serum samples, in convalescent serum
samples and antibody concentrations after revaccination are shown in Table 2. Most of the
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patients had low (or unknown) anti-Hib antibody titers at the time of disease, with the
exception of patient m, who had antibody concentrations well above the level considered to be
protective. On the base of analysis of convalescent serum samples, two patient groups could
be distinguished: I) a group with persistently low anti-Hib antibody titers after invasive
infection (patients a-f) and II) a group of patients with an IgG anti-Hib antibody response
> 1 µg/mL following the invasive Hib infection (patients g-n). The mean age of patients of




IgG anti-Hib (µg/mL) IgG1 anti-Hib (µg/mL) IgG2 anti-Hib (µg/mL)
0 I II III 0 I II III 0 I II III
a 1,5 < 2.25 < < <
b 1.2 < 9.1 96 0.90 < 10.4 215.8 < < < 4.44
c < < 65 < < 75.5 < < 2.73
d < 1.35 <
e < < 7.3 1.35 < 4.5 < < 16.7
f < < < 1.80 0.9 0.9 < < <
g 1.35 2.7 18 1.8 1.8 59.3 < < 11.3
h < 1.5 27 < 0.9 < <
i 3.3 2.25 <
j < 9 < 4.05 < 5.12
k < 22 6.4 0.90 29.7 12.1 < 4.78 3.41
l < 23 < 23.8 < 1.02
m 23 27 12.6 13.9 1.37 0.68
n 127 28.8 4.44
Table 2. Anti-Hib antibody concentrations during the acute phase (0), after convalescence (I), after revaccination
(II and III) for patients a-n.
The lower level of detection of IgG anti-Hib antibody was 0.9 µg/mL, of IgG1 anti-Hib antibody was 0.45
µg/mL, and of IgG2 anti-Hib antibody was 0.34 µg/mL. Antibody concentrations below these values are shown
as ‘<’.
Mean IgG anti-Hib antibody concentration after three vaccinations in a control group (aged 9-10 months, mean
9.6, median 10, n=83) was 2.8 µg/mL (0.05-6.8), after four vaccinations in a control group (aged 24-43 months,
mean 31, median 31, n=221) was 3.2 µg/mL (0.05-64.1).
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Two (33%) of the 6 patients in group I were subsequently lost for serological follow-up. The
4 other patients (67%) were revaccinated. The three younger patients (patients b, c and f)
received their regular fourth Hib vaccination; the other patient (patient e), who had completed
her series of four Hib vaccinations two years before the onset of disease, received a fifth
vaccination with PRP-T. Three patients in group II were revaccinated, two of them (patients g
and h) because of the fact that their anti-Hib antibody titers had only marginally risen above
the minimal protective level. All but one (patient f) of the evaluable12 patients (92%)
ultimately reached IgG anti-Hib antibody concentrations > 1.0 µg/mL. The patient that did not
respond was the youngest in this series.
Most of the patients who responded with high antibody titers against Hib after their Hib
infection (group II), developed predominantly IgG1 anti-Hib antibodies; only patient j
produced IgG1 and IgG2 in equal amounts. The revaccination with PRP-T after invasive
infection with Hib resulted in patients b and c in an IgG1 anti-Hib response. Both patients
were rather young at the time of disease and revaccination. In the older patients, relatively
more IgG2 was produced after booster vaccination, although only one patient (patient e)
showed an IgG2-dominated antibody response.
Discussion
Invasive H. influenzae type b (Hib) infections such as meningitis and epiglottitis are primarily
diseases of early childhood, occurring predominantly in children less than 2 years of age,
although considerable morbidity is seen until 5 years of age [7]. This age-related susceptibility to
Hib disease correlates with the absence of serum bactericidal antibodies to Hib polysaccharide.
Natural antibodies specific for Hib polysaccharide begin to appear at approximately 2 years of
age and reach adult levels by about 5 years. Hib polysaccharide by itself does not function as an
effective vaccine in the primary target population [8]. Covalent conjugation of protein carriers to
Hib polysaccharide converts it into an effective immunogen, capable of inducing both IgG
antibody production and memory in infants [9;10]. Vaccination with conjugated Hib vaccine has
resulted in protection against Hib disease and a rapid decline of the number of cases of invasive
Hib disease [11].
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In the Netherlands, the Hib conjugate vaccine also proved to be successfull, with an efficacy of
99,4 % [4]. Before the introduction of the conjugate Hib vaccine in the National Vaccination
Program of the Netherlands, yearly a number of 700 invasive Hib infections was estimated, of
which 90% occurred in children < 5 years of age. About 50% of these invasive Hib infections
concerned meningitis, 15-30% epiglottitis [12]. The highest incidence of Hib meningitis was
found in children aged 6-12 months, whereas Hib epiglottitis concerned mainly children 2-3
years of age. Following the introduction of Hib vaccination in 1993, the number of invasive Hib
infections decreased steadily and sharply: in 1994 106 cases were reported, in 1995 37, in 1996
18 and in 1997 7 cases. Only the minority of these cases were true vaccine failures, with most of
the invasive Hib infections occurring in children that were not vaccinated, -either because of
religious reasons or because they were not covered by the health care system- , or not yet fully
vaccinated because of their age.
We here report the 21 real vaccine failures that have occurred in the Netherlands since the
introduction of the Hib conjugate vaccine. Their average age was higher than the age in the
previous unvaccinated population, namely 26 months for the meningitis patients and 38 months
for epiglottitis patients. The surveillance data obtained during the first three years after the
introduction of the Hib vaccine showed an average age of the cases of invasive Hib infections of
7.4 months [4]. The surveillance data obtained 1997- July 2000 however, showed an increase in
average age of the Hib patients to 15.5 months (unpublished data RBM). The age shift is most
likely due to herd immunity because of reduced circulation of H. influenzae type b after the
introduction of Hib vaccination [13;14].
In literature [15], 35-40% of children who developed invasive Hib disease after a single dose of
conjugated Hib vaccine at the age of >15 months were described to have subnormal
concentrations of serum immunoglobulins. Specifically, a high prevalence of subnormal
concentrations of IgG2 was observed [15;16]. In contrast, reports on Hib polysaccharide vaccine
failures in children older than 18 months of age, showed a low incidence of immunodeficiency:
almost all of these children had normal serum concentrations of immunoglobulins, including
IgG2 [17]. These data suggested immunological differences between populations of children
with polysaccharide and conjugate vaccination failure [16]. However, these results were obtained
in children vaccinated at > 15 months of age. In our series of Hib conjugate vaccine failures after
infant immunization, one of the 14 evaluable children had hypogammaglobulinaemia, and one
had low serum IgG2 concentrations. Although there are only a few patients, this suggests that the
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frequency of humoral immunodeficiency in infant Hib conjugate vaccination failure (14% in our
series) is not different from the conjugate vaccination failures in children vaccinated at > 15
months of age or in polysaccharide vaccine failures (10%) after 18 months of age [16].
We evaluated the specific anti-Hib antibody production in our patients. An important question is
whether vaccination failure resulted from insufficient levels of circulating antibody after
vaccination or from a qualitatively different and suboptimally protective antibody response. In 9
of 10 patients from who data were available we found low levels of specific IgG anti-Hib
antibodies at the time of disease. These data suggest that these children, similar to children with
polysaccharide vaccination failure [16] are low antibody responders to vaccination. However,
low levels of anti-Hib antibodies are more frequently observed in this age group ([18] and own
unpublished data). In considering the correlation of disease susceptibility with antibody
concentrations after Hib conjugate vaccination, account must also be made of the capacity of
conjugate vaccines to induce immunological memory [19]. Even infants who fail to show a
serum antibody response to immunization with conjugate vaccine may be protected from disease
as a result of immunologic priming and the ability to develop a rapid increase in anti-Hib
antibody. However, immunologic priming by conjugate Hib vaccine might not always be
sufficient to confer protection against invasive Hib disease: some children show high antibody
responses to the disease (patient n and [1;15]), and thus were primed, but nevertheless had
acquired the invasive Hib infection.
Evidence of priming by the conjugate vaccination was absent in the 6 patients of group I: the two
patients with the immunoglobulin deficiency (patients a and f), and 4 out of the 12 children with
normal serum immunoglobulin concentrations. They had low anti-Hib antibody concentrations
in convalescent serum samples after invasive Hib disease. The failure to see an antibody
response in younger children after infection (convalesence) is consistent with impaired capacity
of young children to generate antibodies to unconjugated polysaccharides. A defective antibody
response to Hib infection is also found in children with Hib polysaccharide vaccine failure. In
contrast, children with conjugate vaccination failure after vaccination at the age of > 15 months
appear to have normal or even increased antibody responses [16], more alike the children of
group II.
The serum antibody concentration sufficient to confer protection is not known with certainty, but
based on epidemiologic and animal studies it is estimated to be between 0.1 and 1.0 µg/ml [20-
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23]. Apart from the antibody concentration, isotype distribution, avidity and complement
mediated bactericidal capacity all may contribute to the ‘protective’ antibody concentration [24-
26].
The ability to mount an antibody response after Hib-vaccination or disease is in part genetically
determined. This could play a role in the susceptibility to invasive Hib-infections [27-29].
However, ultimately almost all our patients developed anti-Hib antibodies. Several ethnic
populations do respond upon vaccination with Hib conjugate vaccines, but need several extra
booster vaccinations [27]. In Navajo-Indians a variant A2 Vk light chain gene (a gene which is
used in 60% of anti-Hib antibodies) is found, which may explain their aberrant pattern of anti-
Hib antibody development [30]. In patient b and his father (who failed to mount an IgG anti-Hib
antibody titer >1.0 µg/mL after a single Hib conjugate vaccination), molecular analysis did not
reveal this variant light chain gene, nor another abnormality in the A2 Vk light chain gene (data
not shown).
The causes of Hib conjugate vaccine failure are probably multiple and complex. Inadequate
delivery of the vaccine might be a major reason. In most children, vaccination failure does not
appear to be the result of the presence of hypogammaglobulineamia or absence of certain V-
region genes. Certain immunoglobulin allotypes are associated with susceptibility to
polysaccharide encapsulated bacteria [31] and risks of vaccination failure [32]. Risk of infection
with encapsulated bacteria is also increased in patients with the unfavourable Fc gamma receptor
IIa polymorphism [33;34]. The number of vaccine failures in our series for whom we had DNA
available was to small to make firm conclusions with respect to a possible relationship of Hib
vaccination failure with immunoglobulin allotypes or Fc receptor polymorphisms.
In our series of 21 vaccine failures, of which in 14 patients immunological evaluation could
be performed, for one patient a recognized immunodeficiency, namely
hypogammaglobulinaemia, was shown to be underlying the vaccine failure. In the others, the
Hib disease apparently was an isolated event. Many of them failed to mount antibody
responses to Hib, and were therefore at an increased risk of developing second episodes of the
disease. Revaccination was able to overcome this impaired antibody response. We conclude
that it is worthwhile to perform case investigation, including measurement of serum
immunoglobulin levels as well as specific anti-Hib antibodies in case of Hib vaccine failure.
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Haemophilus influenzae type b (Hib) conjugate vaccines are extremely efficacious in
protecting infants and children from invasive Hib infections. However, vaccine failures do
occur. We studied the anti-Hib antibody production both quantitatively and qualitatively in 12
Hib failure patients, all with normal serum immunoglobulin concentrations and without
clinical risk factors for invasive Hib disease. Both anti-Hib antibody concentration and (IgG2)
anti-Hib antibody avidity were significantly lower in Hib failure patients, at onset of disease
as well as after reconvalescence, compared with controls. This finding suggests that the
patients who developed invasive Hib disease despite three or four Hib conjugate vaccinations
were inadequately primed by these vaccinations.
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Introduction
Haemophilus influenzae type b (Hib) conjugate vaccines have proven to be extremely
efficacious in protecting infants and children from invasive Hib infections [1;2]. However, a
very few children still develop invasive Hib disease despite vaccination and are therefore
considered vaccine failures. In the Netherlands, vaccination with Hib conjugate vaccine has
been incorporated into the National Vaccination Program for all children born after April 1,
1993. In the 7 years since the introduction of the vaccine, 21 vaccine failures have been
reported; 14 of these patients have been immunologically characterized (Breukels CID, 2001).
Serum immunoglobulin concentrations, including IgG subclasses, were within the normal
range for age in 12 (86%) of these children; in one patient the serum concentration of IgG2
was below 2 SD of the mean concentration for age, and one patient had a hypogammaglobu-
linaemia. Therefore, in the majority of the cases, no recognized humoral immunodeficiency
was identified as the underlying cause of the Hib vaccination failure.
We hypothesized that quantitative and/or qualitative defects might specifically exist in the
production of anti-Hib antibodies in cases of Hib vaccination failure. Considerable evidence
points towards the importance of antibody avidity as a determinant of protective efficacy
[3-6]. Most likely, avidity plays a role in determining the ability of antibodies to neutralize
Hib when it is encountered in the bloodstream; at low serum concentrations, antibodies of
high avidity are more effective than antibodies of lower avidity. We therefore studied Hib
antibody avidities in sera obtained from the Hib vaccine failures at onset of disease, at
reconvalescence and after revaccination. Children with low antibody titers to Hib after the
regular four conjugate Hib vaccinations without clinical manifestations of Hib disease, who




Cases of invasive Hib infections are defined as vaccine failures when they occur in children
despite at least three infant vaccinations with the Hib conjugate vaccine (or after a single
vaccination in a child over 1 year of age). In the Netherlands, the Hib vaccine used is the
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PRP-T vaccine (polyribosylribitolphosphate (PRP) conjugated to tetanus toxoid, Pasteur
Mérieux Sérums et Vaccins, Lyon, France).
Subjects
The 21 true vaccine failures reported in the seven years since introduction of the conjugate
Hib vaccine in the National Vaccination Program have been described previously (Breukels,
CID 2001). One of these 21 patients had a chromosomal abnormality as clinical risk factor.
Serum samples were drawn from 14 patients at the onset of disease and/or after reconvalescence
(3-4 weeks after the onset of the disease), and after revaccination in case of persistently low Hib
antibody concentrations. In one of these 14 patients the serum concentration of IgG2 was
below 2 SD of the mean concentration for age, and one patient had hypogamma-
globulinaemia. These 2 patients with abnormal serum immunoglobulin concentrations were
excluded from this study, so in total 12 patients were evaluated.
As controls we used sera from 13 children with recurrent respiratory tract infections submitted
to our laboratory in the same time period for immunological evaluation. These children had
received the regular Hib vaccinations (at 3, 4, 5 and 11 months of age) but appeared to have
low Hib antibodies at the time of analysis; they had normal serum immunoglobulin
concentrations. In order to evaluate their immune status, these children were booster
vaccinated with the Hib conjugate vaccine, and Hib antibodies were determined 2-3 weeks
later.
Assays
Total serum concentrations of IgG, IgA and IgM, as well as serum concentrations of IgG
subclasses were determined by radial immunodiffusion (Dade Behringer, Marburg, Germany
and CLB, Amsterdam, The Netherlands).
IgG, IgG1 and IgG2 anti-Hib antibody titers were determined by ELISA as described [7], and
calibrated using a standard anti-Hib hyperimmune serum (CBER standard, kindly provided by
Dr. C. Frasch, FDA, Washington DC, USA). IgG1 anti-tetanus toxoid antibodies were
quantified by an antibody-capture ELISA [8]. In short, the wells of a 96-well polystyrene
microtiter plate were coated with tetanus toxoid (TT, 5 Lf/ml in 0.05 M carbonate buffer pH
9.6), blocked with bovine serum albumin, and incubated with two-fold serial dilutions of
serum samples and standard sera. Anti-TT-antibodies in the IgG1 subclass were measured by
successive incubation with IgG1-specific monoclonal antibodies (MH 161-1, CLB,
Amsterdam, The Netherlands), followed by incubation with alkaline phosphatase-conjugated
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rabbit anti-mouse Ig (Dakopatts, Glostrup, Denmark). After incubation with substrate (p-
nitrophenylphosphate), the reaction was stopped with 3 M NaOH, and the optical density at
405 nm was recorded. The amount of IgG1 anti-TT antibodies in the sera of Hib patients and
controls was calculated by comparison with standard sera containing known amounts of IgG1
anti-TT antibodies.
Avidity indices of IgG1 and IgG2 anti-Hib antibodies were measured by a modification of the
sodium thiocyanate (NaSCN) elution ELISA described by Pullen [9]. Polystyrene microtiter
plates were coated overnight at 37 °C with Hib polysaccharide (PRP) diluted to 1 µg/ml in
PBS pH 7.2, and then blocked for 1 hour at 37 °C with PBS-1% bovine serum albumin. Two-
fold serial dilutions of serum samples and standard serum were incubated for 2 hours at 37
°C. Sera were diluted in PBS-0.05% Tween 20- 1% bovine serum albumin to 50% of the
amount of Hib antibodies which can maximally bind to the plate. After washing, the
chaotropic agent NaSCN diluted in PBS was added in duplicate at concentrations ranging
from 0.0 to 3.5 M. After 15 minutes at 37 °C, the wells were washed, and binding of
remaining antibodies was then detected by subsequent incubation with IgG1- (MH 161-1,
CLB, Amsterdam, The Netherlands) or IgG2- (35-1-27-2, TNO, Leiden, The Netherlands)
specific monoclonal antibodies, followed by incubation with alkaline phosphatase-conjugated
rabbit anti-mouse Ig (Dakopatts, Glostrup, Denmark). After incubation with substrate (p-
nitrophenylphosphate), the reaction was stopped with 3 M NaOH, and the optical density at
405 nm was recorded. The relative avidity index (AI) is defined as the molarity of NaSCN at
which 50% of the amount of IgG1 or IgG2 subclass antibodies bound to the coated antigen in
the absence of NaSCN has been eluted from the antigen. This value represents an estimation
of ‘average’ antibody avidity. The percentile elution contributed by each serial NaSCN
concentration was calculated and these values were used to analyse the heterogeneity of
avidity. Shannon’s coefficient (SC), which represents an index of this avidity heterogeneity,
was calculated from these percentile elution intervals as described [10].
Avidity of IgG1 anti-TT antibodies was determined using a similar procedure as described
above for anti-Hib antibodies. The concentrations of NaSCN applied ranged from 0 to 4.5 M.
Statistics
Antibody titers against Hib and TT, as well as antibody avidity parameters were compared for
significant differences between the two groups by two-tailed Mann-Whitney U test. P-values




Hib conjugate vaccines have excellent immunogenicity in healthy infants and children
[11;12;13] as well as in children with underlying diseases like sickle cell disease and
congenital asplenia [14;15]. These vaccines are highly efficacious in preventing disease, thus
the rare vaccine failures warrant further investigation. Others [16;17] reported that a large
proportion of children with Hib vaccination failure have associated clinical risk factors or
humoral immunodeficiencies. In contrast, in our series (Breukels, CID, 2001) only 3 of the 21
children had such risk factors: one child had a chromosomal abnormality, one was IgG2
deficient and in one child hypogammaglobulinaemia was identified as the underlying cause of
the Hib failure. In accordance with earlier studies [16;17], we found a large proportion of the
children with Hib vaccine failure (6 out of 14) that showed low reconvalescent antibody
responses to Hib. Booster vaccination with Hib conjugate vaccine ultimately resulted in IgG
antibody levels above 1.0 µg/ml in all these children (Breukels, CID, 2001). Here we studied
the specific anti-Hib and anti-TT antibody responses of Hib failure patients not only
quantitatively but also qualitatively. Children with recurrent respiratory tract infections and
with low Hib-antibody titers but no history of invasive Hib disease were used as a control
group.
Antibody concentration
IgG, IgG1 and IgG2 antibody concentrations against Hib, and IgG1 antibody concentrations
against TT, of patient and control sera are summarized in Table 1.
Serum samples obtained at onset of invasive Hib disease were available from 8 patients (0.8-
4.7 years of age) with Hib vaccine failure. Anti-Hib concentrations were generally low
(geometric mean IgG anti-Hib 1.6 µg/ml), and below 1.0 µg/ml in 4 of the patients. Among
these 4 patients were two children that, because of their young age, had only received three
vaccinations with Hib conjugate.
Hib conjugate vaccines prime infants and children for memory responses to subsequent
encounter with Hib polysaccharide [18]. Theoretically, even individuals with low specific
anti-Hib antibody titers will thus be protected from invasive Hib infection. To evaluate
whether the patients with Hib failure had been primed for memory responses by Hib
conjugate vaccination, we compared Hib antibody responses of the12 patients after Hib
disease (0.9-5.2 years of age) with responses after Hib booster vaccination of 13 control
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children (2.0-3.7 years of age) with low anti-Hib antibody concentrations (geometric mean
IgG anti-Hib 0.36 µg/ml) after their regular four Hib vaccinations.
During reconvalescence, the children who developed invasive Hib disease despite having
received at least three Hib vaccinations, mounted significantly lower (p <0.01 for total IgG,
IgG1 and IgG2) anti-Hib antibody responses than did control children after revaccination.
This difference remained significant (p<0.01) after exclusion of the two patients who had only
received three Hib vaccinations prior to developing invasive disease.
Apparently, immunological priming by conjugate vaccination was not sufficient to result in a
vigorous memory response to the invading Hib bacteria, whereas the same priming enabled
the control children to mount high antibody responses to a single booster vaccination. This
suggests that the patients with Hib vaccination failure have an intrinsic defect in specific anti-
Hib antibody production. Alternatively, the difference in memory responses between the two
groups may be explained by differences in immunogenicity between Hib polysaccharide
present in the capsule of living H. influenzae type b bacteria and Hib polysaccharide










Patients tions (years)    range geo     range geo     range geo     range geo     range
A 8 3 or 4 2.4 (0.8- 4.7) 1.6 (0.6 -18) 1.0 (0.4 -11) 0.2 (0.1 -2.9) 2.5 (0.4 -16)
B 12 3 or 4 2.8 (0.9- 5.2) 6.6 (1.1 -29) 3.3 (0.5 -24) 1.2 (0.1 -15) 2.4 (0.7 -25)
C 10 4 3.2 (1.7- 5.2) 9.4 (1.9 -54) 4.6 (0.8 -24) 1.9 (0.3 -15) 2.5 (0.7 -25)
D 4 5 3.3 (1.7- 5.1) 17 (4.6 -80) 9.3 (2.2 -108) 8.1 (2.4 -25) 16.7 (7.4 -34)
E 12 4 or 5 3.0 (1.2- 5.2) 17 (1.9 -80) 9.6 (1.3 -108) 4.2 (0.1 -25) 5.4 (1.0 -34)
Controls
F 13 4 2.5 (1.6- 3.1) 0.4 (0.3 -0.9)
G 13 5 2.9 (2.0- 3.7) 96 (1.5 -582) 66 (1.5 -567) 19 (0.2 -249) 24 (2.2-495)
Table 1. Anti-Hib and anti-tetanus toxoid antibody concentrations
IgG, IgG1 and IgG2 anti-Hib antibodies and IgG1 anti-TT antibodies were determined by ELISA in Hib failure
patients (A-E) and controls (F and G). Geometric mean antibody-concentrations as well as the ranges in antibody
concentration are expressed in mg/ml.
A) sera at onset of Hib disease; B) reconvalescent sera; C) reconvalescent sera from fully (4 times) vaccinated
patients; D) sera from patients boostered after reconvalescence; E) the 12 Hib-failure patient sera after disease or
booster vaccination: from each patient the serum with maximal antibody concentration is included; F) sera of
controls after four Hib conjugate vaccinations); G) sera of controls after five Hib vaccinations.
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We therefore booster vaccinated the 4 patients with low reconvalescence anti-Hib antibody
concentrations with Hib conjugate vaccine. The two young patients received their regular
fourth Hib conjugate vaccination (booster 1) as well as an additional booster vaccination
(booster 2). These 4 patients thus received five Hib vaccinations in total. We compared their
antibody responses to booster vaccination with those of the controls after booster vaccination.
Although IgG anti-Hib antibody concentrations in the Hib patients were still lower (geometric
mean 17.4 µg/ml compared with 96 µg/ml in controls) due to the small groups this difference
did not reach significance (p=0.062). The same trend was observed for IgG1 and IgG2 anti-
Hib antibodies (Table 1).
Ultimately, with or without booster vaccination, all patients reached anti-Hib antibody levels
above 1.0 µg/ml. However, compared to revaccinated controls, the maximal antibody
concentrations were still significantly lower in the Hib failure patients (p < 0.01, p< 0.01 and
p< 0.05 for total IgG, IgG1 and IgG2, respectively). For this reason, we conclude that in Hib
vaccine failure patients a quantitative defect in Hib antibody production is demonstrable. This
defect may be intrinsic, and thus correlate with susceptibility to Hib disease, but the lower
anti-Hib antibody response in Hib failures may also be caused by the presence of residual Hib
polysaccharide after invasive Hib disease, leading to tolerance, as has been described for other
polysaccharides [19].
Anti-TT antibody concentrations also were much lower in Hib failure patients than in
controls. This may result from the fact that the controls had received one additional
vaccination (Hib polysaccharide conjugated to TT) containing TT. When the 4 Hib
vaccination failure patients who had received five Hib vaccinations were compared with the
controls having received five Hib vaccinations, no significant difference in IgG1 anti-TT
antibody concentration was found (geometric mean 16.7 µg/ml and 24.3 µg/ml, respectively;
see Table 1).
The Hib conjugate vaccine induces a predominant IgG1 antibody response; indeed in the
control group 78% of IgG antibodies is of the IgG1 subclass. The ratio of IgG1/IgG2 anti-Hib
antibodies, however, does show considerable individual variation both in controls as well as
in patients, with observed ranges in IgG1-anti-Hib antibody as percentage of total antibody
from 13 to 93% in patients and from 12 to 99% in controls. IgG1 anti-Hib antibodies are
generally more effective than IgG2 antibodies in activating complement mediated
bacteriolysis or in opsonic activity, however in some individuals the reverse can be found [20-
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22]. Hib vaccination failure can therefore not be attributed to low IgG1/IgG2 anti-Hib
antibody ratios in some individual patients.
Antibody avidity
Avidity of IgG1 and IgG2 antibodies against Hib and of IgG1 antibodies against TT was
evaluated by two parameters, i.e. the avidity index (AI) and the Shannon’s coefficient (SC).
Results are summarized in Table 2. Because of low IgG, IgG1 and/or IgG2 anti-Hib antibody
concentrations, Hib avidity-assays could not be performed on all serum samples nor for all
isotypes.
vaccina- age Hib IgG1 Hib IgG2 TT IgG1
n tions (years)      range
Patients n AI SC n AI SC N AI SC
A 8 3 or 4 2.4 (0.8 -4.7) 4 0.37 10.0 1 0.07 7.0 8 1.85 14.2
B 12 3 or 4 2.8 (0.9 -5.2) 10 0.33 10.4 6 0.10 7.6 12 1.93 14.5
C 10 4 3.2 (1.7 -5.2) 10 0.33 10.4 6 0.10 7.6 10 2.05 14.6
D 4 5 3.3 (1.7 -5.1) 4 0.35 10.8 4 0.12 7.2 4 2.71 14.9
E 12 4 or 5 3.0 (1.2 -5.2) 12 0.30 11.0 10 0.12 7.5 12 2.19 14.7
Controls
G 13 5 2.9 (2.0 -3.7) 13 0.52 11.0 11 0.40 9.6 13 2.58 14.2
Table 2.  Avidity of anti-Hib and anti-tetanus toxoid antibodies
Avidity of IgG1 and IgG2 antibodies against Hib and of IgG1 antibodies against tetanus toxoid (TT) was
evaluated by the relative avidity index (AI) and heterogeneity of avidity by the Shannon’s coefficient (SC). The
average AI and SC are given for the individual groups. The number of vaccinations received is indicated, as well
as the number of sera that could be analyzed by elution ELISA (n).
A) sera at onset of Hib disease; B) reconvalescent sera; C) reconvalescent sera from fully (4 times) vaccinated
patients; D) sera from patients boostered after reconvalescence; E) the 12 Hib-failure patient sera after disease or
booster vaccination: from each patient the serum with maximal antibody concentration is included; G) sera of
controls after five Hib vaccinations.
The relative AI of IgG1 anti-Hib antibodies at onset of disease, after reconvalescence as well
as after booster vaccination, was comparable with that in control sera (Table 2).
From 5 individual patients, consecutive serum samples could be analyzed by elution ELISA;
an increase in avidity of IgG1 anti-Hib antibodies was observed in three of these patients,
whereas in the two others no avidity maturation was observed (Figure 1). The avidity of IgG2
Chapter 7b
168
anti-Hib antibodies was lower in patients compared with controls (Table 2), and no
maturation was observed in the 3 individual patients from whom consecutive serum samples
could be analyzed (Figure 1). At the time of maximal IgG2 anti-Hib antibody concentrations,
the relative avidity index was 0.1 in patients, compared with 0.4 in controls (p=0.08). Avidity
heterogeneity of IgG2 anti-Hib antibody as represented by the Shannon’s coefficient was also
lower in patients than in controls (SC 7.5 and 9.6, respectively, p=0.05).
Figure 1. Avidity maturation of IgG1 and IgG2 anti-Hib antibodies in 5 individual patients during Hib disease
and after booster vaccination.
In two young patients the regular fourth Hib vaccination is marked ‘boost 1’; and a fifth Hib vaccination, ‘boost
2’, respectively. Horizontal bars depict the average avidity index (± SEM) in control sera.
In most control children, the similarity of IgG1 and IgG2 anti-Hib avidities was striking; in 5
out of the 10 analyzed Hib failure patients the IgG2 avidity was significantly lower than the
IgG1 avidity (Figure 2).
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Figure 2. Correlation between IgG1 and IgG2 anti-Hib antibodies in controls after revaccination (n=11) and in
Hib failure patients at maximal antibody concentration (n=10).
The relative AI of IgG1 anti-TT antibodies was significantly lower in the reconvalescence
sera of 12 patients than in the sera of 13 controls (p<0.01). This observation may result from
the fact that the controls had received one additional vaccination containing TT (Hib
polysaccharide conjugated to TT) after completion of the National Vaccination Program.
When the Hib vaccination failure patients that were vaccinated five times were compared with
those controls, no significant difference in anti-TT antibody avidity was found. Alternatively,
the low relative AI of IgG1 anti-TT antibodies in the reconvalescent sera from fully
vaccinated patients compared to the controls suggested that also the maturation of the
antibody response to protein antigens might be delayed in Hib failure patients.
In both patients and controls, the avidity parameters of IgG1 anti-TT antibodies are
significantly higher (p<0.01) than those of anti-Hib antibodies, as exemplified in Figure 3.
This finding is probably a reflection of the different nature of Hib and TT antigens. The
limited variety of available Hib capsular polysaccharide epitopes is known to be associated
with an oligoclonality of the serum anti-Hib antibody response [23] and a restricted use of VH
genes [24;25]. The restricted VH gene usage makes avidity maturation of anti-Hib-antibodies




Figure 3. Thiocyanate elution profiles of IgG1 and IgG2 Hib antibodies and IgG1 anti-TT antibodies of a control
and a Hib failure patient.
Each histogram bar represents the percentage (right y-axis) of total antibody eluted by the thiocyanate
concentration indicated on the X-axis. The black squares (n) represent the percentage of restbinding (left y-axis)
after each elution step. The relative avidity index is defined as the thiocyanate concentration resulting in 50%
restbinding.
We thus conclude that Hib failure patients not only have a quantitative defect in the
production of anti-Hib antibodies, but also a qualitative defect. This qualitative defect also
appears to be selective for Hib, and more particular for IgG2 anti-Hib antibodies. This is
illustrated by the low relative AI for IgG2 anti-Hib antibodies, and by the low SC suggesting a
limited diversity of IgG2 anti-Hib producing B cell clones.
Conclusions
Protective function of anti-Hib polysaccharide antibody depends upon the density of
antibodies present on the bacterial surface. This density will depend not only on antibody
concentration, but also on antibody avidity. Correlations between antibody avidity and
effector functions have been observed [4;26;27] and the effect of lower overall avidity should
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become more pronounced in situations where antibody concentrations are limited. Hib
conjugate vaccines prime for memory responses, which are characterized by rapid production
of antibodies of relatively high avidity. Antibody concentration and avidity measures are
therefore correlated surrogates of protection. High antibody responses following encounter
with the antigen indicate successful priming, as does the presence of high avidity antibodies.
In individuals with low antibody titers, antibody avidity may be able to discriminate between
those subjects successfully primed in infancy -who may be considered to be protected-, and
those with low-avidity antibodies, who thus are not primed sufficiently, and therefore may be
at risk of invasive disease.
In patients with Hib vaccination failure without obvious clinical risk factors or obvious
immunological deficiencies, we found both quantitative and qualitiative defects in the specific
anti-Hib antibody production. Our findings have to be substantiated further by the
investigation of a large group of vaccine failures and healthy controls. Furthermore, it would
be informative to investigate the opsonic activity of sera obtained from patients and controls
against H. influenzae type b.
The low specific anti-Hib antibody responses after invasive Hib disease and the relatively low
avidity of (IgG2-) anti-Hib antibodies suggest that the patients who developed invasive Hib
disease despite three or four Hib conjugate vaccinations were inadequately primed by these
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Antibodies to capsular polysaccharides are essential in the defense against encapsulated
bacteria such as Streptococcus pneumoniae and Haemophilus influenzae type b.
Polysaccharide vaccines induce a protective antibody response in adults and children older
than 18-24 months of age, leaving the group most at risk for infections with encapsulated
bacteria, infants and young children, unprotected. Polysaccharide-protein conjugate vaccines
are immunogenic in infants and toddlers, and also in several other groups at risk for infections
with encapsulated bacteria due to impaired anti-polysaccharide antibody production. In this
thesis, the immunobiology and the application of polysaccharide- and polysaccharide
conjugate vaccines were studied in an experimental rat model and in selected patient groups.
The importance of the splenic marginal zone in the anti-polysaccharide antibody
response
The concept that marginal zone B cells are involved in the response to polysaccharide
antigens originates from the observation that high expression of complement receptor 2
(CD21) on marginal zone B cells occurs only late in ontogeny; a time frame that coincides
with the acquisition of anti-polysaccharide antibody responsiveness. The importance of
splenic marginal zone B cells, complement receptors, and complement in the antibody
response to TI-2 antigens has been shown in recent studies in C3-/-, CRI/II-/-, and Pyk2-/- mice
[1]. In these studies, splenic marginal zone B cells expressing high levels of CD21 appeared
to be an absolute requirement for the generation of an antibody response to the synthetic TI-2
antigen TNP-Ficoll. It is likely that the ability of TI-2 antigens to activate complement and to
bind in particular to C3d facilitates the localization of these antigens on marginal zone B cells.
In addition, the ability of complement-factor C3d to activate B cells by cross-linking of B cell
receptor and CD21 may directly facilitate marginal zone B cells to induce TI-2 antibody
responses [2].
We studied the initiation of the anti-polysaccharide antibody response in a rat model
(chapters 2 and 3). The induction of anti-capsular antibodies by polysaccharide vaccine
proved to be complement-dependent, most likely because polysaccharide localization on
splenic marginal zone B cells depends on complement. This localization on marginal zone B
cells seems crucial for the initiation of an anti-polysaccharide antibody response. This is
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supported further by our results in splenectomized rats which show impaired anti-
polysaccharide antibody responses following polysaccharide vaccination (chapter 3).
In man, functional or anatomical asplenic individuals are highly susceptible to infections with
encapsulated bacteria and this is thought to reflect the critical role for the splenic marginal
zone in alerting the immune system to these pathogens. The localization of marginal zone B
cells is at the point were blood enters the spleen, so that marginal zone B cells are well
situated for the capture of blood-borne pathogens. In addition, marginal zone B cells have a
distinct phenotype, with high expression of complement receptor 2 (CD21), which greatly
enhances the B cell response to complement-coated bacteria. This strategic localization and
expression of CD21 makes marginal zone B cells remarkably well suited for the capture of
complement-coated bacteria. In vitro studies have established that when antigen is recognized,
marginal zone B cells differentiate with unmatched speed into antibody secreting cells [3]. A
number of studies (reviewed in [4]) suggest that marginal zone B cell responses can be
amplified or switched through cytokines released by non-conventional helper cells. This help
might come from CD1 restricted T cells [5], which are known to secrete very promptly
cytokines such as IL-4 and IFN-g. The CD1 family of proteins are non-classical MHC
molecules, evolutionarily highly conserved and prominently expressed on professional
antigen presenting cells. This suggests that CD1 proteins may function in recruiting a form of
innate help from cytokine-producing T cells to antigen-presenting cells. Certain CD1 family
members (notably CD1d) are specialized in presenting glycolipids. This would also allow for
presentation of polysaccharides because the biosynthesis of these molecules starts on lipid
carriers and capsular polysaccharides do carry terminal lipid tails. Interestingly, marginal zone
B cells express very high levels of CD1, and this strengthens the idea that they may be
involved in polysaccharide antigen presentation.
It is not known whether the availability of complement and antigen localization on marginal
zone B cells is also important for antibody responses to polysaccharides conjugated to
proteins. There is circumstantial evidence that conjugates do not depend on localization on
marginal zone B cells for induction of an immune response: infants with a low CD21
expression on B lymphocytes still are able to respond to polysaccharide conjugate vaccines.
We showed in chapter 2 that conjugate vaccine can induce anti-polysaccharide antibodies in
the absence of complement. More detailed information came from the rat model, showing
polysaccharide conjugate vaccine to localize in the splenic marginal zone, but in a pattern
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different from polysaccharides (in association with marginal zone macrophages) and in a less
complement-dependent way. This latter splenic localization is not obligatory for the induction
of an antibody response: we demonstrated that an adequate anti-polysaccharide antibody
response can be induced by conjugate vaccines in the absence of a spleen (chapter 3). The
initiation of an anti-polysaccharide response by conjugate vaccines can thus take place in
lymphoid tissue other than the spleen
PPS 19 localisation 2 hours after vaccination
Spleen Liver Thymus Gut Ln 1 Ln 2 Ln 3
1 Sham PPS ++++ ++++ +/- - ++ ++
2 ++++ ++++ +/- - +/- +/-
3 PCV +++ +/- - ++ ++
4 ++ ++ +/- - + +/- ++
5 Sx PPS +/- - ++ +++ +++
6 ++++ +/- - ++ ++ ++
7 PCV ++ + ++ ++
8 +++ +/- - +/- + ++
9 Auto Tx PPS ++++ +++ +/- + +++ ++
10 ++++ +++ +/- ++ +++ + ++
11 PCV ++++ +++ +/- - +++ ++ +++
12 ++++ +++ +/- - +++ +++ ++
PPS 14 localisation 2 hours after vaccination
Spleen Liver Thymus Gut Ln 1 Ln 2 Ln 3
1 Sham PPS ++ +++ +/- - + +/-
2 ++ +++ +/- - + -
3 PCV ++ ++ +/- - + +/- +/-
4 ++ ++ - - +/- - +/-
5 Sx PPS +/- - +/- +/-
6 ++ - - +/- - +/-
7 PCV ++ +/- +/- +/-
8 ++ - - +/- +/-
9 Auto Tx PPS + ++ +/- - +/- -
10 ++ ++ +/- - - - +
11 PCV +/- ++ +/- - + - -
12 +/- ++ +/- - + - +/-
Table 1. Localization pattern of pneumococcal polysaccharide vaccine (PPS, containing 25 µg polysaccharide of
the serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and pneumococcal conjugate vaccine (PCV, containing the
polysaccharides of the pneumococcal serotypes 4, 9V, 14, 19F and 23F and an oligosaccharide of serotype 18C
(2 mg each) and polysaccharide type 6B (4 mg), conjugated to CRM197 carrier protein (Wyeth Lederle Vaccines
and Pediatrics, Rochester, NY) two hours after intraveneous (in the tail vein) and subcutaneous (in the hind leg)
injection. Rats were sham operated (Sham), splenectomized (Sx) and splenectomized followed by
autotransplantantion (Auto Tx). Ln 1=abdominal lymph node; Ln 2=cervical lymph node, Ln 3=axillary lymph
node. Localization of PPS-14 and PPS-19 is evaluated by immunohistochemistry using specific antibodies on 4
micron frozen tissue sections using a semiquantitative scale.
Recent additional experiments showed that in splenectomized rats, two hours after injection,
conjugated polysaccharides localize most obviously in lymph nodes (Table 1). This suggests
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that lymph nodes are an important site of antigen localization after polysaccharide conjugate
vaccination. After splenectomy, polysaccharides are also mostly found in lymph nodes (Table
1). Because the antibody response to a polysaccharide vaccine is abrogated after splenectomy
(chapter 3), this indicates that mere localization of polysaccharides in lymph nodes is not
sufficient for the induction of an anti-polysaccharide response. For the induction of an
antibody response by nonconjugated polysaccharides additional factors are required, and
apparently these requirements can not be met in an environment other than the splenic
marginal zone. In contrast, the induction of an antibody response to polysaccharide conjugates
does not require this specialized splenic marginal zone compartment.
The role of T cells in the anti-polysaccharide antibody response
Chapter 3 also provides insight in the way T cells can influence the in vivo antibody response
to polysaccharides. By definition, TI-2 polysaccharide antigens can induce an antibody
response in the absence of T lymphocytes. Also by definition, T lymphocytes can augment the
antibody response to polysaccharides. The T lymphocytes that exert this effect differ from
classical MHC restricted, antigen specific CD4+ T helper cells and therefore are operational
defined as "amplifier T cells". As already discussed above, amplifier T cells may be CD1
restricted. In a conjugate, the polysaccharide antigen is covalently coupled to a protein. These
conjugates induce an anti-polysaccharide antibody response with characteristics of a T cell
dependent (TD) antibody response. The prevalent model of how the conjugate would lead to a
TD B cell activation is that polysaccharide-specific B cells receive T cell help from peptide-
specific T cells (see Figure 2 in the Introduction). In chapter 3 we show in the rat model that
admixture of non-conjugated polysaccharides with the conjugate does not lead to a better
response to the native polysaccharide. Yet, both native polysaccharides and conjugated
polysaccharides localize in the same region of the spleen (although polysaccharides localize
specifically on marginal zone B lymphocytes, and the conjugate shows more diffuse presence in
this area). This would indicate that the mere secretion of B cell stimulatory cytokines by peptide-
specific T cells in the proximity of polysaccharide-specific B cells is not sufficient to lead to in
vivo augmentation of the B cell response. This suggests that direct cell-cell contact between




Memory induction and isotype switching
Above data indicate that optimal environment for induction of a primary anti-polysaccharide
response by native polysaccharides is the splenic marginal zone, where co-ligation of CD21
together with antigen-receptor crosslinking stimulates polysaccharide-specific marginal zone B
cells. The requirement for CD21 mediated co-stimulation can be overcome by polysaccharide
conjugates that provide co-stimulation through T-cell-dependent B cell activation. Once
polysaccharide-specific memory B cells are formed by vaccination with conjugate, requirements
for anti-polysaccharide antibody production may be different. This is illustrated by the fact that
infants who have been primed by conjugate vaccines are capable of producing anti-
polysaccharide antibodies following booster vaccination with native polysaccharides, even at an
age when their marginal zone is still immature and they normally would be unresponsive to
polysaccharides [6]. Polysaccharide-specific memory B cells, generated by conjugate
vaccination, thus differ from their primary B cell progenitors in that they can be activated by
crosslinking of membrane immunoglobulins by polysaccharides (and, potentially, co-stimulation
of CD21) without the need for the specialized marginal zone environment. Also the in vitro
experiments described in chapter 4 do support the concept that polysaccharide specific memory
B cells differ from virgin B cells in their activation requirements. We showed that
polysaccharide-specific B cells that are in vivo activated by polysaccharide-conjugate
vaccination, do not require direct contact with T cells for in vitro production of anti-
polysaccharide antibodies.
Once polysaccharide-specific memory B cells are generated by polysaccharide-conjugate
priming, isotype switching can be facilitated by boosting with a polysaccharide vaccine (chapter
5). In young children a primary immunization with pneumococcal conjugate vaccine induces a
predominant IgG1 type anti-pneumococcal antibody response. After priming with pneumococcal
conjugate vaccine, booster vaccination with 23-valent pneumococcal polysaccharide vaccine
leads to IgG2- and IgA-type anti-pneumococcal antibody production in these young children.
Booster vaccination with conjugate does not induce this isotype switching. The relevance and
impact of this finding on vaccination strategies might be substantial, as will be discussed below.
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Protection against mucosal infections
One of the main purposes of the development of pneumococcal conjugate vaccines is to
reduce the incidence of mucosal infections like acute otitis media (AOM), sinusitis and
bronchitis, that are often caused by S. pneumoniae. In healthy infants and toddlers,
immunization with pneumococcal conjugate vaccines indeed leads to reduction of
nasopharyngeal carriage of pneumococci, and is shown to induce immune responses at
mucosal membranes [7]. For this reason, pneumococcal conjugate vaccines are candidate
tools that can lead to reduction of respiratory tract infections. Data from the first two large
efficacy trials in healthy infants show a reduction in the occurrence of AOM caused by
vaccine-serotypes up to 57% [8;9]. In this respect the more than 90% reduction of invasive
infections [8] is more convincing. This suggests that the requirements for protection at
mucosal surfaces are different from those for protection against invasive infections. In infants
and young children, IgG1 type antibodies dominate the antibody response against
polysaccharide-conjugate vaccines, and these antibodies are apparently effective in protecting
against invasive disease. However, IgG2 and IgA antibodies may be more important for
protection against mucosal infections with encapsulated bacteria, which might explain the less
convincing protective efficacy for otitis media of vaccination schedules using only
pneumococcal conjugate vaccines in infants.
Otitis prone children as well as other patient groups at risk for mucosal infections with
encapsulated bacteria are often characterized by low IgA and IgG2 type anti-pneumococcal
antibodies [10;11]. We demonstrated the induction of IgG2- and IgA anti-pneumococcal
antibodies by pneumococcal conjugate priming followed by booster immunization with 23-
valent pneumococcal polysaccharide vaccine in children with frequent recurrent upper
respiratory tract infections such as recurrent (AOM) (chapter 5), even in those with partial IgG2
and/or IgA deficiency (chapter 5b). Sequential immunization with pneumococcal conjugate
vaccine followed by polysaccharide vaccine thus overcomes the apparent class switch defect in
this patient group, which might be of utmost importance for protection against mucosal
infections with encapsulated bacteria.
In the Netherlands, a large double-blinded randomized clinical trial measuring the efficacy of
this vaccination schedule in preventing recurrent episodes of AOM in otitis prone children




Next to establishing the clinical efficacy of pneumococcal conjugate vaccines, the OMAVAX-
study and other efficacy trials will yield a valuable set of laboratory and clinical data which will
facilitate the development and validation of laboratory correlates of protection against invasive
disease and mucosal infections. Since opsonophagocytosis is crucial in the defense against
encapsulated bacteria, functional antibody levels measured by phagocytosis assays may be used
as correlates of protection. We employed an assay that uses human polymorphonuclear
leukocytes (PMN) as phagocytic cells to evaluate the opsonophagocytic activity of sera obtained
after vaccination of healthy adults with pneumococcal conjugate vaccine (chapter 6). The level
of phagocytosis correlates with IgG2 anti-pneumococcal antibody concentrations, suggesting
that not only after polysaccharide vaccination but also after conjugate vaccination, the
functionally most active antibodies are of the IgG2 isotype. These data correspond with findings
of others [12;13] supporting an important role for IgG2 and IgA in the host defense against
pneumococci. Together with clinical data on pediatric otitis-prone patients characterized by
normal or even high IgG1, but low IgG2 and IgA type anti-pneumococcal antibodies [10;11],
these results are consistent with the view that IgG2 and IgA represent the main opsonins in
conferring clinical protection against mucosal pneumococcal infections.
Receptors for the constant region of antibodies (FcR) play a crucial role in the process of
opsonophagocytosis. Two subclasses of the leukocyte IgG receptor (FcgR) family, FcgRIIa
(CD32) and FcgRIIIb (CD16) are constitutively expressed on PMN. Both receptors exhibit
genetically determined functional polymorphisms. Both FcgRIIa and FcgRIIIb can bind IgG1-
and IgG3-containing complexes, but only FcgRIIa–H131 can effectively interact with
complexed IgG2 [14]. The capacity to clear IgG2-opsonized particles thus depends on
FcgRIIa genotype. We indeed found that the H131/R131 FcgRIIa polymorphism on PMN had
profound influence on phagocytic efficiency (chapter 6).
Vaccination strategies for risk groups
The efficacy of polysaccharide conjugate vaccines in protecting infants and young children
against invasive disease is high: this holds true for both the heptavalent pneumococcal
conjugate vaccine [8] and the Haemophilus influenzae type b conjugate vaccine [15].
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Introduction of latter conjugate vaccine in childhood vaccination programs has dramatically
reduced the incidence of invasive H. influenzae type b disease; only sporadically cases of
vaccine failure are reported (chapter 7). These successes of conjugate vaccines in infants may
open up ways to apply conjugate vaccines in other groups at risk for infections with
encapsulated bacteria and impaired responses to the plain polysaccharide.
The fact that in rats polysaccharide conjugate vaccines are able to induce robust anti-
polysaccharide antibody levels after splenectomy (chapter 3) suggests that asplenic or
hyposplenic patients may benefit from polysaccharide-conjugate vaccines. Another group to
benefit from (pneumococcal) conjugate vaccine may be the elderly. They are, next to children
under 5 years of age, the group at greatest risk for invasive pneumococcal infections and
pneumococcal pneumonia. Elderly respond sub optimally to pneumococcal polysaccharide
vaccines, particularly those with underlying disease. Furthermore, because polysaccharide
vaccines do not induce classical immunological memory, antibody levels to clinically
important serotypes decline to prevaccination values within 3-7 years. Although revaccination
with polysaccharide vaccines is safe and may prolong the duration of protection, many older
individuals will remain incompletely protected. The enhanced immunogenicity of
pneumococcal conjugate vaccines, and more importantly, their potential for prolonged
protection because of memory induction, opens new possibilities to develop pneumococcal
conjugate vaccination strategies for additional risk groups like elderly and patients with a
secondary immune deficiency.
A limitation of the conjugate vaccines in adults and elderly is the limited coverage of
pneumococcal serotypes causing invasive disease in these age-groups. In developed countries
an 11-valent pneumococcal conjugate vaccine would cover 75-85% of invasive isolates in
young children (not counting possibly cross-reacting serotypes) but only 65-68% of those in
adults. Yet, among these 11 vaccine-serotypes a substantial number is relatively poorly
immunogenic, and the 11-valent conjugate vaccine includes virtually all of the serotypes
associated with resistance to antimicrobials. Therefore, adults at risk for pneumococcal
infections may benefit from the existing pneumococcal conjugate vaccines, even though
serotype coverage is limited. To extend serotype coverage, both in adults and in children,
pneumococcal conjugate vaccines could be part of a vaccination schedule that also includes a
dose of 23-valent polysaccharide vaccine.
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Impact of conjugate vaccination on carriage and antimicrobial resistance
A very important feature of polysaccharide conjugate vaccines is their effect on
nasopharyngeal carriage. Nasopharyngeal carriage rates of H. influenzae type b are reduced in
vaccinated populations, and immunization with pneumococcal conjugate vaccines also results
in reduction in the prevalence of nasopharyngeal carriage of pneumococci of the vaccine
serotypes. The serotype specificity of these conjugate vaccines has led to the concern that
their use might result in increased carriage of and disease from serotypes not included in the
vaccine. Replacement has not occurred with the use of H. influenzae type b conjugate
vaccines, but increased nasopharyngeal carriage of non-vaccine type pneumococci has been
found in trials with pneumococcal conjugate vaccines. In an early study in Gambian infants
immunized with a pentavalent pneumococcal conjugate vaccine, and then reimmunized with a
23-valent pneumococcal polysaccharide vaccine, a reduction of the prevalence of
nasopharyngeal carriage of pneumococci of the conjugate vaccine types was shown.
However, replacement with pneumococci of non-vaccine serotype(s) occurred, so the overall
pneumococcal carriage in vaccinated children changed little [16]. A second study of Gambian
children 1-4 months after completion of a primary course of vaccination with a nonavalent
pneumococcal conjugate vaccine at the ages of 2, 3 and 4 months showed a similar trend [17].
Although a first study in Israel did not find evidence for replacement [18], a subsequent study
did so [19]. In a study in Soweto, South Africa, where 500 infants were vaccinated with a 7-
valent pneumococcal conjugate vaccine at 6, 10 and 14 weeks of age, nasopharyngeal carriage
rates of vaccine serotypes decreased in vaccinees at 9 months of age (from 36% to 18%), but
carriage rates of non-vaccine serotypes increased from 25% to 36%. Of concern is that
carriage of one of the non-vaccine serotypes most commonly isolated in invasive
pneumococcal disease in South Africa, serotype 15, was significantly increased in vaccinees
compared with controls [20]. Whether this replacement will lead to the increase of invasive
disease or respiratory tract infections caused by non-vaccine serotypes is difficult to predict.
Pneumococci of non-vaccine serotypes may be inherently poor at causing disease, and
increased carriage and transmission of these isolates might remain without clinical
consequences. Alternatively, pneumococci of some non-vaccine serotypes that compete
poorly with vaccine serotypes for colonization of the nasopharynx might become equally




High level antibiotic resistance is almost exclusively found among pneumococci of the
vaccine serotypes, presumably because selective pressure for resistance is strongest on
isolates carried in the nasopharynx of children, which are predominantly vaccine serotypes.
Immunization should therefore lead to reduced prevalence of resistant isolates. However,
selection pressure induced by vaccination, in combination with pressure from continued
exposure to antibiotics might favor the appearance of non-vaccine serotype variants of major
resistant clones.
Because the full effects of conjugate vaccination on the pneumococcal serotype distribution
spectrum may be observed only after a few years of vaccine implementation, when immune
selective pressures are maximal, close monitoring of pneumococcal colonization in the
following years is necessary. It should be possible to incorporate capsular polysaccharides of
non-vaccine serotypes into the conjugate vaccine, if and when they become important causes
of disease. The number of additional serotypes that can be incorporated in a single conjugate
vaccine however is technically limited.
The current pneumococcal conjugate vaccines certainly are an important, but possibly not the
final solution in the prevention of pneumococcal disease, particularly not concerning mucosal
infections. Additonal prevention strategies therefore should also be explored.
Furthermore, with the increasing prevalence of antibiotic-resistant pathogens, judicious use of
antibiotics is warranted [21]. The Dutch guidelines on AOM, the most frequent reason for
prescribing antibiotics in childhood, advise physicians to manage AOM in children older than
2 years with an initial observation period of three days, and to limit prescription of antibiotics
to children with severe illness, to those who have an irregular course of AOM, to infants, and
to children considered high risk. The percentage of patients given antibiotics for AOM in the
Netherlands is limited to only 31%, whereas in many countries the prescription rate exceeds
95% [22]. As a consequence of the limited use of antibiotics, the percentage of penicillin
resistant S. pneumoniae in the Netherlands is currently still under 1% [23].
Alternative prevention strategies
The use of antibiotic prophylaxis for recurrent otitis media may be unnecessary if alternative
strategies to decrease the rate or intensity of colonization of the respiratory tract by bacterial
pathogens are effective. Xylitol has been shown to inhibit growth and adherence of S.
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pneumoniae [24;25] and daily use of oral xylitol reduced the incidence of AOM by 40% [26].
However, the doses of xylitol required to achieve protection are high, which limits its
practical use. More importantly, oral xylitol intake does not lead to a reduction in
pneumococcal carriage. Oligosaccharides that can inhibit binding of several bacteria to
epithelial cells may also prevent AOM [27;28], although in a first randomized placebo-
controlled trial oligosaccharides had no beneficial effect on the occurrence of AOM in
children or on the nasopharyngeal carriage of bacteria [29].
Although pneumococcal conjugate vaccines have a promising capability in the prevention of
invasive disease, these vaccines have certain shortcomings, particularly in prevention of
mucosal infections. Their efficacy in preventing AOM in healthy infants for pneumococcal
serotypes included in the vaccines, is less than 60% [9], and more effective vaccines would be
desirable. Stronger immunity against pneumococcal polysaccharides may be induced in the
future by using pneumococcal vaccine with immunomodulating cytokines or lymphocyte
stimulating antibodies [30;31]. Pneumococcal polysaccharides have also been used as
mucosal vaccines, together with novel adjuvants, and both serum and mucosal immune
responses have been successfully induced [32;33]. They may be an alternative approach to
current strategies to protect against mucosal infections by encapsulated bacteria.
Furthermore, research into vaccines that can provide protection against disease caused by
pneumococci of all serotypes should be continued. Inactivated pneumolysin toxin, PspA and a
37-kDa metal-binding lipoprotein (PsaA) are commonly mentioned as potential
pneumococcal protein vaccines [34]. They can be used either as a pure protein [35-37] or
conjugated with pneumococcal polysaccharides [38;39].
Concluding remarks
Vaccines represent some of the most important tools available for prevention of disease.
Vaccines protect the immunized individual from developing a potentially serious disease, and
they also help to protect the community by reducing the spread of infectious agents.
Vaccination as a deliberate attempt to protect humans against disease has a long history.
Edward Jenner, in his “Inquiry to the Causes and Effects of the Variolae Vaccinae” in 1798
was the first to observe that pustular material from the lesions of cowpox when inoculated
into humans, protected them from infection with smallpox [40]. Since then, vaccination has
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controlled nine major disease, at least in parts of the world: smallpox, diphtheria, tetanus,
yellow fever, pertussis, poliomyelitis, measles, mumps and rubella. In the case of smallpox,
the dream has been fulfilled, as this disease is eradicated [41].
Prevention of these diseases, caused by viruses or bacterial toxins, is achieved by vaccination
with protein antigens, such as attenuated virus strains and toxoids. Control of diseases caused
by encapsulated bacteria, necessitating the use of polysaccharides for vaccine production, has
proven to be more difficult. However, covalent attachment of polysaccharides to carrier
proteins has been shown to enhance the immunogenicity of polysaccharides [42]. Conjugate
vaccines of capsular polysaccharides from Haemophilus influenzae type b (Hib),
Streptococcus pneumoniae, and several other bacteria are now available for human use.
Since the introduction of Hib conjugate vaccines in several countries, the incidence of
invasive Hib disease in these countries has declined dramatically. The Hib conjugate vaccines
have also been demonstrated to markedly reduce carriage of Haemophilus influenzae type b.
It should therefore be possible to eliminate invasive Hib disease with the widespread use of
Hib vaccines. Importantly, neither increases in carriage rates of other H. influenzae serotypes
[43], nor increased incidence of meningitis caused by other encapsulated bacteria have, so far,
been observed.
Recent clinical trials of pneumococcal conjugate vaccines suggest that they, too, are highly
effective at preventing invasive disease caused by vaccine serotypes. However, the
pneumococcal conjugate vaccines target only 7-11 of the more than 90 serotypes, and
replacement of vaccine serotype pneumococci by non-vaccine type pneumococci has
occurred. A major concern is now, whether the incidence of disease caused by non-vaccine
serotype pneumococci will also increase. Eradication of pneumococcal carriage by
vaccination is unlikely to occur; therefore complete elimination of pneumococcal disease by
pneumococcal conjugate vaccination will not be accomplished. However, the development of
these conjugate vaccines, with further adaptations to come, can be considered a major step in
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Klinische en experimentele studies met pneumococcen- en Haemophilus
influenzae type b-conjugaatvaccins
Pneumococcen (Streptococcus pneumoniae) en Haemophilus influenzae type b (Hib) zijn
twee soorten bacteriën die ernstige infecties kunnen veroorzaken. Pneumococcen zijn de
verwekkers van onder andere middenoorontsteking (otitis media), longontsteking
(pneumonie), hersenvliesontsteking (meningitis) en bloedvergiftiging (sepsis). Haemophilus
influenzae type b staat bekend als de verwekker van hersenvliesontsteking en van ontsteking
van het strotklepje (epiglottitis) en kan ook long- en gewrichtsontstekingen veroorzaken.
Het afweersysteem speelt een belangrijke rol bij het voorkómen van infecties door deze
bacteriën. Hib en S. pneumoniae worden bij een aanzienlijk percentage van de gezonde
bevolking in de bovenste luchtwegen aangetroffen, maar dragerschap van de bacterie leidt
slechts in een beperkt aantal gevallen tot ziekte. Met name jonge kinderen, ouderen en
patiënten met een gestoorde afweer zijn kwetsbaar. Pneumococcen en Hib zijn gekapselde
bacteriën; ze worden omhuld door een suiker- (polysaccharide) kapsel dat hen beschermt
tegen het afweersysteem. Pneumococcen kunnen op grond van verschillen in kapsel-
polysacchariden worden onderverdeeld in meer dan 90 verschillende typen; Haemophilus
influenzae bacteriën met het type b-kapsel-polysaccharide zijn verantwoordelijk voor het
overgrote deel van de ernstige Haemophilus influenzae infecties.
In de afweer tegen gekapselde bacteriën spelen antistoffen (immuunglobulines, Ig) een zeer
belangrijke rol. Antistoffen worden geproduceerd door speciale witte bloedcellen, de B-
cellen. Ze herkennen heel specifiek een bepaalde structuur van een bacterie (of virus). In het
geval van gekapselde bacteriën zijn met name antistoffen gericht tegen het kapsel-
polysaccharide (anti-polysaccharide antistoffen) van belang. Deze antistoffen binden aan het
kapsel, en daarmee worden ook andere, minder specifieke componenten van het
afweersysteem geactiveerd, bijvoorbeeld complement-factoren (een reeks eiwitten, C1-C9, in
het bloed). Met antistoffen en complement beladen bacteriën worden herkend door andere
witte bloedcellen, fagocyten, die de bacteriën vervolgens opruimen (fagocytose).
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Afweer moet worden opgebouwd: pas ná contact met een bepaalde bacterie of virus worden
er antistoffen geproduceerd die kunnen beschermen tegen infecties veroorzaakt door die
specifieke verwekker. Door vaccinatie kan de afweer vervroegd op peil worden gebracht.
Reeds op zeer jonge leeftijd kunnen antistoffen worden gevormd tegen bacterie- of virus-
eiwitten, zoals de bestanddelen van het DKTP-vaccin. Vaccinaties leiden, net als natuurlijk
contact met een ziekteverwekker, ook tot geheugenvorming in het afweersysteem. Als er
eenmaal contact is geweest met het vaccinbestanddeel of met de ziekteverwekker zelf, dan zal
het afweersysteem bij hernieuwd contact direct op de ongewenste indringer reageren en deze
versneld onschadelijk maken, zodat het niet tot ziekteverschijnselen komt.
De vorming van antistoffen tegen polysacchariden treedt pas op vanaf de leeftijd van 18-24
maanden. Een tweede groot nadeel van polysaccharide-vaccins is het ontbreken van
geheugenvorming; als een tijd na vaccinatie de antistofconcentraties in het bloed weer laag
zijn, is de bescherming verdwenen. Het onvermogen om vroeg in de ontwikkeling anti-
polysaccharide antistoffen te maken verklaart waarom juist jonge kinderen het meest
kwetsbaar zijn voor oorontsteking, longonsteking, en hersenvliesonsteking met deze
gekapselde bacteriën. Inenting met vaccins die kapsel-polysacchariden bevatten
(polysaccharide-vaccins) is onder de leeftijd van twee jaar dus niet zinvol.
B-cellen kunnen, zoals gezegd, al wel voor de leeftijd van twee jaar antistoffen produceren
tegen eiwitten; dit dankzij de hulp van andere witte bloedcellen, de helper T-cellen. De
antistofvorming tegen eiwitten wordt T-cel afhankelijk genoemd. De boven beschreven
vorming van antistoffen tegen polysacchariden is T-cel onafhankelijk. Dat wil zeggen dat de
B-cel geen hulp van T-cellen nodig heeft om antistoffen tegen polysacchariden te maken. T-
cellen kunnen ook geen polysacchariden herkennen; polysaccharide-specifieke T-cellen zijn
nooit aangetoond. Een T-cel afhankelijke respons onderscheidt zich van een T-cel
onafhankelijke respons door o.a. twee belangrijke kenmerken: een zuigeling kan vanaf de
leeftijd van twee weken al antistoffen maken tegen eiwitten en herhaalde vaccinatie leidt tot
steeds hogere antistofconcentraties dankzij het geheugen dat wordt opgebouwd.
De antistofvorming tegen polysacchariden loopt dus heel anders en is o.a. afhankelijk van de
aanwezigheid van een bepaald type B-cellen in de milt, de zogenaamde marginale zone B-
cellen. Vanaf de leeftijd van 18-24 maanden komt er op het oppervlak van deze cellen een
eiwit-structuur, CD21, in grote hoeveelheden tot expressie. CD21 bindt complement-factor
C3d. Dit C3d wordt geactiveerd en gebonden door bacteriële kapsel-polysacchariden. De
Nederlandse samenvatting
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marginale zone B-cel is dus via CD21-C3d interactie in staat polysacchariden aan zijn
oppervlak te binden. Vervolgens worden B-cellen geactiveerd die specifieke antistoffen tegen
dit kapsel-polysaccharide kunnen maken. De slechte antistofvorming tegen polysacchariden
bij kinderen onder de twee jaar is mogelijk deels te verklaren door het feit dat bij zuigelingen
in de milt CD21 in slechts zeer geringe hoeveelheden tot expressie komt. Er kan dus geen
CD21-C3d interactie plaatsvinden, en B-cellen worden dus niet tot antistofvorming tegen
polysacchariden aangezet.
Koppeling van kapsel-polysacchariden aan eiwitten leidt ertoe dat de antistofvorming tegen
deze polysacchariden T-cel afhankelijke kenmerken krijgt: al op zeer jonge leeftijd worden er
antistoffen tegen kapselpolysacchariden gevormd als deze gekoppeld zijn aan eiwitten.
Blijkbaar is de antistofvorming tegen aan eiwit gekoppelde polysacchariden niet afhankelijk
van de aanwezigheid van rijpe marginale zone B-cellen in de milt -want die zijn er nog niet op
deze jonge leeftijd-, en dus onafhankelijk van CD21-C3d-interactie.
Vaccins bestaande uit polysacchariden gekoppeld aan eiwitten worden polysaccharide-
conjugaat-vaccins genoemd. In hoofdstuk 2 en 3 tonen we in een ratmodel aan dat
pneumococcen-polysaccharide-conjugaat-vaccins (PCV) zich inderdaad heel anders gedragen
dan ‘kale’ polysaccharide-vaccins. In hoofdstuk 2 wordt beschreven dat de kale
pneumococcen-polysacchariden na inspuiting in de bloedbaan van de rat lokaliseren op de
marginale zone B-cellen van de milt. Deze lokalisatie is afhankelijk van de aanwezigheid van
complement. In ratten die zijn behandeld met een bestanddeel van slangengif (Cobra Venom
Factor, CVF), dat de complement-eiwitten in het bloed ‘uitput’, vinden we deze specifieke
milt-lokalisatie niet, en blijft het polysaccharide langer in de bloedbaan. Bovendien is de
antistofvorming tegen kale polysacchariden in met CVF behandelde ratten veel slechter.
Conjugaat-vaccins lokaliseren minder specifiek op marginale zone B-cellen, en ook in
afwezigheid van complement-eiwitten vinden we polysaccharide-conjugaat terug in de milt.
De productie van antistoffen tegen polysaccharide-conjugaten is zelfs beter na CVF-
behandeling. De antistofvorming tegen polysacchariden gekoppeld aan eiwitten is dus minder
afhankelijk van de aanwezigheid van complement dan die tegen kale polysacchariden. Dit, in
combinatie met het gegeven dat antistofvorming tegen conjugaten al op zeer jonge leeftijd kan
plaatsvinden, als er nog vrijwel geen CD21 op marginale zone B-cellen tot expressie komt,
wijst er op dat PCV niet via CD21-complement factor C3d interactie aanzetten tot
antistofproductie.
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In hoofdstuk 3 laten we zien dat de antistofproductie tegen PCV zelfs milt-onafhankelijk is:
in ratten zónder milt is de antistofvorming tegen conjugaat-vaccins minstens even goed als in
ratten mèt milt. De antistofvorming tegen kale polysacchariden daarentegen is bijna afwezig
in ratten zonder milt. De milt is van eminent belang voor de vorming van antistoffen tegen
polysacchariden, en patiënten zonder goed functionerende milt zijn bevattelijk voor ernstig
verlopende pneumococcen-infecties. Als de kapsel-polysacchariden gekoppeld zijn aan
eiwitten, zijn er blijkbaar gebieden buiten de milt waar de antistofproductie tegen
polysacchariden in gang kan worden gezet. Conjugaat-vaccins zouden dus niet alleen
preventief kunnen worden toegepast bij jonge kinderen, maar ook bij patiënten zonder milt, en
andere patiënten met verhoogd risico voor infecties met gekapselde bacteriën.
Hóe conjugaat-vaccins de productie van antistoffen tegen polysacchariden stimuleren is nog
grotendeels onduidelijk. Wel duidelijk is dat het polysaccharide daadwerkelijk gebonden moet
zijn aan het eiwit. Menging van losse kapsel-polysacchariden met een conjugaat-vaccin leidt
niet tot een betere antistofvorming tegen het losse polysaccharide (hoofdstuk 3). Het
veronderstelde werkingsprincipe van conjugaat-vaccins is dat helper T-cellen het
eiwitgedeelte van het conjugaat herkennen, en hulp verlenen aan naburige B-cellen die
specifiek het polysaccharidedeel herkennen. De T-cellen zouden activerende factoren
produceren waardoor de B-cel aangezet kan worden tot antistofvorming tegen
polysacchariden zonder afhankelijk te zijn van activatie via CD21-C3d interactie. Het is
daarbij nodig dat de T- en B-cellen in elkaars nabijheid liggen; het polysaccharide-eiwit-
conjugaat-vaccin bewerkstelligt dit nauwe contact. In laboratoriumproefopstellingen (in een
reageerbuis) liggen T- en B-cellen sowieso heel dicht bij elkaar, en is menging van eiwit en
polysaccharide voldoende om een antistofrespons tegen het polysaccharide te krijgen
(hoofdstuk 4). Toch blijkt er ook dan een verschil te bestaan tussen de antistofvorming tegen
eiwitten en polysacchariden: de antistofproductie tegen polysacchariden kan op gang worden
gebracht door B cel-activerende oplosbare factoren alleen, terwijl voor de antistofproductie
tegen eiwitten contact van B- met T-cellen nodig is.
Tot nu toe is er steeds gesproken over antistoffen in het algemeen, maar antistoffen
(immuunglobulines, Ig) kunnen verder onderverdeeld worden in een aantal klassen,
aangeduid met een hoofdletter: IgG, IgM, IgA, IgE en IgD. IgG en IgA worden nog verder
onderverdeeld in de subklassen IgG1, IgG2, IgG3 en IgG4, en IgA1 en IgA2. Voor de afweer
zijn met name IgA, IgG en IgM van belang. IgA is de antistofklasse die met name op de
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slijmvliezen van luchtwegen, darm en urinewegen voorkomt, maar ook in het bloed; IgG is de
belangrijkste antistofklasse in het bloed. Tegen eiwitten worden voornamelijk IgM en IgG1-
type antistoffen gemaakt. Vaccinatie met polysaccharide-conjugaat-vaccins geeft bij jonge
kinderen IgM en meestal ook IgG1 antistoffen. Volwassenen maken na inenting met
pneumococcen-vaccins IgM en met name IgG2-antistoffen.
Afwijkingen in de antistofproductie leiden tot verhoogde infectiegevoeligheid. Patiënten die
veel te weinig of helemaal geen antistoffen maken (patiënten met een hypo- of a-
gammaglobuliniaemie) zijn relatief zeldzaam. Veel vaker komt een verminderde
antistofvorming in een van de (sub-) klassen voor. Voldoende IgG2- en IgA
antistofconcentraties tegen polysacchariden lijken van belang voor adequate bescherming
tegen infecties met gekapselde bacteriën. Patiënten met frequent terugkerende
luchtweginfecties en ernstige middenoorontstekingen hebben vaak een verlaagde concentratie
IgG2-antistoffen in het bloed. IgA-antistofdeficiëntie (het niet kunnen maken van IgA
antistoffen) gaat ook vaak gepaard met een verhoogde infectiegevoeligheid. In 1985 werd
voor het eerst een patiënt beschreven die normale totale concentraties van IgM, IgA, IgG en
IgG subklassen had, en een goede antistofproductie tegen eiwitten, maar die geen specifieke
antistoffen kon maken tegen bacteriële kapsel-polysacchariden. Deze patiënt had zeer vaak
long- en oorontstekingen doorgemaakt. Dit was de eerste beschrijving van de relatie tussen
het optreden van frequente, ernstige luchtweginfecties en een selectieve antistofdeficiëntie
tegen polysacchariden. Sindsdien zijn er meerdere studies verschenen over patiënten met
frequent recidiverende bacteriële luchtweginfecties en verlaagde antistoffen tegen
polysacchariden.
Kinderen met recidiverende bacteriële luchtweginfecties produceren meestal wel IgM- en
IgG1-, maar vaak verminderd IgG2- en IgA anti-pneumococcen-polysaccharide antistoffen.
Dit in tegenstelling tot gezonde controlekinderen, die wel IgG2 en IgA anti-polysaccharide
antistoffen kunnen maken. IgG2- en IgA-antistoffen tegen polysacchariden lijken dus een
factor voor optimale bescherming tegen oorontstekingen en andere luchtweginfecties
veroorzaakt door gekapselde bacteriën als de pneumococ. Omdat ook na vaccinatie met het
pneumococcen-polysaccharide-vaccin deze kinderen slecht IgG2 en IgA anti-pneumococcen-
antistoffen maken, werkt het vaccin onvoldoende beschermend. In hoofdstuk 5a en 5b laten
we zien dat bij kinderen met frequent terugkerende bacteriële luchtweginfecties inenting met
een pneumococcen-conjugaat-vaccin, gevolgd door een vaccinatie met een polysaccharide-
vaccin, wèl leidt tot IgG2- en IgA-antistofvorming. Dit geldt voor patiënten met normale
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totale concentraties aan IgG2- en IgA in het bloed (hoofdstuk 5), en zelfs voor patiënten met
verlaagde totale concentraties aan IgG2- en/of IgA (hoofdstuk 5b). In Nederland is
momenteel een grote, dubbelblinde studie gaande (de OMAVAX-studie), die in kinderen met
recidiverende oorontstekingen, de zogeheten otitis-prone kinderen, meet of dit vaccinatie-
schema, pneumococcen-conjugaat-vaccin gevolgd door pneumococcen-polysaccharide-
vaccin, ook daadwerkelijk het optreden van oorontstekingen voorkómt.
Voor een goede afweer tegen gekapselde bacteriën is opname van bacteriën door witte
bloedcellen noodzakelijk. Dit opname-proces wordt fagocytose genoemd. Voor efficiënte
fagocytose moeten antistoffen worden gebonden aan het oppervlak van de bacterie. Deze
binding heet opsonisatie, het ‘lekker maken’ van de bacterie, zodat de fagocyt de bacterie
makkelijker opneemt. Fagocyterende witte bloedcellen zijn uitgerust met structuren op hun
oppervlak die antistoffen binden, en aldus de geopsoniseerde bacterie kunnen opnemen. Deze
structuren heten Fc-receptoren, waarvan er verschillende soorten zijn. Voor de herkenning
van IgA is er de Fca-receptor (FcaRI), en voor de herkenning van de verschillende IgG
subklassen zijn er een groot aantal Fcg-receptoren, onderverdeeld in 3 klassen (FgRI, FcgRII,
FcgRIII) die weer in subklassen worden onderscheiden. Voorts bestaan er individuele
verschillen in de structuur van FcgR (zogeheten polymorfismen), die de interactie met IgG
subklassen kunnen beïnvloeden. IgG tegen pneumococcen blijkt de fagocytose van
pneumococcen voornamelijk te bevorderen via FcgRIIa. Er bestaan twee polymorfismen van
FcgRIIa, R131 en H131. FcgRIIa-H131 is de enige receptor die IgG2 kan binden. Fagocyten
met FcgRIIa-H131 op hun oppervlak fagocyteren bacteriën beladen met IgG2 veel beter dan
fagocyten zonder deze receptor. In hoofdstuk 6 tonen we aan dat, na vaccinatie van gezonde
volwassenen met pneumococcen-conjugaatvaccin, de hoeveelheid IgG2-antistoffen tegen
pneumococcen-polysaccharide correleert met de efficiëntie van fagocytose door fagocyten
met FcgRIIa-H131 op hun oppervlak. Er is geen relatie tussen fagocytose en IgG1-
antistofconcentratie. Ook na vaccinatie met conjugaat, dat zoals gezegd voornamelijk IgG1-
antistoffen induceert, lijkt IgG2 dus de meest functionele antistofklasse.
Koppeling van kapsel-polysacchariden aan eiwitten ligt aan de basis van de ontwikkeling van
conjugaat-vaccins. Vaccinatie met polysaccharide-conjugaat-vaccins leidt er toe dat de afweer
tegen polysacchariden kenmerken krijgt van de afweer tegen eiwitten: naast het feit dat er al
op zeer jonge leeftijd antistofvorming mogelijk is, wordt er ook geheugen opgebouwd. Bij elk
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volgend contact met het polysaccharide (als vaccin of als hele bacterie) reageert het
afweersysteem met snelle productie van veel antistoffen. Deze antistoffen worden ook
kwalitatief beter: als er vaker contact met het polysaccharide is geweest, worden er sterker
bindende antistoffen (antistoffen met gemiddeld een hogere affiniteit voor het polysaccharide,
zogenaamde hoog-avide antistoffen) gevormd. Bovendien blijken conjugaat-vaccins ook het
dragerschap van gekapselde bacteriën te sterk verminderen. Het daadwerkelijk optreden van
infectie kan daarmee worden voorkomen.
Het Hib-conjugaatvaccin, bestaande uit het kapsel-polysaccharide van Haemophilus
influenzae type b (Hib) gekoppeld aan tetanus-toxoid, dat in Nederland sinds 1993 gegeven
wordt aan kinderen op de leeftijd van 2, 3, 4 en 11 maanden, heeft geleid tot een enorme
reductie in het aantal ernstige infecties veroorzaakt door Haemophilus influenzae type b. Vóór
introductie van het Hib-vaccin werden jaarlijks bijna 700 ernstige Hib-infecties gemeld. Sinds
opname van het Hib-vaccin in het Rijks Vaccinatie Programma heeft slechts een klein aantal
kinderen -gemidddeld 3 per jaar- ondanks volledige vaccinatie, dat wil zeggen na tenminste 3
Hib-inentingen, nog een hersenvliesontsteking of ontsteking van het strotklepje doorgemaakt.
In die sporadische gevallen spreken we van ‘Hib-vaccinatie-falen’. In andere landen waar het
Hib-vaccin wordt gegeven, worden soortgelijke successen behaald.
Wij waren in staat om bij het merendeel van de kinderen met Hib-vaccinatie-falen, namelijk
14 van de 21, onderzoek te doen naar de afweer. Twee van deze 14 kinderen bleken een
algemene afwijking in antistofproductie te hebben: een meisje had een
hypogammaglobulinaemie, en een jongen had een lage concentratie totaal IgG2 in het bloed.
Een stoornis in de specifieke anti-Hib antistofproductie bleek vaker voor te komen: een deel
van de kinderen had onvoldoende antistoffen tegen Hib gemaakt na vaccinatie en/of na
infectie, zoals blijkt uit lage anti-Hib antistofconcentraties die werden gevonden in bloed
afgenomen tijdens of na het doormaken van de infectie (hoofdstuk 7a en 7b). Lage
concentraties anti-Hib antistoffen worden vaker gezien bij kinderen, zeker als de vaccinatie
een tijd geleden is gegeven. Maar na Hib-conjugaat-vaccinatie zou er geheugenvorming
moeten zijn opgetreden, en bij hernieuwd contact met Hib zou er dus snel een hoge
antistofrespons moeten optreden die infectie zou moeten voorkomen. Het feit dat er ook na
doormaken van een Hib-infectie slechts lage anti-Hib antistofconcentraties worden gevonden
wijst er dus op dat er bij de patiënten met Hib-vaccinatie falen geen goede geheugenvorming
is opgetreden. En als er bij deze patiënten al antistoffen tegen Hib geproduceerd werden, na
ziekte of na opnieuw vaccineren, dan bleken deze antistoffen bovendien van minder goede
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kwaliteit te zijn: de bindingssterkte (aviditeit) van de anti-Hib antistoffen van patiënten met
Hib-falen was geringer dan de aviditeit van anti-Hib-antistoffen van controles. Dit is ook een
aanwijzing voor onvoldoende antistofrespons tegen Hib. Deze zowel kwantitatief als
kwalitatief slechtere anti-Hib antistofrespons kan de verhoogde vatbaarheid voor Hib-infectie
verklaren.
In hoofdstuk 8 worden nog enkele algemene opmerkingen betreffende pneumococcen- en
Haemophilus influenzae type b-conjugaat-vaccins geplaatst. Het succes van het Hib-
conjugaat-vaccin, dat het dragerschap van en infecties veroorzaakt door Hib sterk heeft
verminderd, heeft de ontwikkeling van pneumococcen-polysaccharide-conjugaat-vaccins
(PCV) een extra impuls gegeven. De productie van PCV is echter ingewikkelder, omdat in
plaats van slechts één type (type b in het geval van Hib), nu meerdere typen polysacchariden
in het vaccin moeten zitten. Het is technisch nog niet mogelijk om meer dan 7 tot 11
pneumococcen-typen in het vaccin op te nemen. Gekozen is om díe kapsel-polysacchariden te
includeren, die bij kinderen (in de Westerse wereld) het vaakst verantwoordelijk zijn voor
infecties. Inmiddels is uit eerste grote studies bij jonge kinderen gebleken dat deze
pneumococcen-conjugaat-vaccins erg effectief zijn in het voorkómen van longontsteking,
hersenvliesontsteking en bloedvergiftiging (zogenaamde invasieve infecties) veroorzaakt door
pneumococcen die in het conjugaat-vaccin vertegenwoordigd zijn. PCV zijn helaas minder
effectief in het voorkómen van ‘oppervlakkige’ infecties van de slijmvliezen, zoals acute
middenoorontsteking. Blijkbaar zijn de eisen die worden gesteld aan het afweersysteem om te
kunnen beschermen tegen infecties van de slijmvliezen anders dan die voor bescherming
tegen invasieve infecties. Na inenting met PCV worden voornamelijk IgG1-antistoffen
gevormd, en deze antistoffen zijn dus effectief in het voorkómen van invasieve
pneumococceninfecties. Voor afdoende bescherming tegen ‘oppervlakkige’ luchtweginfecties
zijn misschien IgG2- en IgA-antistoffen tegen pneumococcen-polysacchariden nodig, die niet
of nauwelijks worden geproduceerd na vaccinatie met PCV. Mogelijk leert de eerder
beschreven OMAVAX-studie die momenteel in Nederland gaande is welke antistoffen nodig
zijn voor bescherming tegen oorontsteking.
Vaccinatie met PCV leidt niet alleen tot reductie van het aantal infecties met pneumococcen
die in het vaccin zitten, maar ook tot vermindering van dragerschap van deze types. In de
bestaande PCV zijn de meeste pneumococcen-types opgenomen die resistent zijn tegen veel
gebruikte antibiotica. Een voordeel van uitgebreide vaccinatie met PCV kan dus zijn dat
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resistente pneumococcen worden teruggedrongen. Maar uit de studies die tot nu toe gedaan
zijn blijkt ook dat vaccin-type pneumococcen worden vervangen door pneumococcen die niet
in het vaccin zitten. Het is denkbaar dat vervolgens ook het aantal infecties veroorzaakt door
niet-vaccin typen zal oplopen, en dus de vaccin-samenstelling zal moeten worden veranderd.
Omdat vaccinatie met Hib-vaccins ook het Hib-dragerschap vermindert, zonder dat er
toename lijkt op te treden in dragerschap van andere Haemophilus influenzae types, zou het
mogelijk moeten zijn om door wereldwijde vaccinatie met Hib-conjugaat-vaccins ernstige
Haemophilus influenzae infecties te elimineren. Bij pneumococcen is er echter het risico van
verschuiving van vaccin-type-dragerschap naar dragerschap van niet-vaccin type
pneumococcen. Alternatieve preventie-strategieën zullen moeten worden ontwikkeld. De
bestaande PCV zijn dus zeker niet de definitieve oplossing, maar wel een belangrijk middel
om ernstige pneumococceninfecties te helpen voorkómen.
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